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Abstract
The aim of this thesis was to examine and quantify the influence of diet fatty
acid composition on membrane fatty acid composition in the rat, as well as the effect on
body composition and metabolic rate. To achieve “normal” conditions (and thus allow
best extrapolation to the normal human situation) the rats were young adults from the
outbred Sprague Dawley strain to ensure genetic variation. The experimental diets were
fed for a reasonable time period of 8 weeks, which is equivalent to ~ one year in
humans. The twelve experimental diets were moderate-fat (25% of total energy) and the
dominant fats were 18-carbon, which is the normal situation for the diet of both rats and
humans.
Diets differed only in their fatty acid profiles, with saturate (SFA) content
ranging from 8-88% of total fatty acids, monounsaturate (MUFA) 6-65%, total
polyunsaturate (PUFA) 4-81%, n-6 PUFA 3-70% and n-3 PUFA 1-70%. The balance
between n-3 and n-6 PUFA is defined as the PUFA balance (n-3 PUFA as % of total
PUFA) and ranged 1-86% in the diet. The membrane fatty acid composition was
measured for a number of tissues including skeletal muscle, heart, liver, brain, adipose
tissue and red blood cells (RBC). In addition, the daily metabolic rate and body
composition of each rat was determined.
In these young adult outbred rats fed a moderate-fat diet that included only 18carbon PUFA, fat profile of the diet had only modest influence on body mass
composition and food intake (with higher body fat content associated with increased
diet SFA content and elevated food intake related to increased SFA / decreased n-6
PUFA content). Of all the metabolic parameters, diet fat profile showed the greatest
influence on metabolic rate with a higher mass-specific minimum metabolic rate
associated with increased diet n-3 PUFA and PUFA balance.
The conformer/regulator paradigm was used to analyse the results of this study,
where the slope of the relationship indicates how responsive the membranes are to diet
fat profile. That is, a slope of one indicates the membrane is conforming to diet fat
profile while a slope of zero shows that the membrane is strictly regulating fatty acid
composition.
This analysis revealed that under “normal” conditions membrane fatty acid
composition is in general regulated relatively constant despite extensive changes in diet
v

fatty acid composition (for all tissues except adipose tissue). Diet SFA had essentially
no influence on membrane SFA composition (slopes ≤0.02), with a slightly greater
response to diet MUFA and PUFA (slopes ≤0.12 and ≤0.09 respectively). Membranes
showed a greater responsivity to the individual PUFA classes (n-3 PUFA slopes ≤0.17
and n-6 PUFA slopes ≤0.24).
The balance between diet n-3 and n-6 PUFA (PUFA balance), however, showed
the greatest effect on membrane composition for all tissues measured. The response to
diet PUFA balance was biphasic for most tissues (skeletal muscle, heart, liver, brain and
RBC), indicating that a diet PUFA balance of ~10% is the critical level required to
maintain membrane PUFA balance. At diet PUFA balances < 10% the membrane
PUFA balance of these tissues was highly responsive (slopes of 0.65 – 1.47), indicating
that the membranes are essentially completely conforming to diet PUFA balance at
these low levels. Furthermore, reduced membrane PUFA balance was associated with a
significantly reduced mass-specific minimum metabolic rate.
One of the major findings of this thesis was the strong influence of diet PUFA
balance on membrane arachidonic acid (20:4n-6) content for all tissues. Low diet PUFA
balance was associated with significantly increased membrane 20:4n-6 levels. This has
potential implications for human health due to the central role membrane 20:4n-6 plays
in many parts of metabolic syndrome and chronic inflammation.
If the results from this study in rats also apply to humans, an average PUFA
balance of 9.5% in the modern human diet is of considerable concern, as it indicates
there are huge numbers of people consuming a diet with a very low and likely
inadequate PUFA balance without knowing it.
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Chapter 1

Introduction

1.1 Fatty Acids
Fatty acids consist of a hydrocarbon chain with a carboxylic (-COOH) and methyl
group (-CH3) at either end. Naming systems for fatty acids denote the hydrocarbon
chain length and position/number of double bonds. The omega abbreviation system,
first introduced by Holman (1964), will be employed here. The ‘omega’ carbon is the
last carbon in the fatty acid chain (furthest away from the carboxyl group) and the
position of the double bond closest to this methyl end is denoted by ‘n-’. See Table 1.1
for some naturally occurring fatty acids.
There are four main types of fatty acids, classified by the number and position of
the double bonds present. Saturated fatty acids (SFA) have no double bonds present and
are therefore saturated with hydrogen. Monounsaturated fatty acids (MUFA) have only
one double bond. Polyunsaturated fatty acids (PUFA) have more than one double bond
present and can be further classified into n-3 PUFA and n-6 PUFA. Unsaturated fatty
acids can occur as cis or trans geometric isomers, but most naturally occurring fatty
acids have double bonds in the cis configuration.
Table 1.1 Examples of some commonly occurring fatty acids, demonstrating the omega
abbreviation system in the right-hand column (from Hulbert et al. 2005).
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1.2 Phospholipids & Membrane Bilayers
Fatty acids are present in triglycerides and phospholipids. Triglycerides consist of
a glycerol backbone with three fatty acyl chains attached and are used primarily as fat
stores in the adipose tissue. Phospholipids, on the other hand, play important structural
and functional roles in the membrane bilayer. The fatty acid composition of this
phospholipid bilayer is also very important for membrane properties and function, thus
the focus of this thesis will be on the fatty acid composition of these membrane
phospholipids.
Phospholipids consist of a 3-carbon glycerol backbone (hence the common
name of glycerophospholipid), each carbon denoted as a sn-1, sn-2 or sn-3 position,
with a phosphate and alcohol head group attached at the sn-3 and two fatty acyl chains
attached at the sn-1 and sn-2 positions. The classification of each phospholipid depends
on the nature of the head group esterified to the phosphoric acid. These head groups
include choline (phosphatidylcholine or PC), ethanolamine (phosphatidylethanolamine
or PE), inositol (phosphatidylinositol or PI) and serine (phosphatidylserine or PS).
Bisphosphatidyl glycerol or cardiolipin is another glycerophospholipid (classified as a
polyglycerophospholipid) where the backbone and head group are formed from
repeating units of phosphoryl and glycerol moieties (Schlame 2008). Cardiolipin is a
minor constituent of mitochondrial membranes (~20% of total phospholipids).
Sphingomyelin is another type of phospholipid and is part of a class of lipids called
sphingolipids. Instead of a glycerol this lipid contains a sphingosine backbone and only
one attached fatty acyl chain. These lipids are important in neural tissues.
Phospholipids are further sub-classified according to differences in the chemical
bond between the fatty acyl chain to the sn-1 position of glycerol, such as acyl, ether
and vinyl-ether bonds (Yamashita et al. 1997). In general the highest occurring
glycerophospholipid species in cell membranes is PC, followed by PE, sphingomyelin,
PS and then PI, although these proportions vary between different cell types (Hodson et
al. 2008).
Membrane phospholipids typically consist of at least 50% unsaturated fatty
acids, with the sn-1 position usually a SFA or MUFA and the sn-2 position always
taken up by an unsaturated acyl chain (usually PUFA; see Lands 2000). In some tissues,
however, there is a higher proportion of unsaturated fatty acids present in the
phospholipid, which increases the fluidity of the membrane (for example, in the brain
2

and eye). Each class of phospholipids also has a specificity for certain acyl groups, for
example the predominant PI molecular species is 18:0-20:4n-6, while the majority of PS
molecular species include 18:0 acyl chains, such as 18:0-18:1, 18:0-20:4n-6 and 18:022:6n-3 (Yamashita et al. 1997).
Membranes provide a barrier within and around the cells of all living organisms.
Biological membranes primarily consist of a lipid bilayer and embedded proteins. The
lipid bilayer includes both phospholipids and cholesterol, but the phospholipids are the
most important structural component of the membrane (Figure 1.1). The basic structure
of lipid membranes was described in 1972 as the Fluid Mosaic Model (Singer and
Nicolson 1972). The hydrophobic hydrocarbon tails of the phospholipids face each
other to form an oily centre and the polar head groups face outwards towards the
aqueous solutions on either side of the membrane. Only small hydrophobic solutes are
able to pass through this barrier and there is low permeability for polar inorganic
compounds and ionic molecules, giving the cell control over processes occurring across
the cellular membrane.

Figure 1.1 Structure of a typical biological membrane (modified from
http://fig.cox.miami.edu/Faculty/Dana/membrane.jpg; visited 05/08/08)

The physical properties of the lipid bilayer are affected by its lipid composition,
as well as the temperature and membrane pressure (Williams 1998). Temperature
affects a lipid membrane by reducing the order in the bilayer as the temperature is
increased (Cronan and Gelmann 1975). Increasing the length of the fatty acyl
hydrocarbon chain and the degree of unsaturation (i.e. number of double bonds) will
affect the fluidity of the lipid bilayer. The presence of a double bond in the acyl chain
3

creates more freedom of movement at the carbon next to the double bond, thus the
hydrocarbon chains are more loosely packed than those of saturated fatty acids in the
lipid bilayer. The ability of the fatty acids to affect both physical and chemical
properties of the lipid membrane is the reason for the focus on fatty acids in this thesis.

1.3 Essential versus Non-essential Fatty Acids
Higher animals can synthesise both SFA and MUFA from non-lipid sources, but
are unable to synthesise de novo both n-6 and n-3 PUFA (see Figure 1.2). Mammals
lack the two separate desaturase enzymes required to make 18-carbon (18C) n-6 PUFA
and n-3 PUFA and are also incapable of interconverting these two classes of
polyunsaturates (Pan et al. 1994; Sprecher 2000). Consequently both n-6 and n-3 PUFA
are separate essential dietary components (i.e. essential fatty acids or EFA). It has long
been known that n-6 and n-3 PUFA are essential to the diet of rats (Burr and Burr
1929), however it was not until the 1970’s that n-6 PUFA was found to be essential to
humans (Collins et al. 1971) and then another decade to establish this for n-3 PUFA
(Holman et al. 1982).
Plants are able to synthesise n-3 PUFA as 18:3n-3 and n-6 PUFA as 18:2n-6.
Once consumed, animals can alter these 18C PUFA in the endoplasmic reticulum
membrane by employing enzymes to create more double bonds (desaturase) and
increase the chain length (elongase). The pathways for biosynthesis of the n-9, n-6 and
n-3 series are shown in Figure 1.2. Competition exists between these three series of
fatty acids for the desaturase and elongase enzymes, with the conversion of 18:1n-9,
18:2n-6 or 18:3n-3 via Δ6-desaturase thought to be the rate limiting step (Food and
Agriculture Organization 1995). The Δ6-desaturase shows higher affinity for more
unsaturated substrates (Sprecher 2000), with a preference of 18:3n-3 > 18:2n-6 > 18:1n9. This means that 18:1n-9 will only be converted to 20:3n-9 (mead acid) and esterified
to the membrane phospholipids under conditions of diet PUFA deficiency (Holman
1960).
Due to the essential nature of the PUFAs, the n-3 PUFA and n-6 PUFA will be a
special focus of this thesis. In particular the balance between these two PUFAs will be
an important concept, due to the separate and often opposing influence n-3 PUFA and
n-6 PUFA exert on membrane function and molecular signaling (to be discussed later).

4

Figure 1.2 Pathway for biosynthesis of n-9, n-6 and n-3 fatty acids modified from both
Pat et al. 1994 and Sprecher 2000. Enzymes include elongase (E) and the desaturases
(Δ5, Δ6, Δ9 and Δ12). Solid arrows represent reactions occurring in the endoplasmic
reticulum. Dashed arrows indicate partial β-oxidation occurring in the peroxisomes. The
blue arrows denote reactions occurring only in plants (higher animals lack the Δ12 and
Δ15 desaturases).

1.4 Essential Fatty Acids in Membranes
The n-3 PUFA and n-6 PUFA are considered essential fatty acids in the diet as
higher animals are unable to synthesise them, but they are also considered as essential
components of the membrane bilayer due to important functional aspects. Membrane
fatty acid composition can influence both the physical properties of the membrane (for
example, they are considered important in the membrane pacemaker theory of
metabolism) and chemical properties (as a source of signalling molecules derived from
membrane phospholipids). In both cases membrane PUFA composition is of utmost
importance, with membrane 20:4n-6 content particularly important for the production of
chemical signals (Hansen and Artmann 2008).
5

Physical Properties - Membrane Pacemaker Theory of Metabolism
The physical properties of membranes have been shown to be important for
many processes, for example, receptor binding, carrier-mediated transport and
properties of membrane-bound enzymes (Spector and Yorek 1985). However, in this
thesis I will concentrate on their proposed importance for the determination of cellular
metabolic activity.
Basal metabolic rate (BMR) represents the minimal cost of living and is a
measure of the metabolic rate of an adult animal at rest in a thermoneutral environment
and a postabsorptive state (Hulbert and Else 2004). Mass-specific BMR varies between
species and is known to be inversely related to body size in a wide range of animals,
with an allometric relationship of ~0.75 power of body mass (Kleiber 1932). The
membrane pacemaker theory of metabolism was developed to explain these differences
in BMR between species (Hulbert and Else 1999; Hulbert 2007). This theory proposes
that variation in BMR results from both changes in organ size and cellular metabolic
rate.
Organ mass is an important determinant of metabolic rate, with certain tissues,
such as liver, heart, kidney, brain and gastrointestinal tract known to have mass-specific
metabolic rates much higher than the body as a whole (Holliday et al. 1967; Selman et
al. 2001). However, a large proportion of cellular metabolic rate relates to membraneassociated processes, with the amount of oxygen consumed during BMR associated
with the following: ~10% non-mitochondrial, ~20% by mitochondria to offset the
proton leak, and ~70% for mitochondrial ATP production, which further consists of 2025% for Na+K+-ATPase activity, 20-25% for protein synthesis, ~5% for Ca2+-ATPase,
~7% for gluconeogenesis , ~2% for ureagenesis, ~5% for actinomyosin-ATPase activity
and ~6% for all other ATP-consuming process (Rolfe and Brown 1997). An important
factor influencing these membrane-associated processes is membrane fatty acid
composition, and it has been shown that a higher BMR is associated with increased
membrane PUFA levels (Gudbjarnason et al. 1978; Hulbert and Else 1989; Brand et al.
1991; Couture and Hulbert 1995).
The influence of membrane PUFA content on cellular metabolism is partly due
to changes in physical properties of the membrane (Wu et al. 2001). Increasing the
membrane PUFA content has been shown to increase the molecular activities of
membrane-bound enzymes such as the sodium pump (Na+K+-ATPase; Hulbert and Else
1999). This increased activity is associated with an increase in the molecular activity of
6

individual sodium pumps and not simply an increased number of pumps (for example,
rat/cane toad comparison by Else et al. (1996)). Furthermore, the sodium pump
molecular activity was much higher in the kidney and brain of the rat, coinciding with a
higher unsaturation index (average number of double bonds per 100 fatty acyl chains)
and an increase in n-3 PUFA with a corresponding decrease in n-6 PUFA content in the
rat tissues (Else and Wu 1999; Wu et al. 2001).
A correlation was discovered in 1978 between the heart rate of animals, ranging
in size from whales to mice, and the amount of 22:6n-3 in their cardiac phospholipids
(Gudbjarnason et al. 1978). Heart rate is an indicator of metabolic rate and increasing
the percentage of long-chain n-3 PUFA in the cell membranes should lead to increased
“leakiness” and molecular activity across the cell membrane as suggested by the
membrane pacemaker theory (Hulbert and Else 1999). Increased membrane content of
22:6n-3 has also been linked to higher Ca2+-ATPase activity (Infante 1987), which is
also an important component of BMR.
The association between membrane PUFA content and increased metabolic rate
seems to hold true for between species comparisons, although this relationship is less
clear for within species comparisons. Rodent studies have demonstrated no relationship
between BMR and membrane fatty acid composition (Brzek et al. 2007; Haggerty et al.
2008). Similarly in dogs, the higher metabolic rate of small dogs relative to large dogs
was associated with relative organ size, rather than membrane composition (A.J.
Hulbert, personal communication). Although no relationship between BMR and
membrane fatty acid composition has been established within rodents, this relationship
has never been quantified under “normal” conditions.

Chemical Properties – Signalling Molecules
There are a number of lipid mediators derived from the enzymatic degradation
of membrane phospholipids, including platelet-activating factor, diacylglycerols,
phosphatidylinositol 1,4,5-triphosphates, eicosanoids, docosanoids, endocannabinoids
and lysophospholipids (Farooqui 2009). The eicosanoids (which includes prostacyclin)
and endocannabinoids are both derived from membrane 20:4n-6 and this thesis will
concentrate on discussion of these important signalling molecules.
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Eicosanoids
Arachidonic acid is an extremely biologically active unsaturated fatty acid and
forms many oxygenated derivatives. Eicosanoids are signaling molecules derived from
20-carbon

PUFAs

and

include

prostaglandins,

thromboxanes,

leukotrienes,

hydroxyeicosatetraenoic acids, epoxy-derivatives and hepoxilins (Hansen and Artmann
2008). See Figure 1.3 for the pathways involved in eicosanoid synthesis from
phospholipid 20:4n-6, 20:5n-3 and 22:6n-3. Arachidonic acid is cleaved from the
glycerophospholipid by phospholipase A2 and is converted to eicosanoids (Hishikawa et
al. 2008). This process produces 2-series prostaglandins. The eicosanoids produced
from 20:5n-3 and 20:3n-6 are called 1- and 3-series prostaglandins respectively (Zhou
and Nilsson 2001). These latter prostaglandins have a much lower biological activity
when compared to the 20:4n-6 derivative and also compete for the same prostaglandin
enzyme-binding site, so that the 1- and 3-series prostaglandins can reduce the
production and efficacy of 2-series prostaglandins (Zhou and Nilsson 2001).
A number of steps are involved in the resolution of an inflammatory response.
Firstly, there is switch

from synthesis of 20:4n-6-derived prostaglandins and

leukotrienes to the anti-inflammatory mediators called lipoxins (Serhan and Savill
2005). This also coincides with the biosynthesis of resolvins and protectins from 20:5n3 and 22:6n-3, which are known to promote the termination of inflammation.

Figure 1.3 Synthesis of eicosanoids from membrane 20:4n-6, 20:5n-3 and 22:6n-3;
from Pischon et al.(2003).
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Eicosanoids derived from 20:4n-6 are considered to be pro-inflammatory and
the presence of chronic inflammation is common to many disorders, including the
metabolic syndrome, obesity, type 2 diabetes, coronary heart disease and arthritis.
Inflammation may lead to increased insulin resistance, which leads to obesity, diabetes,
hypertension and dyslipidaemia (Rana et al. 2007). Inflammation is an essential
component of tissue repair and is beneficial in the short-term, however the prolonged or
chronic inflammation that is present in many of the aforementioned diseases is
detrimental. Therefore, 20:4n-6 signaling can be considered useful at low
concentrations, but harmful in excess.
Potential competition between n-3 and n-6 PUFA derived eicosanoids exists at a
number of steps in the biosynthesis pathway. The first step involves incorporation into
the lipid bilayer, which is controlled by the acyltransferases. To enter into the
eicosanoid pathway 20:4n-6 and 20:5n-3 must be hydrolysed from the membrane via
phospholipase A2. Acyltransferase and phospholipase A2 show no discrimination
between 20:4n-6 and 20:5n-3 (Lands et al. 1982; Smith 2005). However, the next step
involving cycoloxygenase prefers 20:4n-6 (Smith 2005), so for the reduced production
of the pro-inflammatory 20:4n-6 derived eicosanoids the most important level of
competition would seem to be at the level of incorporation into the cell membrane.
Human and animal studies have shown that low levels of 20:4n-6 in the diet can
have a significant effect on membrane fatty acid composition and therefore on
eicosanoid production (Zhou and Nilsson 2001). Dietary long-chain n-3 PUFA are more
effective than 18:3n-3 in reducing 20:4n-6 derived eicosanoid production (Whelan
1996), which is probably due to their higher capacity to displace 20:4n-6 from
membrane phospholipids. This confirms the requirement for a diet balanced towards
high n-3 PUFA and low n-6 PUFA, to successfully combat disorders where chronic
inflammation occurs from increased 20:4n-6 derived eicosanoid production.

Prostacyclin
As well as the inflammatory mediators, membrane 20:4n-6 is a precursor for
prostacyclin or prostaglandin I2 (PGI2; see Figure 1.3). This eicosanoid is known for
promoting adipogenesis in rats and humans (Ailhaud et al. 2008), and may be of
importance in the development and maintenance of obesity. Previous studies have
shown that diets with low levels of n-3 PUFA relative to n-6 PUFA lead to increased
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production of adipose tissue, including increased adipocyte number and size (Fickova et
al. 1998; Massiera et al. 2003; Ailhaud et al. 2006). Rodent studies have shown that
increasing dietary 18:2n-6 intake leads to increased tissue 20:4n-6 levels, resulting in
elevated prostacyclin production, which then stimulates signalling pathways for
adipogenesis (including phospholipase and/or cyclo-oxygenase activation; see Ailhaud
et al. 2008). This highlights the potential influence of increased membrane 20:4n-6 in
promoting the development of obesity.

Endocannabinoids
Membrane

arachidonic

acid

is

also

important

precursor

for

the

endocannabinoids. The first two endogenous cannabinoid receptor ligands, anandamide
(N-arachidonoyl ethanolamine) and 2-AG (2-arachidonoyl glycerol), were discovered in
the early 1990’s (Di Marzo and Matias 2005). At least five endocannabinoids derived
from membrane 20:4n-6 have discovered to date (see Figure 1.4). Endocannabinoids
are biosynthesized on demand and released from the cell immediately following
production (Bisogno 2008).

Figure 1.4 Chemical structure of endocannabinoids derived from membrane 20:4n-6;
from Bisogno (2008).
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The endocannabinoid system is important in inducing food intake and control of
energy balance. Endocannabinoids exert their effects by binding to cannabinoid
receptors. The first cannabinoid receptor (CB1) is most abundant in the brain, but is also
present in peripheral tissues, such as adipose tissue and the gastrointestinal system
(Pagotto et al. 2005). The second subtype (CB2) is predominantly found in immune
cells (Di Marzo and Matias 2005), but has also been recently shown to be present in the
brainstem (Van Sickle et al. 2005). Both CB1 and CB2 have similar biological effects
and are involved in the control of energy balance, body mass and also the perceived
palatability of food. Stimulation of CB1 receptor with plant and endogenous
cannabinoids in animals has been demonstrated to stimulate eating while a selective
CB1 antagonist is known to have an anorectic effect (Di Marzo and Matias 2005).
The endocannabinoid system may play an important role in the progress and
maintenance of obesity. It has been shown in animal models that genetically induced
obesity leads to over-stimulation of the endocannabinoid system, which may be the
mechanism for maintaining high levels of obesity (Pagotto et al. 2005). Antagonists for
CB1 and CB2 have been associated with reduced food intake and adipocytes lipogenesis
in animal models and humans (Hansen et al. 2006). Significantly higher levels of
anandamide have been found in the plasma of obese humans (Monteleone et al. 2005).
This has also been demonstrated in the visceral fat of obese patients, where there was a
significant increase in 2-AG, but not anandamide (Matias et al. 2006b).
Limited studies have been performed to investigate the effect of dietary fat on
endocannabinoid levels. However, from the studies that have been completed, it seems
that increasing the diet n-3 PUFA relative to n-6 PUFA leads to reduced tissue
anandamide and 2-AG levels. In mice fed a moderate-fat diet for 4 weeks, those on the
18:2n-6 diet (99.7% of total PUFA) had higher brain 2-AG levels than mice fed a n-3
PUFA diet (87% of total PUFA; Watanabe et al. 2003). A study in rats showed that fish
oil feeding for 1 week (n-3 PUFA 44% of total PUFA) resulted in significantly reduced
2-AG and anandamide levels in the liver (Artmann et al. 2008). High-fat feeding with a
low n-3 PUFA content (7% of total PUFA) in mice showed a similar trend with liver
anandamide levels significantly increased after 14 weeks (Osei-Hyiaman et al. 2005).
Together these results in rodents indicate that the balance between n-3 and n-6 PUFA in
the diet may be important in determining tissue 2-AG and anandamide levels, however,
the effect of diet fat profile on tissue endocannabinoid levels is yet to be quantified.
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1.5 Regulation of Membrane Fatty Acid Composition
Membrane fatty acid composition is different between species, for example, the
membranes of small metabolically-active mammals contain increased levels of 22:6n-3
compared to larger mammals (Hulbert et al. 2002). Membrane fatty acid composition
appears to be regulated not only within species, but also within certain strains. For
example, differences in membrane fatty acid composition have been demonstrated
between a wild-derived mouse strain (Idaho) and an outbred laboratory-derived mouse
strain, with the Idaho mice having significantly reduced 22:6n-3 levels in liver and
skeletal muscle membranes (Hulbert et al. 2006). This difference in membrane
composition could not be attributed to diet fat profile (i.e. they were consuming the
same diet). The precise mechanisms involved in the regulation of membrane fatty acid
composition within a species are not known, however, the enzymes involved in
membrane remodeling (acyltransferases) are likely important.
Membranes fatty acid composition is regulated to ensure that optimal fluidity is
maintained and thus the proper functioning of membrane-associated processes (Clamp
et al. 1997). This regulation of membrane fluidity by altering the degree of unsaturation
in the fatty acyl chains was first described in 1974 and is known as “homeoviscous
adaptation” (Sinensky 1974). The degree to which biological membranes can alter
fluidity depends primarily on the activity of the desaturase enzymes (Brenner 1981; Los
and Murata 1998), which have the highest affinity for n-3 PUFA over less unsaturated
fatty acids (Sprecher 2000). So within the limits of homeoviscous adaptation there is
some room for altering the membrane lipid profile.
Phospholipid acyltransferases were discovered by William Lands in the early
1960s (Lands and Merkl 1963; Merkl and Lands 1963) and are important enzymes in
the regulation of membrane fatty acid composition. These enzymes catalyse the
biosynthesis of phospholipid molecular species via de novo pathways and also regulate
remodeling of fatty acids in the sn-1 and sn-2 positions of tissue phospholipids. Specific
acyltransferases selectively place SFA on the sn-1 position, while other acyltransferases
place an unsaturated fatty acid on the sn-2 position either during de novo synthesis (for
16 and 18-carbon UFA) or the re-tailoring process (for 20 and 22-carbon UFA; Lands et
al. 1990). There is rapid turnover of the fatty acyl component of glycerophospholipids
at the sn-2 position and this is thought to be due to the activation of a number of
phospholipase A2 and lysophospholipid acyltransferase enzymes (Hishikawa et al.
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2008). Lands et al. (1982) found that the acyltransferases for the sn-2 position prefer
PUFA as a substrate, but do not seem to discriminate between the n-6 and n-3 PUFA.
Importantly this means that the relative availability of dietary n-3 PUFA and n-6 PUFA
will likely greatly impact the content of these EFA in the membrane lipids, and this
might significantly impact on a number of health outcomes (to be discussed later).
The PUFA primarily found in most cellular membranes include 20:4n-6 and
22:6n-3, while others are present in much lower amounts (i.e. 18:2n-6, 22:4n-6, 22:5n6, 18:3n-3, 20:5n-3 and 22:5n-3). Arachidonic acid can be synthesised directly from
18:2n-6 via pathways in the endoplasmic reticulum or alternatively from
retroconversion of longer-chain metabolites in the peroxisomes via β-oxidation. DHA
(22:6n-3) on the other hand is preferentially removed from the peroxisomes following
β-oxidation of 24:6n-3 (Sprecher 2000). Subsequently, both 20:4n-6 and 22:6n-3 are
preferentially esterified to the sn-2 position of the membrane phospholipids leading to
increased levels in the membranes relative to other PUFA.

1.6 Influence of Diet Fatty Acid Profile on Membrane Fatty Acid
Composition
Although diet fatty acid profile is known to influence membrane fatty acid
composition of most tissues to some degree (discussed below), the fatty acid profile of
the membrane is also recognised as a highly regulated parameter. Due to the important
influence n-3 and n-6 PUFA have on the acyltransferase enzymes, however, it is
plausible that changing the diet PUFA composition may have the greatest impact on
membrane fatty acid composition.
Many previous animal and human studies have established that dietary fatty acid
composition effects tissue cell membrane fatty acid composition (for example, Lands et
al. 1990; Pan and Storlien 1993; Ayre and Hulbert 1996a; Ayre and Hulbert 1996b;
Andersson et al. 2002); however there have been few previous studies in rodents that
have quantified the effect of a wide range of dietary fatty acids on the cell membrane
fatty acid composition of a wide range of tissues. For example, many studies have
considered only a single tissue (e.g. McLennan 1993; Ayre and Hulbert 1996b) or only
the effect of a particular fat, such as essential fats (e.g. Stubbs and Kisielewski 1990;
Broughton et al. 1991).
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A problem with many previous studies in rodents is that the experimental
conditions do not allow for extrapolation to the “normal” human condition. Differences
in lipid metabolism exist between humans and rodents, with rodents having a higher
capacity to convert 18-carbon PUFA to their longer-chain metabolites, due to increased
Δ5-desaturase activity (Willis 1981). Dietary 18:3n-3 has been shown to increase mice
plasma levels of 20:5n-3 to a greater extent than in humans, however the impact on
plasma 22:6n-3 and 20:4n-6 was similar for mice and humans (Whelan and Jones
2006). This previous study concluded that rodent diets including n-3 PUFA based on a
% of total energy are most suitable for determining equivalent doses for humans, with
achievable human doses for 18:3n-3 <2 %en (% of daily energy intake; Whelan and
Jones 2006).
These differences in lipid metabolism between rats and humans may be due to
the relationship between body size and the rate of metabolic processes. That is,
metabolic processes are slower in large mammals compared to small mammals (Kleiber
1961). So, for example, eight weeks in a rat is equivalent to ~ one year in a human (in
terms of metabolic rates). This emphasises the importance of taking relative time into
account when extrapolating from rodents to humans. There is a lot of variation between
rodent studies in the length of time that animals are fed experimental diets, which can
range from 1 week (e.g. Fickova et al. 1998) up to 20 weeks (e.g. Lands et al. 1990).
This can affect the degree to which membrane fatty acid composition is modified.
The total fat content of the diet is also important for extrapolation from rodent
studies to the “normal” human situation. The recommended fat intake for humans is 2035%en (NHMRC 2003; Lichtenstein et al. 2006; Ryan-Harshman and Aldoori 2006).
Many previous rodent studies investigating the influence of diet fatty acid profile on
membrane fatty acid composition have employed high-fat diets, containing from 41 –
59%en from fat (for example, Storlien et al. 1991; Vajreswari and Narayanareddy 1992;
Pan and Storlien 1993; Liu et al. 1994; Fickova et al. 1998). This is clearly not
comparable to normal human conditions.
Another problem is that many rodent studies investigating the influence of
dietary n-3 and n-6 PUFA use 20-22C n-3 PUFA from fish oil and the 18C n-6 PUFA
found in vegetable oils, such as corn oil or sunflower oil (for example, Broughton et al.
1991; Ayre and Hulbert 1996a; Ayre and Hulbert 1996b; Fickova et al. 1998; Soriguer
et al. 2000). This makes comparisons between studies difficult as these diet PUFA
sources are not equivalent in terms of fatty acid metabolic pathways. Furthermore, the
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“normal” diet of laboratory rats consists of 18C PUFA, with no 20-22C PUFA present
(see fatty acid composition of the rat chow “initial” group in Table 2.4).
The relationship between membrane and dietary fatty acid composition can be
viewed using the classic conformer / regulator concept, where membrane fatty acid
composition is plotted against dietary fatty acid composition (Figure 1.5). The slope of
the resulting curve indicates how responsive the membrane is to diet fat profile. For
example, a slope of 1 indicates a strict membrane conformer (i.e. the membrane is
influenced by diet fat profile) and a slope of zero indicates a strict membrane regulator
(i.e. membrane is not influenced by diet composition).

Figure 1.5 Concept of conformers & regulators used to quantify the influence of diet fat
profile on membrane fatty acid composition, where a slope of 1 indicates that membrane
is conforming to diet fat (red line), while a slope of 0 shows that the membranes is
perfectly regulating it’s fatty acid composition (black line; see Campbell et al. 1999).
This concept was introduced in a review by Hulbert et al. (2005) where the
relationship between dietary fatty acid and membrane composition was plotted for data
taken from previous studies by other authors (see Figure 1.6). Membrane lipid data
included those for liver plasmalemma (Clamp et al. 1997), cardiac sarcolemma
(Vajreswari and Narayanareddy 1992) as well as cerebral synaptosomes and myelin
(Srinivasarao et al. 1997). The slope of each relationship denotes the degree of
conformity between the diet and membrane fatty acid composition. It can be seen from
Figure 1.6 that the SFA and MUFA content of membranes for all tissue types is
regulated relatively constant across a wide range of dietary SFA and MUFA amounts
(i.e. slopes close to zero). The n-3 PUFA and n-6 PUFA for all membranes seem to be
more responsive to dietary fatty acid composition, with slopes up to 0.22 for n-6 PUFA
and 0.75 for n-3 PUFA. However, the diet n3/n6 ratio seems to have the greatest
influence on the fatty acid composition of various cellular membranes (Figure 1.6b),
with slopes ranging from 0.24 – 1.72. As higher animals can produce both SFA and
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MUFA de novo it makes sense that levels of these fatty acids in the cell membrane
would be regulated, whereas the n-3 and n-6 PUFA relies on dietary intake to be able to
incorporate these fatty acids into cellular membranes. The competition between n-3 and
n-6 PUFA for incorporation into phospholipids indicates the importance of the relative
abundances of these two PUFAs in the diet and the increased sensitivity of the
membrane to their dietary fatty acid composition.

Figure 1.6 Changes in membrane fatty acid compositions from various tissues in
relation to the dietary fatty acid composition: a) SFA, MUFA, n-6 PUFA and n-3
PUFA; b) n3/n6 ratio; values represent the slope of each relationship; modified from
Hulbert et al. (2005).
From Figure 1.6 it can be concluded that the n3/n6 ratio of the diet has the
greatest influence on membrane fatty acid composition. However, the slope of this
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relationship is largely determined from the data of one high n3/n6 diet for all four
studies (see Figure 1.6b) and this high n3/n6 diet is a fish oil diet. This highlights the
common problem encountered when attempting to quantify the influence of diet fat
profile on membrane fatty acid composition, with n-3 PUFA either absent from the diet
or present at high levels in fish oil. Interpretation of the n3/n6 ratio used to describe the
interaction between n-3 and n-6 PUFA in this figure can also be difficult (as discussed
in the next section), however, expressing the n-3 and n-6 PUFA as proportions can
overcome these problems.

1.7 Essential Fatty Acids in the Diet
“PUFA balance” versus the “n-6/n-3 PUFA ratio”
Traditionally the interaction between n-3 and n-6 PUFA has been described
using the n-6/n-3 ratio, particularly when describing the affect of diet fat profile on
membrane composition (for example, Lands et al. 1990; Pan and Storlien 1993).
However, the use of ratios can create some mathematical difficulties due to their nonlinear nature (i.e. the range of ratios is zero to infinity).
Throughout this thesis the term “PUFA balance” (defined as “n-3 PUFA as % of
total PUFA”) will be used instead of the n-6/n-3 ratio to analyse the interaction between
n-6 PUFA and n-3 PUFA. “PUFA balance” is analogous to a proportion (or a ratio
where the two values sum to 100%) and this creates a linear scale ranging from 0 to
100, making comparisons between values much more simple.
The term “PUFA balance” will be used here because as a "proportion" it
provides advantages over the more common use of "ratios". For example, using the n3/n-6 ratio, when n-6 PUFA dominates in a mixture of the two, the value of the ratio
will be between 0 and 1, however when n-3 is the dominant PUFA in the mixture the
range of values will be 1 to ∞.
Comparing (or averaging) ratios can be complicated, whereas the advantage of
the PUFA balance is that the range of values are more even, ranging from 0% – 49%
when n-6 PUFA dominate a mixture and 51% -100% when n-3 PUFA are dominant.
Another advantage of using PUFA balance is that it can be more readily used to average
out dietary intake. For example, if a subject consumes two meals both with the same
total PUFA content but one having a PUFA balance of 10% (n-3/n-6 ratio = 0.11) and
the other 90% (n-3/n-6 ratio = 9.0), then the average PUFA balance of these meals is
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50%, which is the actual situation of equal consumption of both PUFA types. However,
averaging the n-3/n-6 ratios (=4.6) does not give the same conclusion. These
considerations suggest that PUFA balance has benefits in easier analysis of diets from
the combinations of foods and meals.
For these reasons the term PUFA balance will be used to describe the interaction
between n-3 and n-6 PUFA for both diet and membrane fatty acid composition
throughout this thesis.
Diet Fat Sources
As the fatty acid profile of the diet can influence membrane fatty acid
composition, it is important to understand the sources of the different diet fat types. As
discussed earlier, the diet n-3 PUFA an n-6 PUFA are particularly important in
determining membrane composition, thus in this section attention will be paid to these
essential fatty acids.
Although not essential dietary requirements, saturated and monounsaturated fats
can be acquired from various sources in the diet. MUFA are found in vegetable oils,
notably olive and canola oils (75 and 61% of total fatty acids respectively), and also
meat products (49% of total fatty acids in beef tallow), nuts and avocadoes. SFA are
common in dairy products, meat and animal products and a number of vegetable oils,
including coconut and palm oils (91 and 51% of total fatty acids respectively).
Essential fatty acids can be obtained from plant sources, with 18:3n-3 found
mostly in the green leafy plants and 18:2n-6 the main component of vegetable oils, nuts
and seeds. Linolenic acid (18:3n-3) is found in flaxseed, hempseed and canola oils (57,
25 and 10 % of total fatty acids respectively), while linoleic acid (18:2n-6) is found in
safflower, sunflower and soybean oils (77, 66 and 54 % of total fatty acids respectively)
(Meyer et al. 1999).
The PUFA balance of some common food items is shown in Figure 1.7. These
plots show that vegetable oils and grain-based foods are highly biased towards n-6
PUFA, for example, safflower oil has a PUFA balance of 0% (or n-3 PUFA 0% : n-6
PUFA 100%). The green-leaf vegetables differ quite substantially, with n-3 PUFA
making up most of the total PUFA, for example, spinach has a PUFA balance of 82%.
Animal tissues are the main source of dietary preformed 20-22C PUFA. Fish is a
rich source of long-chain n-3 PUFA, including 20:5n-3 and 22:6n-3. Figure 1.7 shows
the PUFA balance of some common meats and animal fats, with a higher PUFA balance
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seen in lamb, butter and cheese (34%, 31% and 43% respectively), while pork, chicken
and lard consist of a lower balance of n-3 PUFA relative to n-6 PUFA (PUFA balances
10%, 6% and 9% respectively). The PUFA balance of meat depends on an animal’s
diet, with a higher PUFA balance in grass fed beef compared to grain feeding (31% and
11% respectively; see Figure 1.7 and Cordain et al. 2002).

Figure 1.7 PUFA balance (n-3 PUFA as % of total PUFA) calculated for some common
food items (including the amount of total PUFA (g/100g)). (Calculated from Gerrior et
al. 2004; FSANZ 2006)
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Changes in the Human Food Chain & Health Implications
Humans evolved consuming a diet with about equal proportions of n-3 and n-6
PUFA, with the PUFA balance estimated to be ~40% (calculated from Cordain 2002).
However major changes have occurred in the past 150 years (Simopoulos 1999) with
increasing levels of n-6 PUFA and concomitant decreases in n-3 PUFA in the diets of
most humans (Figure 1.8). The total amount of fat consumed by humans has also
increased up to ~40%en, which is well above the recommended levels of 20-35%en for
fat intake (NHMRC 2003; Lichtenstein et al. 2006).
Availabilities in fats in the United States foods supply from 1909 to 1999 have
changed dramatically with total PUFA availability increased from 12g.person-1.day-1 up
to 34g.person-1.day-1, which is predominantly due to the increase in the high n-6 PUFA
soybean oil (Hibbeln et al. 2002). Consequently, current U.S. dietary fat intakes have a
much lower PUFA balance, with n-3 PUFA making up only 9.5% of the total PUFA
consumed (calculated from Ervin et al. 2004). U.S. intakes of 18:2n-6 are about 7%en.
Of the n-3 PUFA that is consumed in the U.S. about 1.3g/d (<1%en) is consumed as
18:3n-3 while only ~100mg/d is a combination of the long-chain 22:6n-3 and 20:5n-3
(Arterburn et al. 2006). This shows that the average human n-3 PUFA intake is
primarily 18:3n-3. Australian intakes of n-3 PUFAs in 2000 were also low, at 0.6%
energy (Ratnesar et al. 2000).

Figure 1.8 Changes in human dietary fat intakes over time. (CAD; coronary artery
disease) (Leaf and Weber 1987).

20

Current fatty acid intake recommendations vary between different governing
groups and there are no specific recommendations for the balance of n-3 PUFA and n-6
PUFA in the diet. The Australian and New Zealand Government recommendations from
2005 are for 610mg and 410mg 20-22C n-3 PUFA/day for men and women respectively
with an 18:2n-6 intake of 4-10%en and 18:3n-3 0.4-1.0%en. The International Society
for the Study of Fatty Acids and Lipids (ISSFAL) recommends 500mg 20-22C n-3
PUFA/day; 18:2n-6 of 2%en; 18:3n-3 of 0.7% en for healthy adults (see
www.issfal.org/index.php/pufa-recommendations-mainmenu-146; accessed 10/01/11 ).
From this it is possible to calculate the recommended diet PUFA balance to be ~30%,
which indicates that current dietary intakes of 9.5% are well below the recommended
levels.
Increasing the diet PUFA balance above the current levels is made difficult by
the lack of information provided to consumers. Food labelling only provides the total
SFA, MUFA and PUFA content of food products in most countries. The different
physiological activities of n-3 PUFA and n-6 PUFA mean that these fats need to be
identified separately on food labels or better still, the balance between these n-3 and n-6
PUFA so that we can more effectively increase our diet PUFA balance (see Turner et al.
in press). This is particularly important as the imbalance between diet n-3 and n-6
PUFA has been associated with a number of diseases which have become prevalent in
today’s society.
Metabolic disorders are reaching epidemic proportions in many countries, for
example, in the U.S. 65% of the population are overweight, 21% obese and 24% have
the metabolic syndrome (Bloomgarden 2005). These trends are evident worldwide,
particularly in Western nations, including Australia (Dunstan et al. 2001). Conditions
such as dyslipidaemia, hypertension, inflammation, depression, abdominal obesity, type
2 diabetes and cardiovascular disease have been associated with the imbalance between
dietary n-3 and n-6 PUFAs that has developed over the past 150 years (McLennan
1993; Rivellese and Lilli 2003; Bourre 2005; Nettleton and Katz 2005).
The appearance of insulin resistance is an important early indicator for the
metabolic syndrome, which includes a number of conditions, such as dyslipidaemia,
hypertension, inflammation, abdominal obesity and type 2 diabetes (Reaven 1988;
Simopoulos 1999). Previous studies in rodents have shown that increasing the diet
PUFA balance (by increasing either diet 20-22C n-3 PUFA or diet 18:3n-3) improves
insulin sensitivity (see Storlien et al. 1987; Storlien et al. 1991; Liu et al. 1994).
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Increased insulin sensitivity is associated with increased membrane n-3 PUFA
content (Ghafoorunissa et al. 2005), however the mechanism for this is currently
unknown. Membrane n-3 PUFA may alter the physical properties of the lipid
membrane, resulting in increased molecular activity of insulin receptors and glucose
transporters and thus increased insulin sensitivity. This has been supported by a number
of human studies that have shown that increased PUFA (Borkman et al. 1993), and
more particularly n-3 PUFA (Kriketos et al. 1996; Riccardi et al. 2004) in the skeletal
muscle membrane is associated with increased insulin sensitivity.
Diet PUFA balance may also influence the development of obesity, which is
thought to be one of the most critical factors in the emergence of metabolic diseases
(Dunstan et al. 2001; Kahn et al. 2006). The rates of oxidation of different dietary fats
may influence amounts of body mass gain, as storage rates of fats will be inversely
related to oxidation (Pan et al. 1994; DeLany et al. 2000). Increasing diet n-3 PUFA
levels has been associated with reduced body mass gain in genetically obese ob/ob mice
(Cunnane et al. 1986), with similar results in rats fed diets with a high PUFA balance
(Pan and Storlien 1993).
Diet PUFA balance has also been implicated in changes in basal metabolic rate
(BMR). Studies in a number of species indicate that increasing the n-3 PUFA content of
the diet relative to n-6 PUFA results in increased BMR in rats (Shimomura et al. 1990;
Pan and Storlien 1993; Takeuchi et al. 1995), birds (Newman et al. 2002), baboons
(Savage and Goldstone 1965) and humans (Couet et al. 1997). This influence on
metabolic rate is likely due to changes in the membrane fatty acid composition, however
to my knowledge no previous study has explicitly quantified the effect of diet fat profile
on both membrane composition and metabolic rate.
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1.8 Aim and Design of Study
The aim of this study was to examine and quantify the influence of the fatty acid
composition of diet on the fatty acid composition of membranes, as well as the effect on
metabolic rate.
In this study rats were used as the model organism with the purpose of
determining the relationship for mammals in general, and especially humans. To allow
best extrapolation to the normal human situation I implemented the following
conditions:
•

The rats used were young adults of an outbred strain (analogous to humans) to
allow for some genetic variation.

•

The fat was present in the diet at moderate levels (25% total energy), to avoid
the development of high-fat diet-induced obesity.

•

The dominant fats in the diets were 18-carbon. This is the normal situation for
the diet of both rats and humans.

•

Diets were isocaloric and designed to include a wide range of all fat types (SFA,
MUFA, n-6 PUFA and n-3 PUFA). Variation in diet fatty acid composition was
achieved by mixing different proportions of various oils, paying particular
attention to the balance between n-3 PUFA and n-6 PUFA.

•

Diets were fed for 8 weeks to assess the steady state relationship between diet
and membrane composition. This time period is equivalent (in terms of relative
metabolic rates) to approximately one year in humans.
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Chapter 2

Methods

All experiments were approved by the University of Wollongong Animal Ethics
Committee (AE 07/04).

2.1 Experimental Animals
Seven-week-old male Sprague–Dawley rats were purchased from Gore Hill
Research Laboratories, Sydney. At 7-weeks old the rats were young adults with some
potential for growth still available. This provided an increased opportunity to highlight
any diet-induced changes in total body fat content (described below).
Rats were housed at 23ºC and an average relative humidity of ~ 40% and kept in
individual cages under a 12:12 h light:dark schedule. Cages measured approximately 44
x 31 x 27cm (length x width x height) and contained wood shavings for bedding, as well
as a plastic tube for environmental enrichment. Water was provided ad libitum. Before
dietary manipulation, all rats were allowed to adjust to these conditions for a week and
fed ad libitum on commercial rodent diet (Y.S. Feeds, Young, Australia), the
composition of which was 13% en (percentage energy) fat, 22% en protein and 65% en
carbohydrate (see Appendix 1 for detailed composition of initial diet).
Following this week rats were randomly assigned to either the initial group or
one of twelve experimental diets. The initial group (n=6) were euthanased to determine
body composition and metabolic rate prior to dietary intervention. The remaining rats
were provided with one of twelve different diets for 8 weeks (n=6 per group). A dietary
period of 8 weeks was chosen to allow membrane fatty acid composition to reach a
steady state in response to changes in diet fat profile. Previous studies in rats have
shown that changes in membrane fat profile appear as early as one week after dietary
manipulation (Fickova et al. 1998; Artmann et al. 2008).
Rats were weighed weekly to ±0.01g using an Ohaus Explorer Balance. The
average body mass of all rats at the beginning of the experiment was 296 ± 3g (n=78)
and at the end of the diet treatment the average body mass was 528 ± 8g (n=72).

2.2 Experimental Diets
Rats were fed ad libitum for 8 weeks on one of twelve complete diets, the
ingredients of which are shown in Table 2.1. All diets were isocaloric and had a total
energy content of 18.51KJ/g. Diets differed only in their fatty acid profile. A wide range
25

of SFA, MUFA, total PUFA, n-3 PUFA, n-6 PUFA and PUFA balance was achieved by
mixing various proportions of the following oils: flaxseed oil, safflower oil, olive oil,
coconut oil, and beef dripping.
Table 2.1 Ingredients of the twelve experimental diets; including the amounts and
energy composition.
Ingredients

Amount (g/kg)

Oil Mix

120

Sucrose

82

Cornstarch

493

Casein

155

Fibre

50

Mineral Mix

40

Vitamin Mix

10

Gelatin

50

Energy Contribution (% total energy)
Carbohydrate

55

Protein

20

Fat

25

Sucrose was obtained from CSR White Sugar, Yarraville, VIC, Australia; maize starch from Fielders
Wheaten Cornflour, PFD Food Services, Wollongong, NSW, Australia; casein from Rogers & Co. Edible
Rennet, Brighton, QLD, Australia; fibre was Vitacel Wheat Fibre Type WF600 (generously donated by
Nutrimonde, Mascot, Australia); mineral mix (AIN-93M) and vitamin mix (AIN-93-VX) from MP
Biomedicals, Seven Hills, NSW, Australia and gelatin from Gelita Gelatine Edible powder, Krio Krush,
Kingsgrove, NSW, Australia.

The oils were acquired from the following sources: flaxseed oil from Nutralife HiOmega, Moorebank, NSW, Australia; safflower oil from Healthy Life Cold Pressed,
Milperra, NSW, Australia; olive oil from Lupi Cold Pressed Extra Virgin, Gosford,
NSW, Australia; coconut oil from Aclara Health Organic Gourmet Cold Pressed Extra
Virgin, Mount Crosby, QLD, Australia; and beef dripping from Allowrie Prime,
Rowville, VIC, Australia.
The fatty acid composition of each oil is provided in Table 2.2. The fatty acid
profile of each diet was achieved by mixing these oils in the percentages shown in
Table 2.3. The oils used in this study contain different non-saponifiable compounds,
including sterols and tocopherols, which were not measured. These compounds could
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potentially influence the results, however, due to cost constraints pure oils could not be
implemented.
Table 2.2 Fatty acid composition of each oil used in the “oil mix” in the experimental
diets.
Oil
8:0
10:0
12:0
14:0
16:0
17:0
18:0

Flaxseed
0.0
0.0
0.0
0.0
4.4
0.0
2.3

Safflower
0.0
0.0
0.0
0.1
7.2
0.0
2.3

Olive
0.0
0.0
0.0
0.0
14.1
0.1
3.1

Coconut
11.8
7.9
51.3
16.5
6.3
0.0
2.1

Beef dripping
0.0
0.0
0.0
3.2
26.7
1.7
19.0

16:1n-7
18:1n-9
18:1n-7

0.0
9.9
0.4

0.5
13.4
0.8

1.2
69.1
0.0

0.0
3.5
0.0

2.7
40.2
1.6

18:2n-6
18:3n-3

11.4
71.0

74.5
0.1

10.9
0.6

0.6
0.0

1.5
0.4

SFA
MUFA
PUFA
n-6 PUFA
n-3 PUFA

7.0
10.5
82.6
11.4
71.2

10.4
15.0
74.6
74.5
0.1

17.9
70.6
11.5
10.9
0.6

95.9
3.5
0.6
0.6
0.0

51.6
46.3
2.1
1.7
0.4

PUFA balance

86.2

0.1

5.2

0.0

20.3

Values are expressed as % of total fatty acids except PUFA balance, which is n-3 PUFA as % of total
PUFA.

Table 2.3 Proportions of oils used in “oil mix” for each of the twelve experimental
diets.
Diet

Flaxseed

Safflower

Olive

Coconut

Beef dripping

1

61

0

39

0

0

2

1

42

2

0

55

3

8

92

0

0

0

4

1

1

6

0

92

5

10

0

90

0

0

6

41

29

30

0

0

7

42

33

0

25

0

8

5

2

0

93

0

9

35

27

0

0

38

10

78

22

0

0

0

11

30

0

0

70

0

12

98

0

0

2

0

Values are expressed as % of total oil mix
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In order to accurately measure food intake each rat was provided with dried
food. All food was dried at room temperature on wire mesh shelves for 8 days.
Following this drying the food was stored in sealed containers and kept at -20ºC until
required. Drying resulted in a loss of 24.8 ± 0.7 % of the food’s original weight. There
was no difference in the fatty acid composition of freshly-made and dried food for all
diets (results not shown).
Each individual rat was provided daily with a known amount of fresh dry food
(excess to daily intake). Remaining food from the previous day was weighed to ±0.01g
using an Ohaus Explorer Balance and daily food consumption calculated. Preliminary
investigation showed that negligible food was lost from the hopper (data not shown).
Total food consumed for each week was calculated as the sum of the daily intakes.
The fatty acid composition of each diet was measured by methods described in
section 2.6. It is presented here rather than in the results section. The fatty acid
composition of each diet is presented in Table 2.4. The relative proportions of diet SFA,
MUFA, n-6 PUFA, n-3 PUFA are presented in Figure 2.1 in the bar graph, and the
PUFA balance of each diet is shown in the upper pie graph section. The fatty acid
composition of the initial rat chow group is also included in Table 2.4 and Figure 2.1.
The experimental diets were numbered in order of increasing PUFA balance (1-86%)
and are presented in Table 2.4 and Figure 2.1. The amount of each fat type varied
between the individual diets. SFA content ranged 8-88% of total fatty acids, MUFA 665%, total PUFA 4-81%, n-6 PUFA 3-70% and n-3 PUFA 1-70%. Fat types were
mixed in different combinations to achieve a great degree of variation between diets.
For example, diets 11 and 12 both have very high PUFA balance (84 and 86%
respectively), but diet 11 has very high SFA content (59%), while diet 12 has a high
proportion of total PUFA (80%). The average fatty acyl chain length was 17·0 ± 0·2
carbons for all diets. No 20-carbon or 22-carbon PUFA were included in the diets.
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Table 2.4 Fatty acid composition (% of total fatty acid) of experimental and initial diets; values are mean ± S.E.M.; n=2, except for diets 1, 2, 5, 7 and 12:
n=3 and initial diet: n=1.
Diet
8:0
10:0
12:0
14:0
16:0
17:0
18:0

1
0.0 ± 0.0
0.0 ± 0.0
0.0 ± 0.0
0.1 ± 0.0
10.2 ± 0.2
0.1 ± 0.0
2.6 ± 0.0

2
0.0 ± 0.0
0.1 ± 0.0
0.2 ± 0.1
1.9 ± 0.1
18.6 ± 0.4
0.9 ± 0.0
11.2 ± 0.0

3
0.0 ± 0.0
0.0 ± 0.0
0.0 ± 0.0
0.1 ± 0.0
7.4 ± 0.4
0.0 ± 0.0
2.3 ± 0.1

4
0.0 ± 0.0
0.0 ± 0.0
0.1 ± 0.0
3.0 ± 0.1
26.3 ± 0.8
1.5 ± 0.0
17.3 ± 0.0

5
0.1 ± 0.1
0.0 ± 0.0
0.1 ± 0.1
0.1 ± 0.0
13.3 ± 0.1
0.1 ± 0.0
3.0 ± 0.0

6
0.0 ± 0.0
0.0 ± 0.0
0.0 ± 0.0
0.1 ± 0.0
8.3 ± 0.4
0.1 ± 0.0
2.5 ± 0.1

7
3.7 ± 0.2
2.4 ± 0.1
12.9± 0.1
5.0 ± 0.0
6.2 ± 0.2
0.0 ± 0.0
2.3 ± 0.0

8
15.6 ± 0.2
10.3 ± 0.1
30.5 ± 0.2
19.8 ± 0.0
8.6 ± 0.0
0.0 ± 0.0
2.8 ± 0.0

9
0.0 ± 0.0
0.0 ± 0.0
0.1 ± 0.0
1.3 ± 0.1
13.9 ± 0.5
0.6 ± 0.0
8.4 ± 0.2

10
0.0 ± 0.0
0.0 ± 0.0
0.0 ± 0.0
0.1 ± 0.0
5.4 ± 0.5
0.1 ± 0.0
2.5 ± 0.2

11
10.8 ± 0.1
7.1 ± 0.0
26.9 ± 2.4
14.4 ± 0.3
6.9 ± 0.2
0.0 ± 0.0
2.5 ± 0.1

12
0.3 ± 0.0
0.2 ± 0.0
1.3 ± 0.2
0.5 ± 0.1
4.5 ± 0.1
0.0 ± 0.0
2.3 ± 0.0

Initial
0.0
0.2
0.2
0.2
16.0
0.1
2.5

16:1n-7
18:1n-9
18:1n-7

0.8 ± 0.0
34.7 ± 0.3
0.3 ± 0.3

1.9 ± 0.1
28.8 ± 0.5
0.5 ± 0.3

0.5 ± 0.0
12.9 ± 0.4
0.3 ± 0.1

2.8 ± 0.3
41.4 ± 1.1
0.6 ± 0.6

1.1 ± 0.0
62.9 ± 0.2
0.0 ± 0.0

0.5 ± 0.0
27.9 ± 0.3
0.4 ± 0.4

0.2 ± 0.0
9.3 ± 0.2
0.3 ± 0.0

0.0 ± 0.0
5.4 ± 0.0
0.1 ± 0.0

1.3 ± 0.1
21.9 ± 0.6
0.3 ± 0.3

0.2 ± 0.0
10.9 ± 0.0
0.3 ± 0.1

0.0 ± 0.0
6.1 ± 0.2
0.2 ± 0.0

0.0 ± 0.0
9.8 ± 0.0
0.3 ± 0.0

0.1
24.1
1.9

18:2n-6
18:3n-3

49.9 ± 0.2
0.3 ± 0.0

33.2 ± 0.2
1.1 ± 0.1

69.8 ± 0.0
5.7 ± 0.1

2.9 ± 0.0
1.2 ± 0.1

11.0 ± 0.0
7.6 ± 0.0

30.2 ± 0.2
29.2 ± 0.6

28.9 ± 0.4
28.2 ± 0.0

3.4 ± 0.0
3.3 ± 0.0

25.4 ± 0.0
25.4 ± 0.3

25.0 ± 0.2
54.9 ± 0.9

4.0 ± 0.1
20.9 ± 1.2

11.0 ± 0.0
69.1 ± 0.3

47.8
5.1

SFA
MUFA
PUFA
n-6 PUFA
n-3 PUFA

13.7 ± 0.2
36.1 ± 0.1
50.3 ± 0.2
49.9 ± 0.2
0.3 ± 0.0

33.6 ± 0.5
32.0 ± 0.4
34.3 ± 0.2
33.2 ± 0.3
1.1 ± 0.1

10.4 ± 0.3
14.0 ± 0.3
75.5 ± 0.0
69.8 ± 0.0
5.7 ± 0.1

49.4 ± 0.9
46.3 ± 0.9
4.4 ± 0.0
3.1 ± 0.1
1.3 ± 0.1

17.1 ± 0.3
64.3 ± 0.3
18.6 ± 0.0
11.0 ± 0.0
7.6 ± 0.0

11.4 ± 0.3
29.1 ± 0.1
59.5 ± 0.4
30.2 ± 0.2
29.3 ± 0.6

32.9 ± 0.6
10.0 ± 0.2
57.1 ± 0.4
28.9 ± 0.4
28.2 ± 0.0

87.8± 0.1
5.5 ± 0.0
6.7 ± 0.1
3.4 ± 0.0
3.3 ± 0.0

24.9 ± 0.7
24.2 ± 0.4
50.9 ± 0.3
25.4 ± 0.0
25.5 ± 0.3

8.4 ± 0.6
11.5 ± 0.1
80.1 ± 0.7
25.1 ± 0.1
55.1 ± 0.9

68.8 ± 1.6
6.3 ± 0.2
24.9 ± 1.4
4.0 ± 0.1
21.0 ± 1.3

9.4 ± 0.3
10.3 ± 0.0
80.3 ± 0.3
11.1 ± 0.1
69.2 ± 0.3

20.2
26.6
53.1
47.9
5.3

0.7 ± 0.1

3.2 ± 0.4

7.5 ± 0.1

29.9 ± 2.2

41.0 ± 0.2

49.2 ± 0.7

49.4 ± 0.4

49.6 ± 0.2

50.1 ± 0.3

68.7 ± 0.5

84.0 ± 0.3

86.2 ± 0.0

9.9

PUFA
Balance
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Figure 2.1 Fatty acid profile (% of total fatty acids) and PUFA balance (n-3 as % total PUFA) of initial diet (13 %en fat) and twelve experimental diets
(25 %en fat); see Table 2.4 for values.
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2.3 Metabolic Rate
After 8 weeks of feeding on the experimental diets, oxygen consumption of each
rat was continuously measured over 24 hours using open-system respirometry. Each
day, rats from three different diets were placed in individual metabolic chambers inside
a temperature-controlled cabinet maintained at 23ºC with a 12:12 h light:dark schedule
(i.e. conditions identical to those in the animal house during the experimental diet
period). No food or water was provided during this time. Metabolic chambers were
clear perspex cylinders (455 x 190mm; length x diameter) with metal mesh flooring,
which included a solid metal floor section, as required by the animal ethics committee
(approximately 1/3 of the total area). This area of the chamber was also covered
externally with a cloth. The metabolic chambers are shown in Figure 2.2 (cloth not
present).

Figure 2.2 Metabolic chambers used to measure 24 hour oxygen consumption of three
rats at a time inside temperature-controlled cabinet maintained at 23ºC.
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Inlet and outlet oxygen content of each metabolic chamber was measured using a
Sable Systems Oxzilla Oxygen Analyser (Sable Systems International, Henderson,
Nevada, USA). Air was supplied to each chamber at a rate of 820 ml/min using a Sable
Systems Flow Meter (Sable Systems International, Henderson, Nevada, USA). Oxygen
consumption in each chamber was selectively sampled for 10 minutes every 30 minutes
using a Sable Systems Respirometer Multiplexer V2.0 (Sable Systems International,
Henderson, Nevada, USA).
Data was collected using a Datataker DT500 (Thermo Fisher Scientific Australia
Pty Ltd, Scoresby, Australia) and analysed using LabAnalyst software (Warthog
Systems, University of California, Riverside, USA). Results were analysed as 5 minute
blocks and daily VO2 was calculated as the average value of the entire 24 hour period
(daily metabolic rate or DMR). Minimum VO2 was calculated as the average of the
lowest five values (minimum metabolic rate or MMR). These values were obtained
towards the end of the 24 hour period of measurement at which time the rats were
resting and fasted. These values, however, do not correspond to BMR, as rats were not
in their thermoneutral zone and were thermoregulating. All metabolic rate
measurements were expressed as L O2.day-1 or ml O2.hr-1.g-1 total body mass.

2.4 Tissue Collection
Following measurement of their 24 hour metabolic rate rats were euthanased via
intraperitoneal injection (200 mg/kg body mass) of Lethabarb (sodium pentobarbitone,
Virbac, Peakhurst, NSW, Australia). Blood was removed via intra-ventricular puncture
with a heparin-lined syringe and immediately spun at 13.2 rcf for 10 minutes to separate
plasma and RBC. Approximately 1-3mls of plasma and 1ml of RBC was collected,
snap-frozen in liquid nitrogen and stored at -80ºC for later analysis. Spare plasma
(~2mls per rat) was stored in liquid nitrogen for potential future analysis.
Following this, the tissue samples were removed, placed on ice, weighed and
similarly snap-frozen and stored at -80ºC. Tissues collected included liver, heart,
perirenal adipose tissue, skeletal muscle (medial gastrocnemius) and brain (cerebral
hemisphere). Tissues were weighed to ±0.1mg using a Chyo Balance (model JL-200;
Japan). Aliquots of ~200mg of each tissue were collected for fatty acid analysis. A
further aliquot of ~1g of spare tissue was collected and stored at -80ºC (liver, heart,
adipose tissue, skeletal muscle) or in liquid nitrogen (brain only). Any excess tissue was
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returned to the carcass and the remaining rat carcass was stored at -20ºC for later
analysis of whole body fat content (NB. rats were fasted for at least 24 hours prior to
euthanasia, so it is unlikely the gut contained any significant amount of food).

2.5 Total body fat content
Total body fat content of each rat was measured using Soxhlet extraction. Rat
carcasses (including gut and hair) were cut-up and then roughly homogenised using an
industrial-strength meat processor (Robot Coupe, R10 Series5; France) at 3000rpm. The
meat processor was cleaned after each rat processed and the rough homogenates were
refrozen at -20ºC in plastic resealable bags. Homogenised rat carcasses were partially
defrosted and weighed before further homogenisation with dry ice to produce a frozen,
powdered homogenate. Sub-samples of this homogenate were transferred into two preweighed cellulose extraction thimbles (Whatman, Crown Scientific, Moorebank, NSW,
Australia). Carbon dioxide from the dry ice was allowed to evaporate from the sample
overnight at 4ºC. Samples were then freeze-dried for 25 hours (to provide dry mass) and
processed in the Soxhlet apparatus for 5 hours using 40-60ºC petroleum ether
(Chemsupply, Crown Scientific, Moorebank, NSW, Australia). Following removal of
extraction thimble from the Soxhlet apparatus, remaining solvent was evaporated from
each sample overnight prior to weighing (to obtain fat-free dry mass). The average
difference between all replicates was 2% and this was deemed to be an acceptable level
of variance. Total body fat content was extrapolated from the average thimble fat
content.

2.6 Fatty Acid Analysis
All solvents used were HPLC grade (Crown Scientific, Moorebank, Australia)
and contained 0.01% w/v butylated hydroxytoluene (Sigma Aldrich, Sydney, Australia).
The approximate amount of each tissue used for the fatty acid analysis was: 200mg of
skeletal muscle, heart, brain and liver, 100mg for adipose tissue, 1ml of plasma, and
400μL

for

red

blood

cells

(RBC).

Total

lipids

were

extracted

using

chloroform:methanol (2:1, v:v) and glass/glass homogenizers as previously described
(Folch et al. 1957). RBC samples were lysed in 1ml Milli-Q water prior to lipid
extraction using chloroform:methanol (2:1, v:v). Phospholipids were separated from
total lipids using Sep-Pak® Classic Silica Cartridge (Waters, Rydalmere, Australia) and
15ml hexane. The triglyceride fraction was also collected for adipose tissue and plasma,
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using 30ml and 15ml ethyl acetate respectively. Phospholipids and/or triglycerides were
transmethylated (Lepage and Roy 1986) and fatty acid methyl esters were measured by
gas chromatography (Shimadzu GC-17A, Rydalmere, New South Wales, Australia)
using a Varian WCOT Fused Silica Column (50m x 0.25mm ID, CP7419, Sydney, New
South Wales, Australia) with the following temperature program: 150°C initial
temperature, 17.5°C/min to 170°C, 0.5°C/min to 178°C, 15°C/min to 222°C and
2°C/min to 232°C. The split ratio was set at 25:1 for all analyses except for adipose
tissue phospholipids, which were analysed with a split ratio of 10:1. Individual fatty
acids were identified by comparison with an external standard (FAME Mix C4-C24;
Sigma Aldrich, Sydney, Australia) and then expressed as mol % of total fatty acids.

2.7 Statistical Analysis
Statistical analysis was performed using JMP 5.1 (SAS Institute Inc. NC, USA).
All results are expressed as means ± S.E.M. with P<0.05 set as the level of significance.
The only exception to this was for the weekly comparisons of body mass (g), food
intake (g) and food conversion efficiency (weekly body mass gain / weekly food
intake), where a Bonferroni correction was applied for the multiple weekly
comparisons. This resulted in significance levels of P<0.006 for these comparisons
only.
All data was tested for normality using the Shapiro-Wilk W test and
homogeneity of variance using the O’Brien and Brown-Forsythe tests. Data not
normally distributed were compared using nonparametric Wilcoxen/Kruskal-Wallis
tests and any data showing unequal variance were compared using a Welch ANOVA. A
one-way ANOVA was completed with diet group as the independent variable. The
dependant variables included metabolic variables (including body mass composition,
food intake, DMR, MMR) and membrane fatty acid composition. Means were then
compared using Tukey-Kramer HSD.
Linear regression was employed to determine any relationships between
metabolic variables (e.g. DMR and food intake), diet/membrane fatty acid composition
and membrane/metabolic rate. This analysis was followed by a one-way ANOVA as an
indication of fit. Data for individual rats was used for all linear regression analyses
(n=72 data points), however, only the mean and S.E.M. for each diet group are plotted
in the figures. Data for the initial group rats is also plotted in some figures (shown as
solid

squares),

but

was

not

included
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in

any

linear

regression

analysis.

Chapter 3
Results: Effects of diet on body mass, body composition,
food intake and metabolic rate
This chapter presents the changes in body mass and food intake measured over
the entire 8 week experimental period. It also presents the 24 hour oxygen consumption
as well as the lean body mass and body fat mass measured for the initial rat group and
each diet group at the end of the experimental period.
•

I will first present the changes in body mass and food intake which were
measured for each individual rat. The effects of diet on body composition
and metabolic rate were determined by comparing results for diet groups at 8
weeks to the respective values for the initial group. These results represent
those that were measured directly during the study.

•

Secondly, the interactions between these parameters will be presented. This
includes relating total food intake to both total body mass gain and fat/lean
body mass gain, and also the association of daily metabolic rate with food
intake, body mass and body composition. This provides some insight into the
possible influence of these variables (food intake, mass gain, body
composition and metabolic rate) on one another.

•

Finally, the influence of each type of fat in the diet (SFA, MUFA, PUFA, n6 PUFA, n-3 PUFA and PUFA balance) on body composition, food intake
and metabolic rate will be examined. This will demonstrate the relative
importance of each fat type for each of these variables.
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3.1 Effect of diet group on changes in body mass, food intake, metabolic
rate & body composition
Changes in Body Mass and Food Intake
A time course of the weekly changes in body mass and food intake for each diet
group is provided in Figure 3.1 and Figure 3.2 respectively. For these figures the diet
groups are divided into three groups in order of increasing diet n-6 PUFA content (i.e.
Figure 3.1a-low, 3.1b-mid and 3.1c-high n-6 PUFA). This is an arbitrary division and is
used so that data points for each experimental group of rats can be easily seen in the
figures.
In terms of body mass, it is clear that all rats grew during the 8 week dietary
period (Figure 3.1). Rats began the experiment as young adults with well-developed
bodies, but with potential for extra growth. Body mass showed a high rate of increase
up to the 2nd week and then became more gradual over the remaining six weeks.
Although there is no significant difference in body mass between diet groups at any
week (with significance level of P<0.006 set due to Bonferroni correction), there is a
clear trend for increased variation between diet groups by week 8. In week 8, the largest
rats are from diets 10 and 11, while the smallest rats are from diet groups 3 and 12.

Figure 3.1 Changes in body mass (g); (a) low (b) medium (c) high diet n-6 PUFA
content. Values are mean ± S.E.M.; n=6 for all data points. See Table 2.4 for fatty acid
composition of each diet.
For the weekly food intake, there is also an increased spread between diet
groups in week 8 food consumption (Figure 3.2), although these differences are not
significant at any week (P>0.006). Food intake is elevated in week 1 for all diet groups
and then decreases, remaining stable for the rest of the experimental period. Daily food
intakes for week 1 were compared between diet groups (data not shown) and showed no
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significant difference between diet groups on any day. This indicates that all diet groups
responded equally to the change in diet in the first week of experimental feeding. In
week 8 the rats consuming the highest amounts of food are from diet groups 8, 10 and
11, while those with lowest food consumption are found in diet groups 3, 5 and 12.

Figure 3.2 Changes in food intake (g/week); (a) low (b) medium (c) high diet n-6
PUFA content. Values are mean ± S.E.M.; n=6 for all data points. See Table 2.4 for
fatty acid composition of each diet.
The food conversion efficiency is derived from the body mass and food intake
data (Figure 3.3) and represents the amount of body mass gained per gram of food
consumed. The food conversion efficiency of all diet groups is elevated in week 1, but
these values decrease in week 2 to remain fairly constant thereafter (Figure 3.3). Results
for week 7 show a marked decrease in efficiency for diet group 4, which is due to a
decreased body mass gain in two rats from this group. No significant difference
between diets is observed in any week (P>0.006) and there is very little variation in
food conversion efficiency evident between the diet groups throughout the study. Rats
with the highest food conversion efficiency are found in diet groups 10 and 11, and
those with the lowest efficiency are from diets 3 and 12.

Figure 3.3 Changes in food conversion efficiency (body mass gain per g of food); (a)
low (b) medium (c) high diet n-6 PUFA content. Values are mean ± S.E.M.; n=6 for all
data points. See Table 2.4 for fatty acid composition of each diet.
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The coefficient of determination (R2-value) provides an indication of the relative
influence of diet group on each variable, describing how much variation in the main
variable is explained by the applied model. Diet group had no significant effect on body
mass or food intake during the experimental period and by week 8, diet group explained
only 21% and 23% of the variation in body mass and food intake respectively. So
factors other than diet group may be of more importance in explaining the high degree
of individual variation in both body mass and food consumption.

Changes in Metabolic Rate
Daily metabolic rate (DMR) for each rat was calculated from the average 24
hour O2 consumption measured whilst in metabolic chambers. The results comparing
DMR of the initial group to the experimental diet groups at week 8 are presented in
Figure 3.4. Lines joining the initial group to each experimental diet group do not
represent the true change in DMR (as they are not measured on the same rats), but are
provided for the sake of comparison between initial rats and experimental rats measured
8 weeks later. Metabolic rate values for each group are provided in Table 3.1.
Minimum metabolic rate (MMR) is also provided in Table 3.1 for comparison to DMR,
however, most discussion of metabolic rate will be in terms of DMR in this chapter.

Figure 3.4 Daily metabolic rate of rats expressed as a) L O2.day-1 and b) ml O2.hr-1.g-1
total body mass. For the sake of comparison metabolic rate of the initial group is plotted
separately to values for rats after 8 weeks on experimental diets. Only means are plotted
(see Table 3.1 for S.E.M., sample size and statistical analyses).
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Table 3.1 Daily and minimum metabolic rate (both expressed as: L O2.day-1 and ml
O2..hr-1.g-1 total body mass); values are mean ± S.E.M.; for minimum metabolic rate
n=6 for all diets; for daily metabolic rate n=6 for all diets, except for diets 4 and 12
(n=5) and diets 7 and 11 (n=4); values without a common superscript are significantly
different (P < 0.0001).

Daily Metabolic Rate
L.day-1
Initial
Diet
1
2
3
4
5
6
7
8
9
10
11
12

Minimum Metabolic Rate

ml.hr-1.g-1

L.day-1

ml.hr-1.g-1

3.52 ± 0.14 C

1.10 ± 0.05 AB

2.81 ± 0.13 E

0.88 ± 0.04 AB

4.79 ± 0.24 B
4.70 ± 0.13 BC
4.51 ± 0.16 BC
5.16 ± 0.19 AB
4.68 ± 0.22 BC
5.21 ± 0.26 AB
5.91 ± 0.42 AB
4.76 ± 0.18 BC
4.59 ± 0.21 BC
4.85 ± 0.29 AB
5.76 ± 0.29 AB
6.17 ± 0.63 A

0.82 ± 0.04 C
0.82 ± 0.03 C
0.87 ± 0.05 BC
0.90 ± 0.02 ABC
0.82 ± 0.02 C
0.85 ± 0.04 BC
1.04 ± 0.12 ABC
0.79 ± 0.04 C
0.82 ± 0.02 C
0.78 ± 0.04 C
0.88 ± 0.03 ABC
1.14 ± 0.13 A

3.74 ± 0.21 CDE
3.68 ± 0.19 CDE
3.55 ± 0.16 DE
4.54 ± 0.50 ABCD
3.62 ± 0.17 DE
4.14 ± 0.21 ABCDE
5.27 ± 0.40 ABC
3.76 ± 0.12 BCDE
3.61 ± 0.13 DE
3.77 ± 0.20 BCDE
5.45 ± 0.64 A
5.39 ± 0.62 AB

0.64 ± 0.03 B
0.64 ± 0.04 B
0.68 ± 0.04 B
0.79 ± 0.08 AB
0.63 ± 0.01 B
0.68 ± 0.03 B
0.89 ± 0.07 AB
0.63 ± 0.03 B
0.65 ± 0.02 B
0.61 ± 0.04 B
0.86 ± 0.11 AB
0.99 ± 0.12 A

.

.

All whole-rat values of DMR increased by 134 – 175% after 8 weeks of dietary
treatment, compared to initial DMR (Figure 3.4a). This result is largely due to the
increase in body mass that occurred during the experiment. The increase in whole-rat
DMR is significant for just over half the diet groups (R2=0.55; P<0.0001; for diet 1, 4,
6, 7, 10, 11 and 12; see Table 3.1).
The mass-specific DMR showed similar trends when characterised as either per
gram of total body mass (Figure 3.4b) or lean body mass (results not shown) so from
herein all discussion of mass-specific DMR will be in terms of total body mass only.
There is no change in mass-specific DMR for diet groups 7 and 12, while the remaining
diet groups tend to decrease by week 8 to values of approximately 70 – 80% of the
initial mass-specific DMR (Figure 3.4b). Significant reductions in mass-specific DMR
are seen in diet groups 1, 2, 5, 8, 9 and 10 (R2=0.50; P<0.0001; see Table 3.1).
Mass-specific DMR is highly variable between individual rats, ranging between
0.58 – 1.47 ml O2.hr-1.g-1 total body mass. Rats with an increased DMR may have been
more physically active during the measurement of 24 hour O2 consumption, however,
rats with high DMR also have high MMR, indicating that the elevated DMR is not
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simply due to increased activity levels. In fact, there is a very strong positive correlation
found between mass-specific DMR and MMR (DMR = 9.2 + 1.2*MMR; R2 = 0.95; P <
0.0001).
Diet group has a significant effect on mass-specific DMR at week 8 with 42% of
the variation in DMR explained by diet group (P=0.0008). As expected the influence of
diet group on mass-specific MMR is similar, with an R2-value of 44% (P=0.0001).
These results indicate that diet group is an important factor influencing metabolic rate in
this study.

Changes in Body Composition
Results for the body composition of the initial group and experimental diet
groups are presented in Table 3.2. This includes total body mass (g), as well as lean
body mass and body fat mass expressed both in grams and % of total body mass. The
results comparing the lean mass and body fat content of the initial group to the
experimental diet groups at week 8 are presented in Figure 3.5. Note again that the lines
joining the initial group to each experimental diet group are an artifice (as they were not
measured on the same individuals) included only to aid in this comparison.
Table 3.2 Total body mass (g), lean body mass and fat body mass (g and % of total
body mass); values are mean ± S.E.M.; n=6 for all diets; values without a common
superscript are significantly different (P < 0.05).

Total Mass
Initial
Diet
1
2
3
4
5
6
7
8
9
10
11
12

g

g

Lean Mass

277.5 ± 12.1 B

256.8 ± 12.4 B

510.0 ± 36.3 A
499.5 ± 24.6 A
452.7 ± 21.4 A
497.5 ± 15.1 A
494.7 ± 19.5 A
530.7 ± 27.7 A
515.5 ± 26.2 A
520.7 ± 17.6 A
483.7 ± 25.6 A
539.5 ± 19.2 A
555.0 ± 34.1 A
471.5 ± 13.7 A

440.8 ± 24.6 A
436.0 ± 20.1 A
407.1 ± 20.3 A
441.9 ± 10.8 A
426.2 ± 18.4 A
458.7 ± 21.8 A
435.6 ± 16.3 A
443.6 ± 11.1 A
420.3 ± 20.8 A
476.9 ± 16.7 A
466.7 ± 13.6 A
429.9 ± 15.4 A

% total

g

Fat Mass

92.5 ± 1.0 A

20.7 ± 2.6 B

87.0 ± 2.3 A
87.4 ± 0.8 A
89.9 ± 1.4 A
89.0 ± 1.7 A
86.1 ± 1.1 A
86.6 ± 1.6 A
84.9 ± 2.4 A
85.3 ± 1.0 A
87.0 ± 1.1 A
88.5 ± 1.5 A
84.9 ± 2.7 A
91.1 ± 0.9 A

69.2 ± 16.6 AB
63.5 ± 5.8 AB
45.6 ± 6.3 AB
55.7 ± 10.2 AB
68.5 ± 5.9 AB
72.0 ± 10.2 AB
79.9 ± 15.9 A
77.1 ± 7.8 A
63.3 ± 7.7 AB
62.6 ± 9.1 AB
88.4 ± 21.4 A
41.6 ± 3.5 AB
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% total

7.5 ± 1.0 A

13.0 ± 2.3 A
12.6 ± 0.8 A
10.1 ± 1.4 A
11.0 ± 1.7 A
13.9 ± 1.1 A
13.4 ± 1.6 A
15.1 ± 2.4 A
14.7 ± 1.0 A
13.0 ± 1.1 A
11.5 ± 1.5 A
15.1 ± 2.7 A
8.9 ± 0.9 A

.
.

Figure 3.5 Lean body mass and total body fat expressed as g (a and b) and % of total
body mass (c and d). For the sake of comparison the initial group is plotted separately to
values for rats after 8 weeks on experimental diets. Only means are plotted (see Table
3.2 for S.E.M., sample size and statistical analyses).
All rats significantly increased in the amount of lean body mass after 8 weeks of
feeding on the experimental diets by approximately two-fold, with very little variation
between diet groups at week 8 (R2=0.64; P<0.0001; Figure 3.5a). Rats also tended to
put on body fat (g) after 8 weeks, but this increase is only significant for diets 7, 8 and
11 (R2=0.34; P=0.0043; Figure 3.5b).
The variation between diet groups at week 8 is much greater for the body fat
mass than the lean body mass, ranging from a two-fold to a four-fold increase in body
fat mass (Figure 3.5). Variation in lean body mass and fat mass within each diet group
is also high (see Table 3.2). In week 8 there is no significant difference between diet
groups for the amount of lean body mass or body fat (Table 3.2), with diet group
explaining only 18% and 21% of the variation in lean and fat body mass respectively
(P=0.31 and 0.18). This indicates that factor/s other than diet group may be important in
influencing body composition. Perhaps a time period longer than 8 weeks for feeding
moderate-fat experimental diets may be required for significant differences in obesity to
manifest.
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The % lean body mass tended to decrease with a corresponding increase in %
body fat after 8 weeks on the experimental diets (Figure 3.5c and Figure 3.5d).
However, these changes were not significant (Table 3.2). Diet group had no significant
effect on the % of lean or fat body mass at week 8, explaining 21% of the variation in
both (P=0.19).
Organ size is another important component of body composition. The wet mass
of kidney, liver, heart and brain was measured for all rats and presented in Table 3.3.
There is no significant change in liver size from the initial group to the experimental
diet groups at week 8 (R2=0.24; P=0.0921). However, there is a significant increase in
tissue size for kidney (diets 2, 5, 6, 10, 11 only; R2=0.33; P=0.0058), heart (all diet
groups, except diet 2; R2=0.43; P=0.0001) and brain (all diet groups; R2=0.43;
P=0.0001).
A comparison between the diet groups at week 8 reveals no significant
difference in the size of liver (R2=0.21; P=0.16), kidney (R2=0.15; P=0.46), heart
(R2=0.19; P=0.28) or brain (R2=0.13; P=0.60; see Table 3.3).

Table 3.3 Tissue mass (g) for kidney, liver, heart and brain; values are mean ± S.E.M.;
n=6 for all diets; values without a common superscript are significantly different (P <
0.05).
Kidney
Liver
Heart
Brain
Initial 2.50 ± 0.08 B
10.8 ± 1.6 A
1.06 ± 0.04 B
1.66 ± 0.02 B
Diet
1
2.89 ± 0.15 AB
12.7 ± 0.9 A
1.57 ± 0.06 A
1.97 ± 0.05 A
A
A
AB
2
3.23 ± 0.11
12.7 ± 0.7
1.46 ± 0.07
2.07 ± 0.04 A
3
3.01 ± 0.11 AB
12.5 ± 0.4 A
1.53 ± 0.08 A
1.97 ± 0.05 A
AB
A
A
4
3.13 ± 0.10
12.8 ± 0.4
1.55 ± 0.08
2.01 ± 0.03 A
5
3.20 ± 0.17 A
13.0 ± 0.5 A
1.73 ± 0.10 A
2.06 ± 0.07 A
A
A
A
6
3.27 ± 0.16
16.0 ± 2.1
1.60 ± 0.11
1.97 ± 0.06 A
AB
A
A
7
3.03 ± 0.15
13.0 ± 1.1
1.64 ± 0.13
1.91 ± 0.07 A
13.1 ± 0.5 A
1.83 ± 0.10 A
1.98 ± 0.07 A
8
3.03 ± 0.10 AB
AB
A
A
9
2.98 ± 0.15
12.3 ± 0.8
1.53 ± 0.08
1.92 ± 0.04 A
10
3.28 ± 0.08 A
15.9 ± 2.0 A
1.66 ± 0.08 A
1.98 ± 0.02 A
A
A
A
11
3.32 ± 0.16
14.3 ± 1.2
1.69 ± 0.13
2.00 ± 0.05 A
12
3.14 ± 0.17 AB
12.7 ± 0.3 A
1.54 ± 0.06 A
1.99 ± 0.05 A
.
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3.2 Interactions between food intake, body composition and metabolic
rate
Correlation between total food intake & total mass gain
There is a strong correlation between the total amount of food consumed and the
amount of body mass gained over the total 8 weeks (Figure 3.6). This confirms that
there is plenty of variation between individual rats in the outbred Sprague Dawley
strain. Those rats that consumed more food gained more body mass. An R2-value of
0.72 shows that variation in food intake explained 72% of the variation in body mass
gain. Diet composition does not seem to be an important factor here, with individuals
from each diet widely spread over this strong linear relationship.

Figure 3.6 Relationship between total food intake and total body mass gain for
individual rats; dotted line represents the extrapolation of the linear regression to show
food intake at zero mass gain; n=72.
Food intake thus appears to be the dominant variable associated with body mass
gain. As the rats began this study as young adults this strong relationship between intake
and body mass is likely a product of the growth that they were undergoing during the
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experiment. However, there does seem to be a pre-disposition for some rats to put on
more body mass than others. Although there is no significant difference between the
rats of the different groups in initial body mass (R2=0.19; P=0.23), there is a significant
positive correlation between initial body mass and body mass after 8 weeks (R2=0.33; P
< 0.0001; n=72). This suggests a propensity for some rats to grow and thus put on more
body mass.
Extrapolating the linear regression between food intake and body mass gain to
zero body mass gain suggests that rats required 520g of food over the total 8 weeks just
to maintain body mass (Figure 3.6). However, all rats consumed more than this
minimum amount. This 520g of food is equivalent to 172 KJ/day (diet contained 18.51
KJ/g food) and can be compared to the energy required for daily metabolic rate and
waste products. Although waste was not measured, the DMR can be converted to
energy units. Assuming an RQ 0.8 (typical RQ at rest equivalent to 20.1 KJ/L O2
consumed per day), this translates to a range of DMR of 77 – 164 KJ/day (mean 101 ± 2
KJ/day; n = 66). This falls well below the energy input from daily food intake. So, on
average, rats were using ~101 KJ/day for daily metabolic rate, with ~70 KJ/day (or
~70%) going to waste products.
Correlation between total food intake & body composition
The increase in the amount of lean body mass and body fat over the 8 weeks of
diet feeding was calculated by subtracting the average total body fat values for the
initial group from the total body fat values measured for the individual rats. For this
reason, the linear regression analysis was based on the average values for each diet
group. Analysis of the total food consumed over the 8 weeks of dietary intervention
produced positive correlations with both lean body mass and body fat gain (P<0.0001;
see Figure 3.7a and b respectively). This relationship is slightly stronger for lean body
mass gain with total food intake explaining 71% of the variation in lean body mass gain
and only 62% of the body fat gain.
Lean body mass gain is also more responsive than body fat gain to total food
intake, with slope values of 0.22 and 0.14 (g body mass per g food intake) respectively.
This indicates that food intake seems to be influencing body mass gain more through
changes in lean body mass rather than gain in body fat mass. Thus for every gram of
food eaten 22% is associated with gain in lean mass and 14% gain in body fat, with a
total of 36%, i.e. 64% is associated with heat production and excretion of waste.
44

Figure 3.7 The relationship between total food intake and the calculated increase in lean
body mass and body fat mass over the experimental period. The increase in lean and fat
mass was calculated as the difference between the value of each diet group compared to
the value of the initial group; values plotted are means; n=6 for all groups.

Correlation between metabolic rate & food intake
The interaction between daily metabolic rate (DMR) and total food intake of
individual rats is shown in Figure 3.8. Whole-rat DMR does not significantly correlate
with total food intake (R2=0.04; P=0.1298; Figure 3.8a), however mass-specific DMR
shows a significant negative correlation with total food intake (R2=0.23; P<0.0001;
Figure 3.8b).

Figure 3.8 The relationship between total food intake (g) and daily metabolic rate of
individual rats. Expressed as a) L O2.day-1 b) ml O2.hr-1.g-1 total body mass; n = 66.
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The three individual rats with disproportionately high DMRs (animals from diets
7 and 12) appear to influence these relationships. As discussed earlier (see section 3.1),
DMR significantly correlates with MMR (R2 = 0.95; P < 0.0001) and these three rats
with a high DMR also have increased MMR, indicating that the elevated DMR is not
due to increased activity levels. Removal of these individuals from the analysis
produces a significant positive correlation between food intake and whole-rat DMR (y =
2.44 + 0.00x; R2=0.27; P<0.0001), while the mass-specific DMR correlation remains
significantly negative (y = 1.17 – 0.00x; R2=0.23; P<0.0001). Therefore, higher food
intakes are associated with increased whole-rat DMR and reduced mass-specific DMR.
Correlation between metabolic rate & total body mass
To determine whether any pre-existing relationships existed between DMR,
body mass and body fat content prior to dietary manipulation an analysis was conducted
using the initial rat group. This analysis (data not shown) revealed no pre-existing
correlation between DMR (L.day-1 or ml.hr-1.g-1 total body mass) and either body mass
(g) or body fat content (g or % of total mass), which indicates that before dietary
manipulation metabolic rate was not related with body mass composition (n=6; P>0.5).
After eight weeks on the experimental diets there is a significant negative
relationship between mass-specific DMR and total body mass (R2=0.18; P=0.0004; see
Figure 3.9a). This relationship remains significant even if the three rats with high
DMRs are removed from the analysis (y = 791– 337x; R2=0.22; P=0.0001), confirming
that an elevated mass-specific DMR is associated with reduced total body mass.

Figure 3.9 Relationship between mass-specific metabolic rate of individual rats and a)
total body mass (g); b) lean body mass (% of total mass); c) body fat (% of total mass);
n = 66.
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Mass-specific DMR is also associated with the partitioning of total body mass
into lean or fat mass. Rats with an increased % of lean body mass and a corresponding
decrease in % body fat have higher mass-specific DMR (R2=0.12; P=0.004 for both; see
Figure 3.9b and Figure 3.9c respectively). These relationships remained significant even
with the removal of the three rats with a high DMR (lean mass: y = 71.7 + 18.6x;
R2=0.17; P=0.0009; and fat mass: y = 28.3 - 18.6x; R2=0.17; P=0.0009).
So rats with an increased mass-specific DMR also have a reduced total body
mass, with higher proportion of lean body mass relative to body fat content. Since lean
tissue has a higher metabolic activity compared to body fat, it makes sense that reduced
body fat content results in an increased mass-specific metabolic rate.
Organ size can also influence metabolic rate, especially the mass of highly
metabolic tissues such as kidney, liver and heart. The only significant positive
relationship found in the present study is between kidney size and whole-rat DMR (y =
2.72 + 0.74x; R2=0.10; P = 0.0096), so organ size appears not to be a major factor in
determining metabolic rate in this study.
Conclusions regarding correlations
A number of conclusions can be drawn from the results of the interactions
between food intake, body mass and metabolic rate. In these young adult, outbred rats
fed a moderate-fat diet differing only in diet fat type, food intake explains most of the
variation in body mass gained (72%). Diet group has no significant influence on these
variables, explaining 21% and 23% of the variation in body mass and food intake
respectively. On the other hand, diet group explains most of the variation in massspecific DMR (42%), while food intake and body mass explain only 23% and 18% of
the variation in mass-specific DMR respectively. This indicates that diet fat type may be
an important factor influencing mass-specific metabolic rate.
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3.3 Effect of fat type on body mass, food intake & metabolic rate
Diet fat type and body mass
The individual relationships between diet SFA, MUFA, PUFA, n-6 PUFA, n-3
PUFA and PUFA balance and all aspects of body mass are analysed in this section. No
relationship exists between any fat type and total body mass or body mass gain over the
8 week experimental period. In addition, there is no correlation between diet MUFA,
PUFA, n-6 PUFA, n-3 PUFA or diet PUFA balance with the lean body mass or body fat
content (grams or % of total body mass).
There is, however, a small but significant influence of dietary SFA content on
the body fat and lean body mass composition (Figure 3.10). Rats with higher diet SFA
content have a slightly increased total body fat content (R2=0.07; P=0.031; see Figure
3.10b), while the % of lean body mass decreases with a corresponding increase in % of
body fat (R2=0.06; P=0.037 for both; see Figure 3.10c and d respectively).

Figure 3.10 The effect of diet SFA content (% of total fatty acids) on lean and fat body
mass (expressed in g (a and b) and % of total mass (c and d)); values plotted are mean ±
S.E.M.; n=6 for all groups.
Diet PUFA content had a tendency (statistically nearly significant) for the
opposite effect (results not shown), with increasing diet PUFA content tending towards
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lower fat mass (R2=0.04; P=0.0797), increase in % lean body mass and a corresponding
decrease in % fat body mass (R2=0.05; P=0.0510).
These results indicate that on a moderate-fat diet that diet fat type has little
influence on body mass and body composition, with diet SFA content explaining only
7% of the variation in body fat content.
Diet fat type and food intake
At the beginning of the experimental period (i.e. week one) there was no
correlation between diet fat type and food intake. Total food intake (over the entire 8
week experimental period) does not significantly correlate with diet MUFA, PUFA, n-3
PUFA, n-6 PUFA or PUFA balance. However, a significant positive relationship is
found with diet SFA content (R2=0.06; P=0.034; Figure 3.11a), indicating that
increased diet SFA content is associated with elevated food consumption. There is also
a strong tendency for higher food consumption to be associated with lower diet PUFA
(R2=0.05; P=0.056; Figure 3.11c) and n-6 PUFA contents (R2=0.05; P=0.064; Figure
3.11d).

Figure 3.11 Effect of diet fat type on total food intake (g); a) SFA b) MUFA c) PUFA
d) n-6 PUFA e) n-3 PUFA (expressed as % of total fatty acids) and e) PUFA balance
(expressed as n-3 PUFA as % of total PUFA); values are mean ± S.E.M.; n=6 for all
diets; * indicates a significant linear relationship (P<0.05).
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A similar pattern exists between the diet fat types and week 8 food intake (see
Appendix 2 for the linear regression equations). Increased food intake in week 8 is
associated with significantly increased diet SFA (R2=0.09; P=0.0097) and decreased
diet n-6 PUFA (R2=0.06; P=0.0386), while diet PUFA gave a negative trend (R2=0.05;
P=0.0736). These results demonstrate that both total food intake and food intake at the
end of the experimental diet period are influenced by diet SFA and n-6 PUFA content.
Diet palatability may have been influencing levels of food consumption. A
previous study showed that rats have a short-term preference for 18:3n-3 over 18:2n-6
followed by 18:1n-9 (Tsuruta et al. 1999), however this does not give an indication for
long-term feeding preferences. Oils used in the current study included safflower oil,
flaxseed oil, olive oil, coconut oil and beef dripping. No correlation exists between diet
oil type (expressed as % of total diet content) and total food intake (results not shown).
Therefore it is unlikely that any taste preference for different oil types was driving food
consumption to any significant degree in this study.

Diet fat type and metabolic rate
Diet SFA, MUFA, PUFA and n-6 PUFA content have no significant influence
on mass-specific DMR (Figure 3.12a, b, c and d respectively). There is a significant
positive relationship between mass-specific DMR and diet n-3 PUFA (R2=0.11;
P=0.0007; Figure 3.12e) and PUFA balance (R2=0.06; P=0.043; Figure 3.12f). These
results show that increasing the total diet n-3 PUFA, as well as the balance of n-3 PUFA
relative to n-6 PUFA, is associated with an elevated mass-specific DMR.
The results show that while diet group explains a large amount of the variation
in mass-specific DMR (R2=42%), the most significant fat type is the diet n-3 PUFA
content, which by itself explains 11% of the variation in mass-specific DMR.
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Figure 3.12 Effect of diet fat type on daily metabolic rate (ml.hr-1.g-1 total body mass);
a) SFA b) MUFA c) PUFA d) n-6 PUFA e) n-3 PUFA (expressed as % of total fatty
acids) and e) PUFA balance (expressed as n-3 PUFA as % of total PUFA); values are
mean ± S.E.M.; n=6 for all diets, except for diets 4 and 12 (n=5) and diets 7 and 11
(n=4).
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Chapter 4
Results: Effects of diet on membrane fatty acid
composition
This chapter presents the results for the membrane (= phospholipid) fatty acid
composition of skeletal muscle, heart, liver, brain, red blood cells (RBC) and adipose
tissue. Differences in membrane fatty acid composition between the twelve diet groups
will be investigated first. The proportion of each individual fatty acid was measured
from the phospholipid classes pooled together.
Next, the relationship between diet fat profile (i.e. SFA, MUFA, PUFA, n-6
PUFA, n-3 PUFA and PUFA balance) and membrane fatty acid composition will be
quantified for all tissues by applying the conformer/regulator paradigm to the results
(see Chapter 1). Each diet fat type is plotted against membrane fatty acid composition
with the slope of each relationship demonstrating how responsive the membrane is to
changes in diet fat profile.
In this study the n-6 PUFA and n-3 PUFA were provided in the diet as 18carbon PUFA, which are precursors for the longer chain 20-22-carbon PUFA (including
20:4n-6 and 22:6n-3). Long-chain PUFA are important components of tissue
membranes, so in the last section of this chapter I will examine the
elongation/desaturation of dietary PUFA by presenting the relationships between these
membrane 20-22-carbon PUFA and the diet precursor PUFA levels. This was achieved
firstly for the n-6 PUFA, with the membrane content of 20:4n-6, 22:4n-6 and 22:5n-6
plotted against both the diet 18:2n-6 amounts as well as against the diet PUFA balance.
Similarly for the n-3 PUFA, the membrane content of 20:5n-3, 22:5n-3 and 22:6n-3 in
each tissue is plotted against both the amount of diet 18:3n-3 and diet PUFA balance.
Throughout Chapter 4 the terms membrane and phospholipid are used
synonymously to describe the membrane tissue fatty acid composition. Membrane will
be used as short-hand for ‘phospholipid’, however, note that the composition of the
plasma phospholipids will not be discussed in this chapter, as the phospholipids present
in the plasma are not part of a membrane. Fatty acid compositions of the plasma
phospholipid and triglycerides, as well as the adipose tissue triglycerides, will be
presented in Chapter 5.
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4.1 Effects of diets on membrane fatty acid composition
The fatty acid composition of each tissue’s phospholipids is presented in the
following tables: skeletal muscle (Table 4.1), heart (Table 4.2), brain (Table 4.3), liver
(Table 4.4), adipose tissue (Table 4.5), and red blood cells (RBC; Table 4.6).
Comparisons are made between diet groups for all fatty acid types. There are significant
differences evident for all the n-6 PUFA and n-3 PUFA in all tissues. The proportion of
total PUFA in the membranes showed significant differences between diet groups for all
tissues except brain and RBC, while total MUFA showed differences between diet
groups for all tissues except brain. For total SFA, the only tissues to show significant
differences are liver and adipose tissue. Within the saturated and monounsaturated fatty
acids there are a number of individual fatty acids with no significant difference between
diet groups. These include 16:0 (muscle, brain and RBC only), 18:0 (muscle, brain,
adipose tissue and RBC only), 22:0 (RBC only), 16:1n-7 (RBC only), 20:1n-9 and
24:1n-9 (brain only).
In the muscle, heart and liver phospholipids, 22:6n-3 accounts for the majority
of the n-3 PUFA content, while 18:2n-6 and 20:4n-6 provide the highest proportions of
the total n-6 PUFA composition (Table 4.1, Table 4.2 and Table 4.4 respectively).
In brain, 22:6n-3 is the main n-3 PUFA found in membranes (only very low
levels of the other n-3 PUFA are present) and 20:4n-6 the main n-6 PUFA present
(Table 4.3). Adipose tissue membranes contain negligible amounts of 20-22C PUFA,
with 18:3n-3 being the main n-3 PUFA and 18:2n-6 the main contributor to total n-6
PUFA (some 20:4n-6 is also present; Table 4.5). So unlike the membranes of the other
tissues (which contain higher levels of long-chain PUFA), the PUFA in the adipose
tissue membranes are possibly being sourced directly from the diet.
In the RBC membranes both 18:2n-6 and 20:4n-6 are the main contributors to
the total n-6 PUFA present, while the n-3 PUFA showed far more variation between
diet groups, with 22:6n-3 the main membrane n-3 PUFA for diet 1-5 and 8; 22:5n-3 the
main contributor for diet 6, 7, 9 and 10; and 20:5n-3 the highest membrane n-3 PUFA
for diets 11-12 (Table 4.6). Mature RBCs cannot synthesise new phospholipids de novo
or modify the chain length or number of double bonds present in the fatty acyl chain
(Kunimoto et al. 1984). RBCs acquire their membrane PUFA from deacylation and
reacylation of plasma fatty acids and by exchange of plasma phospholipids (Dise et al.
1980; Hrboticky et al. 1990). RBC 22:6n-3 and 20:5n-3 levels are similar to plasma
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levels (described in the next chapter), however, 22:5n-3 levels are relatively higher in
the RBC (similar to heart and muscle membrane levels). Perhaps the RBC are acquiring
22:5n-3 from sources other than plasma phospholipids or triglycerides, such as nonesterified fatty acids (which were not measured in the current study). This may have
implications for the omega-3 index, which describes the omega-3 tissue status and is
used as a risk factor for death from coronary heart disease (Harris and von Schacky
2004). This index is calculated from RBC membrane 20:5n-3 and 22:6n-3 content only,
but results from the current study suggest that RBC 22:5n-3 should also be included.
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Table 4.1 Fatty acid composition (% of total fatty acid) of skeletal muscle phospholipids from rats fed experimental and initial diets; values are mean ±
S.E.M.; n=6. See Table 2.4 for diet fatty acid composition.
Diet
14:0 *
16:0
18:0

1

0.1 ± 0.0 D
22.9 ± 1.1
15.3 ± 0.6

2

0.1 ± 0.1 D
24.7 ± 0.1
15.2 ± 0.3

3

0.1 ± 0.0 D
23.3 ± 0.9
15.6 ± 0.6

4

5

0.2 ± 0.1 CD
23.2 ± 0.9
15.1 ± 0.5

0.1 ± 0.1 D
23.8 ± 0.9
13.9 ± 0.3

0.4 ± 0.0 D
3.4 ± 0.1 F
2.1 ± 0.0 EF

1.0 ± 0.1 B
9.8 ± 0.5 A
2.7 ± 0.1 B

0.5 ± 0.0 D
11.0 ± 0.7 A
3.0 ± 0.1 A

6

7

0.1 ± 0.1 D
24.0 ± 0.7
14.4 ± 0.6

0.5 ± 0.1 BC
23.9 ± 0.6
14.8 ± 0.4

8

1.0 ± 0.1 A
25.1 ± 0.7
13.9 ± 0.3

9

0.1 ± 0.1 D
23.7 ± 0.8
15.4 ± 0.5

10

0.0 ± 0.0 D
23.0 ± 0.9
14.9 ± 0.7

11

0.7 ± 0.1 AB
24.7 ± 0.8
14.3 ± 0.3

12

0.1 ± 0.0 D
21.8 ± 1.0
16.1 ± 0.4

Initial__

0.1 ± 0.1 D
25.1 ± 0.2
14.1 ± 0.3

16:1n-7 *
18:1n-9 *
18:1n-7 *

0.5 ± 0.1 D
6.6 ± 0.5 BC
2.6 ± 0.1 BC

18:2n-6 *
20:3n-6 *
20:4n-6 *
22:4n-6 *
22:5n-6 *

17.7 ± 1.7 CDE
0.5 ± 0.0 DE
19.6 ± 1.2 AB
1.1 ± 0.1 A
3.2 ± 0.1 A

14.9 ± 0.3 E
0.6 ± 0.0 CDE
20.4 ± 0.2 A
0.8 ± 0.1 B
1.9 ± 0.3 B

22.3 ± 1.2 ABC
0.5 ± 0.0 E
16.4 ± 0.7 BC
0.6 ± 0.1 C
0.7 ± 0.1 C

15.0 ± 0.6 E
0.9 ± 0.0 A
13.8 ± 0.6 CDE
0.3 ± 0.0 DE
0.5 ± 0.1 C

14.2 ± 1.0 E
0.7 ± 0.0 BC
12.1 ± 0.7 DEF
0.1 ± 0.0 F
0.0 ± 0.0 D

20.3 ± 1.1ABCD 21.6 ± 0.6 ABC
0.6 ± 0.0 CDE
0.7 ± 0.0 CD
EFG
11.5 ± 0.9
10.1 ± 0.5 FGH
F
0.0 ± 0.0
0.1 ± 0.1 F
D
0.0 ± 0.0
0.0 ± 0.0 D

16.3 ± 0.6 DE
0.9 ± 0.1 AB
9.7 ± 0.8 FGHI
0.2 ± 0.0 EF
0.3 ± 0.1 CD

18.6 ± 1.4 BCDE 24.3 ± 1.0 A
0.7 ± 0.0 CD
0.6 ± 0.0 CDE
DEF
11.9 ± 0.6
8.2 ± 0.4 GHI
F
0.1 ± 0.0
0.0 ± 0.0 F
D
0.0 ± 0.0
0.0 ± 0.0 D

18.0 ± 1.3 CDE
0.7 ± 0.0 C
7.4 ± 0.6 HI
0.1 ± 0.0 F
0.0 ± 0.0 D

23.3 ± 1.2 AB
0.6 ± 0.0 CDE
6.5 ± 0.6 I
0.0 ± 0.0 F
0.0 ± 0.0 D

17.8 ± 0.3 CDE
1.0 ± 0.0 A
15.0 ± 0.4 CD
0.6 ± 0.0 CD
0.5 ± 0.0 C

18:3n-3 *
20:5n-3 *
22:5n-3 *
22:6n-3 *

0.1 ± 0.0 D
0.0 ± 0.0 F
1.0 ± 0.1 H
8.1 ± 0.3 F

0.0 ± 0.0 D
0.0 ± 0.0 F
2.0 ± 0.1 GH
10.5 ± 0.5 E

0.2 ± 0.1 D
0.0 ± 0.0 F
2.0 ± 0.1 GH
11.4 ± 0.5 DE

0.0 ± 0.0 D
0.4 ± 0.0 EF
2.5 ± 0.1 FG
13.1 ± 0.3 BCD

0.4 ± 0.0 D
0.7 ± 0.1 DE
3.4 ± 0.2 EF
15.4 ± 0.7 AB

1.3 ± 0.1 C
0.8 ± 0.1 DE
4.1 ± 0.3 CDE
13.0 ± 0.4 CD

1.7 ± 0.2 C
1.0 ± 0.1 CD
4.7 ± 0.2 BCD
12.9 ± 0.4 CDE

0.3 ± 0.1 D
0.8 ± 0.1 DE
3.8 ± 0.2 DE
15.6 ± 0.3 A

1.0 ± 0.1 C
0.8 ± 0.1 DE
4.8 ± 0.3 BCD
13.1 ± 0.6 BCD

3.2 ± 0.2 B
1.4 ± 0.0 BC
5.2 ± 0.4 ABC
11.5 ± 0.6 DE

1.7 ± 0.3 C
1.9 ± 0.3 AB
6.1 ± 0.5 A
14.5 ± 0.8 ABC

4.6 ± 0.3 A
2.2 ± 0.2 A
5.5 ± 0.4 AB
10.9 ± 0.3 DE

0.1 ± 0.1 D
0.4 ± 0.1 EF
2.5 ± 0.1 FG
11.9 ± 0.2 DE

SFA
38.8 ± 0.9
MUFA *
9.8 ± 0.5 BC
PUFA *
51.4 ± 0.5 BCD
n-6 PUFA* 42.3 ± 0.6 A
n-3 PUFA* 9.1 ± 0.4 F

41.0 ± 0.6
7.8 ± 0.2 CDE
51.3 ± 0.5 CD
38.7 ± 0.1 B
12.6 ± 0.6 E

39.5 ± 0.8
6.0 ± 0.2 E
54.5 ± 0.8 AB
40.8 ± 0.8 AB
13.7 ± 0.4 DE

39.5 ± 0.7
14.0 ± 0.6 A
46.6 ± 0.4 G
30.5 ± 0.4 DE
16.0 ± 0.3 D

38.3 ± 0.8
14.8 ± 0.7 A
46.9 ± 0.8 FG
27.1 ± 0.6 FG
19.8 ± 0.6 C

39.1 ± 0.8
9.2 ± 0.2 BCD
51.7 ± 0.6 ABCD
32.4 ± 0.5 CD
19.2 ± 0.3 C

39.7 ± 0.4
7.3 ± 0.4 DE
52.9 ± 0.4 ABCD
32.6 ± 0.5 CD
20.3 ± 0.5 C

40.5 ± 0.8
11.5 ± 0.9 B
47.9 ± 0.8 EFG
27.4 ± 0.9 EFG
20.5 ± 0.2 C

40.5 ± 0.6
8.4 ± 0.7 CD
51.1 ± 0.9 CD
31.4 ± 1.0 D
19.7 ± 0.7 C

38.3 ± 0.4
6.9 ± 0.4 DE
54.8 ± 0.5 A
33.2 ± 0.7 CD
21.6 ± 0.5 BC

40.3 ± 0.7
9.2 ± 0.3 BCD
50.5 ± 0.6 DE
26.1 ± 1.2 G
24.4 ± 1.1 A

38.6 ± 1.0
7.3 ± 0.3 DE
54.2 ± 0.9 ABC
30.5 ± 0.7 DEF
23.7 ± 0.7 AB

40.0 ± 0.3
10.1 ± 0.1 BC
49.9 ± 0.4 DEF
35.0 ± 0.5 C
14.9 ± 0.2 DE

PUFA
Balance *

24.5 ± 0.8 H

25.1 ± 0.8 GH

34.4 ± 0.7 EF

42.2 ± 0.8 BC

37.2 ± 0.6 DE

38.4 ± 0.9 CDE

42.9 ± 0.9 BC

38.7 ± 1.4 CDE

39.5 ± 1.0 BCD

48.3 ± 2.1 A

43.7 ± 0.9 AB

29.9 ± 0.6 FG

17.7 ± 0.8 I

0.6 ± 0.0 CD
4.8 ± 0.2 CDEF
2.3 ± 0.0 CDE

0.5 ± 0.1 D
6.3 ± 0.2 BCD
2.3 ± 0.0 CDE

0.7 ± 0.1 BCD
4.2 ± 0.3 EF
2.2 ± 0.1 DEF

1.6 ± 0.2 A
6.8 ± 0.6 B
3.0 ± 0.1 A

* Values for each fatty acid without a common superscript in each row are significantly different (P<0.0001)
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0.6 ± 0.1 CD
5.5 ± 0.5 BCDE
2.2 ± 0.1 DEF

0.6 ± 0.1 BCD
4.2 ± 0.3 EF
2.0 ± 0.1 EF

1.0 ± 0.1 BC
5.6 ± 0.2 BCDE
2.5 ± 0.1 BCD

0.5 ± 0.0 D
4.7 ± 0.2 DEF
1.9 ± 0.1 F

0.7 ± 0.0 BCD
6.1 ± 0.1 BCDE
3.2 ± 0.1 A

Table 4.2 Fatty acid composition (% of total fatty acids) of heart phospholipids from rats fed experimental and initial diets; values are mean ± S.E.M.; n=6.
See Table 2.4 for diet fatty acid composition.
Diet
14:0 *
16:0 *
17:0 *
18:0 *

1

0.1 ± 0.0 D
9.7 ± 0.3 BCD
0.2 ± 0.0 C
23.8 ± 0.2 AB

2

0.1 ± 0.0 CD
9.7 ± 0.2 BCD
0.5 ± 0.0 AB
23.7 ± 0.2 AB

16:1n-7 *
18:1n-9 *
18:1n-7 *

0.1 ± 0.0 D
4.5 ± 0.2 BC
2.8 ± 0.1 DE

18:2n-6 *
20:3n-6 *
20:4n-6 *
22:4n-6 *
22:5n-6 *

21.1 ± 0.2 C
0.2 ± 0.0 F
24.9 ± 0.1 A
1.7 ± 0.1 A
5.6 ± 0.3 A

22.1 ± 0.5 BC
0.2 ± 0.0 F
24.6 ± 0.3 A
1.1 ± 0.0 B
2.8 ± 0.3 B

18:3n-3 *
20:5n-3 *
22:5n-3 *
22:6n-3 *

0.0 ± 0.0 G
0.0 ± 0.0 D
0.5 ± 0.0 H
4.1 ± 0.2 F

0.0 ± 0.0 G
0.0 ± 0.0 D
1.1 ± 0.0 GH
6.9 ± 0.3 E

0.2 ± 0.0 CD
3.7 ± 0.1 BCDE
2.5 ± 0.0 EF

3

4

5

6

0.1 ± 0.0 CD
10.3 ± 0.2 BC
0.2 ± 0.0 C
23.0 ± 0.5 BC

7

0.1 ± 0.0 D
10.0 ± 0.3 BC
0.2 ± 0.0 C
24.1 ± 0.4 AB

0.1 ± 0.0 CD
10.4 ± 0.2 BC
0.5 ± 0.0 A
23.3 ± 0.2 BC

0.1 ± 0.0 D
10.6 ± 0.3 B
0.2 ± 0.0 C
22.7 ± 0.2 BCD

0.1 ± 0.0 D
2.2 ± 0.1 F
2.4 ± 0.0 EF

0.5 ± 0.1 BC
7.1 ± 0.3 A
3.4 ± 0.1 BC

0.2 ± 0.0 D
8.3 ± 0.6 A
3.4 ± 0.1 B

26.4 ± 0.8 A
0.2 ± 0.0 F
20.5 ± 0.3 C
0.9 ± 0.0 C
1.0 ± 0.1 C

16.0 ± 0.6 D
0.8 ± 0.0 A
22.7 ± 0.4 B
0.3 ± 0.0 E
0.5 ± 0.1 CD

16.5 ± 0.4 D
0.5 ± 0.0 B
20.3 ± 0.3 C
0.2 ± 0.0 EFG
0.1 ± 0.0 D

24.5 ± 0.6 AB
0.3 ± 0.0 EF
17.4 ± 0.3 EF
0.2 ± 0.0 FG
0.1 ± 0.0 D

0.2 ± 0.0 FG
0.1 ± 0.0 FG
D
0.0 ± 0.0
0.2 ± 0.0 CD
FG
1.5 ± 0.1
1.5 ± 0.1 FG
9.3 ± 0.5 BCDE 11.6 ± 0.6 AB

0.4 ± 0.0 EFG
0.4 ± 0.0 BCD
2.6 ± 0.2 DE
12.8 ± 0.6 A

1.2 ± 0.0 CD
1.2 ± 0.1 C
BCD
0.4 ± 0.0
0.6 ± 0.0 BCD
CD
3.3 ± 0.2
4.1 ± 0.2 AB
10.9 ± 0.3 ABCD 10.0 ± 0.2 BCD

0.2 ± 0.0 D
4.5 ± 0.2 BC
2.7 ± 0.1DEF

8

0.1 ± 0.0 C
10.6 ± 0.3 B
0.2 ± 0.0 C
23.3 ± 0.3 ABC

0.6 ± 0.0 A
12.8 ± 0.1 A
0.2 ± 0.0 C
19.6 ± 0.4 E

0.2 ± 0.0 D
2.7 ± 0.1 EF
2.5 ± 0.1EF

1.6 ± 0.2 A
7.1 ± 0.2 A
4.2 ± 0.1 A

26.5 ± 0.7 A
0.3 ± 0.0 DE
16.4 ± 0.3 EF
0.2 ± 0.0 FGH
0.1 ± 0.0 D

23.0 ± 0.3 BC
0.7 ± 0.0 A
16.6 ± 0.3 EF
0.2 ± 0.0 EF
0.2 ± 0.0 D

24.2 ± 0.5 AB
0.3 ± 0.0 DE
18.1 ± 0.1 DE
0.2 ± 0.0 FGH
0.1 ± 0.0 D

0.2 ± 0.0 D
3.2 ± 0.4 CDEF
2.4 ± 0.0 F
27.1 ± 1.1 A
0.3 ± 0.0 DE
15.8 ± 0.2 FG
0.1 ± 0.0 GH
0.0 ± 0.0 D

12

0.1 ± 0.0 D
8.9 ± 0.1 D
0.2 ± 0.0 B
24.8 ± 0.2 A

Initial__

0.1 ± 0.0 CD
11.9 ± 0.1 A
0.4 ± 0.0 B
21.2 ± 0.3 D

0.6 ± 0.1 B
4.7 ± 0.3 B
3.0 ± 0.1 CD

0.2 ± 0.0 D
3.2 ± 0.1 DEF
2.3 ± 0.1 F

0.3 ± 0.0 CD
4.2 ± 0.2 BCD
4.1 ± 0.1 A

23.2 ± 0.8 BC
0.5 ± 0.0 BC
14.2 ± 0.9 GH
0.1 ± 0.0 FGH
0.1 ± 0.0 D

26.5 ± 0.4 A
0.4 ± 0.0 BCD
13.6 ± 0.3 H
0.0 ± 0.0 H
0.0 ± 0.0 D

22.8 ± 0.8 BC
0.4 ± 0.0 CD
19.7 ± 0.3 CD
0.5 ± 0.0 D
0.4 ± 0.0 CD

2.0 ± 0.4 B
1.9 ± 0.4 A
4.2 ± 0.2 AB
10.1 ± 0.8 BCD

3.6 ± 0.1 A
2.0 ± 0.2 A
4.8 ± 0.1 A
8.5 ± 0.4 DE

0.1 ± 0.0 FG
0.1 ± 0.0 D
1.4 ± 0.1 FG
11.4 ± 0.4 AB

33.8 ± 0.3
13.0 ± 0.4 A
53.2 ± 0.1 E
40.8 ± 0.4 DEF
12.1 ± 0.4 DE

34.5 ± 0.2
6.1 ± 0.2 DEF
59.4 ± 0.3 ABC
43.1 ± 0.4 CD
16.4 ± 0.4 B

34.0 ± 0.4
5.8 ± 0.4 EF
60.2 ± 0.1 AB
43.5 ± 1.0 CD
16.7 ± 1.0 AB

35.1 ± 0.3
8.4 ± 0.5 C
56.6 ± 0.4 D
38.2 ± 0.6 FG
18.3 ± 0.4 AB

34.3 ± 0.3
5.8 ± 0.1 EF
59.9 ± 0.2 AB
40.8 ± 0.7 DEF
19.1 ± 0.6 A

34.2 ± 0.3
8.8 ± 0.2 C
57.1± 0.2 D
44.0 ± 0.6 C
13.0 ± 0.4 DE

27.6 ± 0.7 CD

27.8 ± 1.7 BCD

32.4 ± 0.8 A

31.9 ± 1.0 AB

22.9 ± 0.8 F

34.8 ± 0.2
4.8 ± 0.1 F
60.4 ± 0.2 A
49.4 ± 0.7 B
11.0 ± 0.5 E

34.6 ± 0.2
11.2 ± 0.4 B
54.2 ± 0.3 E
40.3 ± 0.6 EFG
13.5 ± 0.6 CD

33.9 ± 0.3
12.1 ± 0.6 AB
54.1 ± 0.4 E
37.7 ± 0.3 G
16.3 ± 0.6 B

34.0 ± 0.4
7.5 ± 0.3 CD
58.5 ± 0.2 C
42.6 ± 0.5 CDE
15.9 ± 0.4 BC

34.8 ± 0.2
5.5 ± 0.2 EF
59.7 ± 0.2 AB
43.7 ± 0.5 C
16.1 ± 0.4 B

PUFA
Balance *

13.7 ± 0.6 H

18.3 ± 0.9 G

25.1 ± 1.1 DEF

30.1 ± 0.9 ABC

27.1 ± 0.7 CDE

26.9 ± 0.6 CDEF 23.0 ± 0.7 EF

* Values for each fatty acid without a common superscript in each row are significantly different (P<0.0001)

2.5 ± 0.1 B
1.0 ± 0.0 B
4.2 ± 0.2 AB
8.9 ± 0.9 CDE

11

0.3 ± 0.0 B
12.1 ± 0.3 A
0.2 ± 0.0 C
21.9 ± 0.3 CD

0.9 ± 0.0 CDE
0.5 ± 0.0 BCD
3.7 ± 0.1 BC
11.2 ± 0.4 ABC

34.4 ± 0.3
6.6 ± 0.1 DE
59.1 ± 0.3 BC
51.0 ± 0.6 B
8.1 ± 0.3 F
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0.2 ± 0.0 D
3.4 ± 0.2 BCDEF
2.4 ± 0.1 EF

10

0.1 ± 0.0 D
9.3 ± 0.2 CD
0.2 ± 0.0 C
24.1 ± 0.3 AB

0.6 ± 0.0 DEF
0.8 ± 0.1 BC
2.0 ± 0.1 EF
8.7 ± 0.3 DE

SFA
34.1 ± 0.2
MUFA *
7.5 ± 0.2 CD
PUFA *
58.4 ± 0.2 C
n-6 PUFA* 53.7 ± 0.2 A
n-3 PUFA* 4.6 ± 0.2 G
7.9 ± 0.4 I

9

0.1 ± 0.0 CD
10.1 ± 0.1 BC
0.4 ± 0.0 B
23.5 ± 0.2 AB

Table 4.3 Fatty acid composition (% of total fatty acids) of brain phospholipids from rats fed experimental and initial diets; values are mean ± S.E.M.; n=6.
See Table 2.4 for diet fatty acid composition.
Diet
16:0
18:0

25.6 ± 0.6
19.8 ± 0.1

1

25.4 ± 0.7
20.0 ± 0.2

2

25.8 ± 0.6
19.9 ± 0.2

3

25.0 ± 0.6
19.5 ± 0.2

4

25.2 ± 0.8
19.7 ± 0.2

24.8 ± 0.6
19.7 ± 0.1

24.5 ± 0.4
19.8 ± 0.2

25.1 ± 0.9
19.9 ± 0.1

24.8 ± 0.5
20.1 ± 0.2

25.1 ± 0.5
19.5 ± 0.2

24.9 ± 0.4
19.7 ± 0.3

25.3 ± 0.8
19.9 ± 0.1

18:1n-9 *
18:1n-7 *
20:1n-9
24:1n-9

17.4 ± 0.3 AB
3.6 ± 0.1 AB
1.3 ± 0.1
1.2 ± 0.2

17.5 ± 0.2 AB
3.6 ± 0.0 AB
1.2 ± 0.1
1.0 ± 0.2

17.4 ± 0.5 AB
3.2 ± 0.3 B
1.2 ± 0.1
1.1 ± 0.2

19.1 ± 0.8 A
3.9 ± 0.1 A
1.4 ± 0.2
1.2 ± 0.3

19.0 ± 0.4 A
3.7 ± 0.1 AB
1.4 ± 0.1
1.2 ± 0.2

18.6 ± 0.5AB
3.7 ± 0.1AB
1.5 ± 0.1
1.2 ± 0.3

19.0 ± 0.5 A
3.8 ± 0.1A
1.4 ± 0.1
1.3 ± 0.2

18.6 ± 0.4 AB
3.8 ± 0.1 A
1.3 ± 0.1
1.2 ± 0.2

17.9 ± 0.6 AB
3.5 ± 0.1 AB
1.3 ± 0.1
1.1 ± 0.2

18.9 ± 0.4AB
3.6 ± 0.1 AB
1.4 ± 0.1
1.3 ± 0.2

19.1 ± 0.4 A
3.7 ± 0.1 AB
1.4 ± 0.1
1.3 ± 0.2

19.0 ± 0.3 A
3.6 ± 0.1 AB
1.3 ± 0.1
1.2 ± 0.2

18:2n-6 *
20:4n-6 *
22:4n-6 *
22:5n-6 *

0.7 ± 0.0 CDE
10.9 ± 0.2 A
3.3 ± 0.0 A
1.5 ± 0.1 A

0.7 ± 0.0 DE
10.9 ± 0.2 A
3.2 ± 0.1 A
0.8 ± 0.1 B

1.1 ± 0.0 A
10.5 ± 0.4 B
3.2 ± 0.1 AB
0.6 ± 0.0 C

18:3n-3 *
20:5n-3 *
22:5n-3 *
22:6n-3 *

0.0 ± 0.0 D
0.0 ± 0.0 D
0.1 ± 0.0 I
12.1 ± 0.2 C

0.0 ± 0.0 D
0.0 ± 0.0 D
0.1 ± 0.0 HI
13.0 ± 0.2 BC

0.0 ± 0.0 D
0.0 ± 0.0 D
0.1 ± 0.0 GHI
13.6 ± 0.2 ABC

0.0 ± 0.0 D
0.0 ± 0.0 CD
0.1 ± 0.0 HI
13.7 ± 0.5 ABC

0.0 ± 0.0 D
0.0 ± 0.0 CD
0.2 ± 0.0 FGH
13.9 ± 0.5 AB

0.0 ± 0.0 CD
0.1 ± 0.0 DE
0.3 ± 0.0 DEF
14.0 ± 0.4 AB

0.0 ± 0.0 BCD
0.1 ± 0.0 DE
0.4 ± 0.0 CD
13.5 ± 0.4 ABC

0.0 ± 0.0 BCD
0.1 ± 0.0 CD
0.2 ± 0.0 EFG
13.6 ± 0.4 ABC

0.0 ± 0.0 CD
0.0 ± 0.0DE
0.3 ± 0.0 DE
14.3 ± 0.3 AB

0.1 ± 0.0 BC
0.1 ± 0.0 BC
0.5 ± 0.0 BC
13.7 ± 0.3 ABC

0.0 ± 0.0 C
0.2 ± 0.0 AB
0.5 ± 0.1 B
13.9 ± 0.2 AB

0.1 ± 0.0 A
0.2 ± 0.0 A
0.7 ± 0.0 A
13.9 ± 0.4 AB

0.0 ± 0.0 D
0.0 ± 0.0 D
0.2 ± 0.0 GHI
15.0 ± 0.4 A

SFA
MUFA
PUFA
n-6 PUFA*
n-3 PUFA*

46.9 ± 0.4
24.0 ± 0.7
29.1 ± 0.3
16.9 ± 0.2 ABC
12.1 ± 0.2 ABC

46.8 ± 0.5
23.9 ± 0.5
29.3 ± 0.2
16.1 ± 0.2 ABCD
13.1 ± 0.2 ABC

47.1 ± 0.5
23.4 ± 0.7
29.5 ± 0.5
15.8 ± 0.4 D
13.7 ± 0.2 A

46.0 ± 0.6
26.2 ± 1.3
27.8 ± 0.8
13.8 ± 0.3 ABC
13.8 ± 0.5 ABC

46.3 ± 0.6
25.8 ± 0.8
27.9 ± 0.5
13.7 ± 0.2 BCD
14.2 ± 0.4 ABC

46.0 ± 0.4
25.5 ± 0.9
28.5 ± 0.5
14.0 ± 0.2 ABCD
14.4 ± 0.4 AB

46.0 ± 0.4
26.0 ± 0.8
28.0 ± 0.5
14.0 ± 0.2 BCD
14.0 ± 0.4 ABC

46.6 ± 0.7
25.5 ± 0.8
27.9 ± 0.3
13.9 ± 0.2 AB
13.9 ± 0.4 BC

46.4 ± 0.4
24.4 ± 0.9
29.2 ± 0.6
14.5 ± 0.4 ABCD
14.7 ± 0.3 ABC

46.6 ± 0.4
25.7 ± 0.7
27.7 ± 0.4
13.2 ± 0.3 BCD
14.4 ± 0.3 ABC

46.1 ± 0.4
26.2 ± 0.7
27.7 ± 0.4
13.0 ± 0.2 A
14.6 ± 0.2 C

46.8 ± 0.8
25.6 ± 0.6
27.5 ± 0.6
12.5 ± 0.3 CD
15.0 ± 0.5 AB

47.2 ± 0.2
22.7 ± 0.6
30.1 ± 0.5
14.9 ± 0.3 ABC
15.1 ± 0.3 A

PUFA
Balance *

41.8 ± 0.5 BCD

45.0 ± 0.4 ABC

46.5 ± 0.7 A

50.1 ± 0.4 BCD

50.9 ± 0.9 ABC

50.7 ± 0.8 ABC

50.1 ± 0.7 ABC

50.0 ± 1.0 CD

50.4 ± 0.7 ABC

52.1 ± 0.7 AB

52.9 ± 0.5 D

54.5 ± 0.8 A

50.4 ± 0.7 ABC

0.3 ± 0.0 H
9.9 ± 0.3 ABCDE
2.8 ± 0.0 CDE
0.4 ± 0.1 CDE

5

0.4 ± 0.0 GH
9.8 ± 0.1 ABCDE
2.8 ± 0.1 CDE
0.2 ± 0.0 EF

6

7

0.8 ± 0.0 BCD
9.8 ± 0.2 ABCDE
2.8 ± 0.1 CD
0.2 ± 0.0 F

8

0.9 ± 0.0 B
9.7 ± 0.2 BCDE
2.7 ± 0.1 CDE
0.2 ± 0.0 F

0.5 ± 0.0 GH
9.9 ± 0.2 ABCDE
2.8 ± 0.1 CD
0.3 ± 0.0 DEF

* Values for each fatty acid without a common superscript in each row are significantly different (P<0.0001)
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9

0.8 ± 0.0 BCD
10.1 ± 0.3 ABCD
2.8 ± 0.1 CD
0.2 ± 0.0 EF

10

0.9 ± 0.0 BC
9.2 ± 0.2 DE
2.5 ± 0.1 DEF
0.2 ± 0.0 F

11

0.6 ± 0.0 FG
9.3 ± 0.2 CDE
2.4 ± 0.0 EF
0.2 ± 0.0 F

12

0.8 ± 0.0 BCD
8.8 ± 0.2 E
2.2 ± 0.1 F
0.2 ± 0.0 F

Initial__
25.4 ± 0.3
20.2 ± 0.2
16.7 ± 0.5 B
3.6 ± 0.1 AB
1.1 ± 0.1
0.9 ± 0.1
0.6 ± 0.0 EF
10.4 ± 0.3 ABC
2.9 ± 0.1 BC
0.5 ± 0.0 CD

Table 4.4 Fatty acid composition (% of total fatty acids) of liver phospholipids from rats fed experimental and initial diets; values are mean ± S.E.M.; n=6.
See Table 2.4 for diet fatty acid composition.
Diet
14:0 *
16:0 *
17:0 *
18:0 *

1

0.1 ± 0.0 D
17.9 ± 0.2 C
0.3 ± 0.0 C
25.1 ± 0.3 A

2

0.1 ± 0.0 D
17.7 ± 0.3 C
0.6 ± 0.0 A
25.5 ± 0.2 A

3

0.1 ± 0.0 D
18.5 ± 0.4 C
0.3 ± 0.0 CD
25.1 ± 0.4 A

4

0.1 ± 0.0 CD
18.7 ± 0.5 BC
0.6 ± 0.0 A
25.1 ± 0.5 A

5

7

8

9

10

0.1 ± 0.0 D
18.8 ± 0.9 BC
0.3 ± 0.0 CD
24.4 ± 0.9 ABC

0.2 ± 0.0 BC
18.7 ± 0.5 BC
0.3 ± 0.0 CD
24.4 ± 0.5 AB

0.5 ± 0.0 A
21.8 ± 0.4 A
0.2 ± 0.0 D
22.3 ± 0.5 BC

0.1 ± 0.0 D
18.0 ± 0.4 C
0.5 ± 0.0 AB
25.5 ± 0.4 A

0.3 ± 0.0 CD
7.1 ± 0.3 A
1.8 ± 0.0 B
0.4 ± 0.1 B

0.3 ± 0.1 CD
4.3 ± 0.5 BC
1.4 ± 0.0 CDE
0.1 ± 0.0 C

0.4 ± 0.0 CD
2.3 ± 0.2 DE
1.4 ± 0.1CDE
0.0 ± 0.0 C

1.3 ± 0.1 A
4.4 ± 0.2 BC
2.3 ± 0.1 A
0.5 ± 0.0 B

0.3 ± 0.0 CD
3.1 ± 0.1 CDE
1.2 ± 0.0 E
0.1 ± 0.0 C

15.1 ± 0.8 ABC
0.8 ± 0.0 C
23.2 ± 0.7 C
0.1 ± 0.0 EF
0.0 ± 0.0 C

10.6 ± 0.2 EF
1.5 ± 0.1 A
17.7 ± 0.6 E
0.2 ± 0.0 DE
0.2 ± 0.0 C

1.0 ± 0.1 C
1.4 ± 0.1 CDE
1.9 ± 0.1 CD
7.2 ± 0.7 DEF

0.2 ± 0.0 D
1.9 ± 0.3 CD
1.9 ± 0.1 CD
11.3 ± 0.3 A

0.8 ± 0.0 C
1.2 ± 0.1DE
1.8 ± 0.1 CD
7.7 ± 0.4 CDEF

1.6 ± 0.2 B
3.0 ± 0.1 BC
2.2 ± 0.1 BC
6.7 ± 0.5 EF

16:1n-7 *
18:1n-9 *
18:1n-7 *
20:3n-9 *

0.3 ± 0.0 CD
3.5 ± 0.3 BCD
1.6 ± 0.1 BCD
0.0 ± 0.0 C

0.3 ± 0.0 CD
3.3 ± 0.1 CD
1.3 ± 0.0 DE
0.0 ± 0.0 C

0.2 ± 0.0 D
1.7 ± 0.1 E
1.3 ± 0.0 DE
0.0 ± 0.0 C

18:2n-6 *
20:3n-6 *
20:4n-6 *
22:4n-6 *
22:5n-6 *

11.0 ± 0.4 DEF
0.4 ± 0.0 D
31.0 ± 0.5 A
0.9 ± 0.1 A
2.3 ± 0.1 A

11.2 ± 0.5 DEF
0.4 ± 0.0 D
30.6 ± 0.4 AB
0.5 ± 0.0 B
0.9 ± 0.2 B

13.7 ± 0.8 CD
0.4 ± 0.0 D
28.4 ± 0.8 AB
0.4 ± 0.0 C
0.2 ± 0.0 C

8.5 ± 0.4 F
1.2 ± 0.0 AB
22.3 ± 0.6 CD
0.1 ± 0.0 EF
0.3 ± 0.1 C

18:3n-3 *
20:5n-3 *
22:5n-3 *
22:6n-3 *

0.0 ± 0.0 D
0.0 ± 0.0 E
0.3 ± 0.0 F
3.9 ± 0.2 G

0.0 ± 0.0 D
0.0 ± 0.0 E
0.5 ± 0.0 F
5.7 ± 0.3 FG

0.1 ± 0.0 D
0.1 ± 0.0 E
0.6 ± 0.0 EF
7.1 ± 0.4 DEF

0.1 ± 0.0 D
0.6 ± 0.1 DE
0.7 ± 0.0 EF
10.1 ± 0.3 AB

0.2 ± 0.0 D
1.2 ± 0.2 DE
1.4 ± 0.2 DE
9.7 ± 0.4 ABC

0.7 ± 0.1 BC
7.0 ± 0.2 A
1.6 ± 0.0 BCD
1.1 ± 0.1 A

6

0.1 ± 0.0 D
19.7 ± 0.3 ABC
0.3 ± 0.0 CD
23.5 ± 0.2 ABC

9.5 ± 0.2 F
1.1 ± 0.1 BC
22.1 ± 0.6 CD
0.1 ± 0.0 EF
0.0 ± 0.0 C

14.3 ± 0.7 BC
0.8 ± 0.1 C
22.3 ± 0.7 CD
0.1 ± 0.0 EF
0.0 ± 0.0 C
0.8 ± 0.1 C
1.1 ± 0.2 DE
1.6 ± 0.2 CD
7.9 ± 0.2 BCDE

14.6 ± 0.4 BC
0.8 ± 0.1 C
23.0 ± 0.4 C
0.1 ± 0.0 EF
0.0 ± 0.0 C

0.1 ± 0.0 D
18.0 ± 0.5 C
0.3 ± 0.0 CD
25.2 ± 0.4 A
0.4 ± 0.1 BCD
3.3 ± 0.7 CD
1.2 ± 0.0 E
0.0 ± 0.0 C
17.0 ± 0.7 AB
1.0 ± 0.1 BC
18.5 ± 0.5 DE
0.1 ± 0.0 F
0.0 ± 0.0 C

11

0.3 ± 0.0 B
21.0 ± 0.7 AB
0.3 ± 0.0 CD
23.3 ± 0.7 ABC
0.6 ± 0.1 BCD
3.2 ± 0.2 CDE
1.7 ± 0.1 BC
0.1 ± 0.0 C
12.8 ± 1.0 CDE
1.1 ± 0.1 BC
16.7 ± 2.2 EF
0.1 ± 0.0 EF
0.0 ± 0.0 C
0.8 ± 0.1 C
4.2 ± 1.0 B
3.0 ± 0.4 A
9.2 ± 0.8 ABCD

12

0.1 ± 0.0 D
17.8 ± 0.4 C
0.3 ± 0.0 C
24.8 ± 0.4 AB
0.3 ± 0.0 CD
3.2 ± 0.2 CDE
1.2 ± 0.0 E
0.1 ± 0.0 C

Initial__

0.2 ± 0.0 CD
20.2 ± 0.8 ABC
0.5 ± 0.0 B
21.7 ± 1.0 C
0.8 ± 0.3 AB
4.9 ± 0.3 B
2.2 ± 0.2 A
0.1 ± 0.0 C

17.7 ± 0.3 A
1.1 ± 0.0 BC
12.7 ± 0.7 F
0.1 ± 0.0 F
0.0 ± 0.0 C

12.4 ± 0.4 CDE
0.8 ± 0.1 C
26.4 ± 1.2 BC
0.3 ± 0.0 CD
0.2 ± 0.1 C

2.8 ± 0.2 A
6.6 ± 0.7 A
2.9 ± 0.1 AB
9.2 ± 0.8 EF

0.2 ± 0.0 D
0.3 ± 0.1 DE
0.7 ± 0.1 EF
6.5 ± 0.5 EF

SFA *
44.1 ± 0.2 CDE
MUFA *
5.7 ± 0.2 BC
PUFA *
50.2 ± 0.1 ABCD
n-6 PUFA* 46.0 ± 0.3 A
n-3 PUFA* 4.1 ± 0.2 F

44.7 ± 0.1 ABCDE 44.8 ± 0.3 ABCD
5.2 ± 0.1 BCD
3.5 ± 0.1 D
ABCD
50.2 ± 0.2
51.7 ± 0.3 A
AB
43.9 ± 0.4
43.7 ± 0.5 AB
EF
6.3 ± 0.3
7.9 ± 0.5 E

45.4 ± 0.2 ABC
9.7 ± 0.3 A
45.0 ± 0.4 E
32.5 ± 0.8 E
11.4 ± 0.4 D

44.3 ± 0.1 BCDE
9.7 ± 0.3 A
46.0 ± 0.3 E
33.1 ± 0.8 DE
12.5 ± 0.5 CD

44.2 ± 0.1 CDE
6.4 ± 0.6 B
49.4 ± 0.6 BCD
37.8 ± 0.7 C
11.5 ± 0.4 D

44.4 ± 0.5 ABCDE
4.4 ± 0.3 CD
51.2 ± 0.4 AB
39.6 ± 0.7 BC
11.6 ± 0.4 D

45.7 ± 0.1 A
8.3 ± 0.3 A
46.0 ± 0.2 E
30.3 ± 0.6 E
15.3 ± 0.4 BC

44.8 ± 0.1 ABCD
4.9 ± 0.1 BCD
50.3 ± 0.1 ABC
38.7 ± 0.4 C
11.5 ± 0.3 D

44.3 ± 0.3 CDE
5.1 ± 0.8 BCD
50.6 ± 0.8 AB
36.8 ± 0.6 CD
13.7 ± 0.3 CD

45.7 ± 0.3 AB
5.8 ± 0.3 BC
48.5 ± 0.4 CD
31.0 ± 1.7 E
17.4 ± 0.2 AB

43.8 ± 0.4 DE
5.1 ± 0.3 BCD
51.2 ± 0.3 AB
31.8 ± 0.7 E
19.2 ± 0.5 A

43.4 ± 0.3 E
8.3 ± 0.6 A
48.3 ± 0.4 D
40.4 ± 0.8 BC
7.7 ± 0.5 E

PUFA
Balance *

12.5 ± 0.7 EF

26.1 ± 1.2 C

27.4 ± 1.2 BC

23.4 ± 0.8 C

22.7 ± 1.5 CD

33.5 ± 1.4 AB

22.8 ± 0.8 CD

27.1 ± 0.8 BC

36.2 ± 3.8 A

37.7 ± 1.5 A

16.1± 1.1 DE

8.2 ± 0.4 F

15.4 ± 0.9 EF

* Values for each fatty acid without a common superscript in each row are significantly different (P<0.0001)
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Table 4.5 Fatty acid composition (% of total fatty acids) of adipose tissue phospholipids from rats fed experimental and initial diets; values are mean ±
S.E.M.; n=6 for all diets, except Diet 3 (n=5). See Table 2.4 for diet fatty acid composition.
Diet
12:0 *
14:0 *
16:0 *
17:0 *
18:0

0.2 ± 0.1 D
0.5 ± 0.1 D
17.6 ± 2.0 AB
0.1 ± 0.0 D
13.6 ± 1.3

16:1n-7 *
18:1n-9 *
18:1n-7 *

1.5 ± 0.3 E
2.5 ± 0.3 BCDE 1.8 ± 0.3 E
BCDE
24.1 ± 1.4
28.4 ± 2.1 B
15.6 ± 1.4 F
C
BC
2.2 ± 0.2
2.3 ± 0.1
1.8 ± 0.1 C

18:2n-6 *
20:4n-6 *
22:4n-6 *
22:5n-6 *

26.7 ± 1.2 B
10.2 ± 0.8 A
0.6 ± 0.2 A
0.5 ± 0.1 A

21.9 ± 1.0 BCD
7.0 ± 1.2 ABC
0.5 ± 0.1 AB
0.1 ± 0.1 B

42.5 ± 2.1 A
5.1 ± 1.3 BC
0.2 ± 0.1 ABC
0.0 ± 0.0 B

8.5 ± 1.0 F
5.9 ± 1.2 ABC
0.1 ± 0.1 CBC
0.0 ± 0.0 B

9.9 ± 0.6 F
3.9 ± 0.9 BC
0.0 ± 0.0 C
0.0 ± 0.0 B

18:3n-3 *
20:5n-3 *
22:5n-3 *
22:6n-3 *

0.3 ± 0.1 E
0.0 ± 0.0 D
0.0 ± 0.0 F
0.3 ± 0.0 B

0.7 ± 0.2 E
0.0 ± 0.0 D
0.1 ± 0.0 EF
0.2 ± 0.0 B

2.0 ± 0.1 DE
0.0 ± 0.0 D
0.1 ± 0.0 EF
0.3 ± 0.1 B

1.0 ± 0.3 E
0.0 ± 0.0 D
0.2 ± 0.0 EF
0.5 ± 0.1 B

2.4 ± 0.1 DE
0.1 ± 0.1 D
0.4 ± 0.1 DEF
0.5 ± 0.1 B

32.6 ± 2.3 B
28.4 ± 2.1 BCD
39.0 ± 1.6 BC
38.4 ± 1.6 B
0.6 ± 0.1 D

35.1 ± 2.3 B
34.1 ± 2.4 B
30.8 ± 2.1 CDE
29.8 ± 2.1 BC
1.0 ± 0.2 D

1.5 ± 0.2 G

3.3 ± 0.9 G

SFA *
MUFA *
PUFA *
n-6 PUFA*
n-3 PUFA*
PUFA
Balance *

1

2

0.4 ± 0.1 D
1.4 ± 0.1 D
19.1 ± 3.0 AB
0.6 ± 0.0 AB
12.7 ± 1.2

3

0.2 ± 0.1 D
0.9 ± 0.1 D
17.8 ± 0.5 AB
0.3 ± 0.1 CD
10.2 ± 1.9

30.0 ± 2.0 B
19.5 ± 1.5 D
50.5 ± 1.0 A
48.0 ± 1.0 A
2.4 ± 0.1 D
4.8 ± 0.2 FG

4

5

6

0.3 ± 0.1 D
1.6 ± 0.1 CD
21.5 ± 1.4 AB
0.6 ± 0.1 A
11.2 ± 1.1

0.3 ± 0.2 D
0.9 ± 0.2 D
19.5 ± 1.3 AB
0.3 ± 0.1 D
9.3 ± 1.5

0.4 ± 0.3 D
1.1 ± 0.2 D
19.3 ± 2.7 AB
0.2 ± 0.0 D
9.6 ± 1.1

3.9 ± 0.6 BC
40.1 ± 1.9 A
2.9 ± 0.1 AB

2.1 ± 0.3 CDE
46.0 ± 2.1 A
3.0 ± 0.2 A

7

3.1 ± 0.4 C
2.7 ± 0.3 C
19.2 ± 1.2 AB
0.2 ± 0.0 D
9.9 ± 1.4

8

11.1 ± 0.7 A
6.8 ± 0.4 A
25.3 ± 0.8 A
0.2 ± 0.1 D
10.3 ± 1.2

9

10

12

Initial__

0.9 ± 0.4 CD
1.2 ± 0.2 D
16.7 ± 1.0 B
0.3 ± 0.0 D
11.2 ± 1.7

0.3 ± 0.1 D
1.2 ± 0.1 D
22.7 ± 0.7 AB
0.3 ± 0.1 BCD
10.8 ± 0.8

2.6 ± 0.2 BCDE 2.9 ± 0.5 BCDE 5.8 ± 0.3 A
27.3 ± 2.3 B
18.8 ± 1.5 CDEF 17.8 ± 1.2 EF
C
2.2 ± 0.1
1.9 ± 0.1C
2.9 ± 0.1 AB

2.7 ± 0.3 BCDE 2.7 ± 0.6 BCDE 3.9 ± 0.3 B
25.8 ± 1.8 BCD 14.9 ± 1.0 F
18.0 ± 0.9 DE
C
C
2.1 ± 0.1
1.7 ± 0.1
2.1 ± 0.1 C

2.0 ± 0.2 DE
16.6 ± 1.3 EF
1.7 ± 0.1 C

3.7 ± 0.3 BCD
26.3 ± 1.3 BC
3.0 ± 0.2 A

20.7 ± 1.4 CD
4.3 ± 0.9 BC
0.1 ± 0.0 C
0.0 ± 0.0 B

19.9 ± 1.5 CD
4.1 ± 0.7 BC
0.0 ± 0.0 C
0.0 ± 0.0 B

8.8 ± 0.5 F
6.3 ± 0.3 ABC
0.1 ± 0.0 C
0.0 ± 0.0 B

9.2 ± 0.6 C
10.2 ± 0.8 C
0.3 ± 0.1 CD
0.4 ± 0.1 BCD
0.6 ± 0.1 BCDE 0.8 ± 0.1 ABCD
0.6 ± 0.1 B
0.5 ± 0.1 B

1.6 ± 0.1 E
0.3 ± 0.0 CD
0.5 ± 0.0 BCDEF
0.7 ± 0.1 B

0.3 ± 0.1 D
1.1 ± 0.1 D
17.6 ± 0.8 AB
0.2 ± 0.0 D
11.5 ± 1.5

11

8.6 ± 1.4 B
5.4 ± 0.6 B
24.4 ± 1.5 AB
0.2 ± 0.1 D
9.4 ± 1.2

23.1 ± 0.9 BC
4.5 ± 0.8 BC
0.3 ± 0.2 ABC
0.0 ± 0.0 B

0.4 ± 0.2 D
1.4 ± 0.2 D
18.6 ± 1.5 AB
0.5 ± 0.0 ABC
12.4 ± 0.7

21.7 ± 1.2 BCD
4.2 ± 0.7 BC
0.1 ± 0.0 C
0.0 ± 0.0 B

11.6 ± 1.5 EF
4.1 ± 0.8 BC
0.0 ± 0.0 C
0.0 ± 0.0 B

16.9 ± 0.9 DE
2.8 ± 0.6 C
0.0 ± 0.0 C
0.0 ± 0.0 B

17.4 ± 0.4 D
7.6 ± 1.1 AB
0.3 ± 0.1 ABC
0.1 ± 0.0 B

8.3 ± 0.6 C
20.2 ± 2.0 B
0.3 ± 0.0 CD
0.8 ± 0.1 ABC
0.8 ± 0.1 ABCD 0.9 ± 0.1 ABC
0.6 ± 0.1 B
0.6 ± 0.1 B

7.7 ± 0.8 CD
0.9 ± 0.3 AB
1.1 ± 0.2 A
0.7 ± 0.1 B

25.8 ± 3.2 A
1.2 ± 0.3 A
1.0 ± 0.2 AB
0.5 ± 0.1 B

1.6 ± 0.2 E
0.0 ± 0.0 D
0.5 ± 0.1 CDEF
1.7 ± 0.2 A

35.9 ± 1.3 B
47.7 ± 2.4 A
16.5 ± 2.1 G
14.8 ± 2.1 F
1.7 ± 0.3 D

30.8 ± 2.0 B
51.8 ± 2.4 A
17.4 ± 1.7 G
14.0 ± 1.5 F
3.4 ± 0.2 D

31.1 ± 1.9 B
32.8 ± 2.6 BC
36.1 ± 2.4 BCD
25.4 ± 2.3 CD
10.7 ± 0.5 C

35.6 ± 0.8 B
24.2 ± 1.8 CD
40.2 ± 1.4 B
28.2 ± 1.9 CD
12.1 ± 0.8 C

54.2 ± 1.3 A
27.1 ± 1.4 BCD
18.7 ± 0.8 FG
15.6 ± 0.7 F
3.1 ± 0.2 D

34.6 ± 1.6 B
31.2 ± 2.2 BC
34.2 ± 2.2 BCDE
24.2 ± 2.1 CDE
10.0 ± 0.6 C

31.2 ± 1.6 B
19.7 ± 1.5 D
49.1 ± 0.8 A
26.3 ± 1.9 CD
22.8 ± 1.7 B

48.6 ± 1.3 A
24.7 ± 1.2 BCD
26.7 ± 1.9 EF
16.0 ± 2.3 EF
10.6 ± 1.0 C

30.8 ± 2.8 B
20.5 ± 1.4 D
48.7 ± 1.8 A
19.8 ± 1.4 DEF
28.9 ± 2.7 A

36.2 ± 1.2 B
33.9 ± 1.7 B
29.8 ± 1.0 DE
26.1 ± 0.9 CD
3.7 ± 0.3 D

11.2 ± 2.2 EFG

20.0 ± 1.3 DE

30.1 ± 2.2 CD

30.4 ± 2.5 CD

16.6 ± 0.6 EF

29.6 ± 2.4 CD

46.4 ± 3.6 B

41.2 ± 5.3 BC

58.8 ± 3.9 A

12.6 ± 0.9 EFG

* Values for each fatty acid without a common superscript in each row are significantly different (P<0.0001)
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Table 4.6 Fatty acid composition (% of total fatty acids) of red blood cells phospholipids from rats fed experimental and initial diets; values are mean ±
S.E.M.; n=6. See Table 2.4 for diet fatty acid composition.
Diet
14:0 *
16:0
17:0 *
18:0
22:0
24:0 *
16:1n-7
18:1n-9 *
18:1n-7 *
20:3n-9 *
24:1n-9 *

1

0.2 ± 0.0 C
27.2 ± 0.6
0.4 ± 0.0 C
15.8 ± 0.5
0.4 ± 0.0
0.9 ± 0.1 BC
0.3 ± 0.1
6.9 ± 0.2 CD
2.2 ± 0.1 CDE
0.0 ± 0.0 C
0.9 ± 0.1 BCDEF

2

0.2 ± 0.1 C
27.0 ± 0.8
0.8 ± 0.0 A
16.9 ± 0.6
0.5 ± 0.0
1.1 ± 0.1 ABC

3

4

5

0.2 ± 0.0 C
29.0 ± 0.4
0.4 ± 0.0 C
16.0 ± 0.5
0.4 ± 0.0
1.2 ± 0.2 ABC

0.3 ± 0.0 C
26.9 ± 0.5
0.8 ± 0.0 A
15.7 ± 0.5
0.5 ± 0.1
0.9 ± 0.1 BC

0.2 ± 0.1 C
28.9 ± 0.8
0.4 ± 0.0 C
15.4 ± 0.9
0.3 ± 0.0
0.7 ± 0.1 C

0.4 ± 0.0
6.1 ± 0.5 CDE
1.9 ± 0.1 DEF
0.0 ± 0.0 C
0.9 ± 0.1 BCDE

0.3 ± 0.1
3.8 ± 0.3 E
1.8 ± 0.1 EF
0.0 ± 0.0 C
0.7 ± 0.1 DEF

0.5 ± 0.0
10.3 ± 0.2 AB
2.3 ± 0.1 CD
0.7 ± 0.1 A
1.4 ± 0.1 A

0.3 ± 0.1
11.0 ± 0.4 A
2.4 ± 0.1 BC
0.2 ± 0.0 B
1.2 ± 0.1 AB

6

7

0.3 ± 0.1 C
28.4 ± 0.7
0.4 ± 0.0 C
16.4 ± 0.8
0.3 ± 0.0
1.1 ± 0.1 ABC
0.3 ± 0.0
7.0 ± 0.4 CD
1.9 ± 0.1 DEF
0.0 ± 0.0 C
0.8 ± 0.0 CDEF

8

9

0.5 ± 0.0 BC
29.1 ± 1.0
0.4 ± 0.0 C
16.6 ± 0.7
0.4 ± 0.0
1.4 ± 0.1 AB

1.1 ± 0.2 A
29.3 ± 0.6
0.4 ± 0.1 C
15.2 ± 1.1
0.74 ± 0.0
1.1 ± 0.2 ABC

0.2 ± 0.0 C
25.8 ± 0.9
0.7 ± 0.0 A
16.6 ± 0.4
0.4 ± 0.1
1.5 ± 0.1 AB

0.4 ± 0.1
4.7 ± 0.6 DE
1.8 ± 0.1 EF
0.0 ± 0.0 C
0.5 ± 0.0 F

0.6 ± 0.1
6.1 ± 0.3 CDE
2.8 ± 0.1 AB
0.2 ± 0.0 B
1.0 ± 0.1 BCD

0.4 ± 0.1
5.9 ± 0.3 DE
1.8 ± 0.1 EF
0.0 ± 0.0 C
0.8 ± 0.0 CDEF

8.0 ± 0.4 DE
0.2 ± 0.0 C
0.9 ± 0.1 A
22.1 ± 1.0 BCD
0.7 ± 0.1 CDE
0.2 ± 0.1 CD

11.5 ± 0.4 AB
0.3 ± 0.0 BC
0.7 ± 0.1 ABC
21.8 ± 0.7 BCD
0.5 ± 0.1 DEF
0.1 ± 0.0 D

10

0.2 ± 0.1 C
28.6 ± 0.5
0.4 ± 0.0 C
16.7 ± 0.7
0.4 ± 0.0
1.5 ± 0.1 AB
0.3 ± 0.0
4.9 ± 0.8 DE
1.7 ± 0.0 F
0.0 ± 0.0 C
0.5 ± 0.0 EF

11

0.9 ± 0.1 AB
28.9 ± 0.4
0.3 ± 0.0 C
15.1 ± 0.9
0.4 ± 0.0
1.4 ± 0.1 ABC
0.5 ± 0.1
6.2 ± 0.6 CDE
2.2 ± 0.1 CDE
0.0 ± 0.0 C
0.7 ± 0.1 CDEF

12

0.3 ± 0.0 C
28.1 ± 1.0
0.5 ± 0.0 BC
18.1 ± 1.0
0.4 ± 0.0
1.6 ± 0.2 A
0.2 ± 0.1
5.4 ± 0.5 DE
1.5 ± 0.1 F
0.1 ± 0.1 C
0.7 ± 0.1 DEF

Initial__

0.4 ± 0.2 C
28.0 ± 1.7
0.7 ± 0.1 AB
13.1 ± 1.9
0.4 ± 0.1
1.0 ± 0.1 ABC
0.6 ± 0.1
8.3 ± 0.7 BC
2.9 ± 0.2 A
0.1 ± 0.0 BC
1.1 ± 0.1 ABC

18:2n-6 *
20:2n-6 *
20:3n-6 *
20:4n-6 *
22:4n-6 *
22:5n-6 *

9.3 ± 0.2 BCD
0.5 ± 0.1 AB
0.4 ± 0.0 EF
27.8 ± 0.7 A
2.8 ± 0.1 A
1.6 ± 0.2 A

9.4 ± 0.4 BCD
0.3 ± 0.0 BC
0.4 ± 0.0 F
26.8 ± 0.9 A
2.4 ± 0.1 AB
0.9 ± 0.1 B

12.2 ± 0.2 A
0.7 ± 0.0 A
0.4 ± 0.0 DEF
25.5 ± 0.3 AB
2.2 ± 0.1 B
0.5 ± 0.1 C

5.5 ± 0.3 F
0.1 ± 0.0 C
0.8 ± 0.0 AB
24.1 ± 0.1 ABC
0.8 ± 0.1 CD
0.3 ± 0.1 CD

6.5 ± 0.2 EF
0.2 ± 0.0 C
0.8 ± 0.1 ABC
21.9 ± 1.1 BCD
0.5 ± 0.1 DEF
0.1 ± 0.0 D

18:3n-3 *
20:5n-3 *
22:5n-3 *
22:6n-3 *

0.0 ± 0.0 E
0.0 ± 0.0 E
0.4 ± 0.0 H
1.2 ± 0.1 D

0.0 ± 0.0 E
0.1 ± 0.0 DE
0.9 ± 0.0 GH
2.0 ± 0.1 CD

0.1 ± 0.0 E
0.1 ± 0.0 DE
1.4 ± 0.1 FG
2.1 ± 0.2 CD

0.1 ± 0.0 E
0.8 ± 0.0 CDE
1.8 ± 0.1 EFG
4.2 ± 0.1 A

0.2 ± 0.0 E
1.5 ± 0.1 CD
2.8 ± 0.1 DE
3.5 ± 0.3 AB

0.6 ± 0.0 D
1.8 ± 0.1 C
3.8 ± 0.1 BC
2.8 ± 0.1 BC

0.6 ± 0.0 D
2.0 ± 0.2 C
4.5 ± 0.2 AB
2.5 ± 0.1 BC

0.2 ± 0.1 E
1.6 ± 0.3 CD
2.8 ± 0.2 CD
4.2 ± 0.2 A

0.6 ± 0.1 D
2.0 ± 0.2 C
4.4 ± 0.2 AB
3.0 ± 0.1 BC

1.3 ± 0.1 B
3.9 ± 0.1 B
4.9 ± 0.2 A
2.3 ± 0.2 C

0.9 ± 0.1 C
6.0 ± 0.8 A
5.4 ± 0.5 A
3.4 ± 0.3 AB

2.2 ± 0.0 A
7.3 ± 0.6 A
5.0 ± 0.2 A
2.0 ± 0.1CD

0.1 ± 0.0 E
0.6 ± 0.3 CDE
2.4 ± 0.3 DEF
4.1 ± 0.5 A

45.4 ± 1.0
10.5 ± 0.2 CD
44.1 ± 1.1
42.4 ± 1.1 A
1.7 ± 0.1 F

47.1 ± 1.4
9.6 ± 0.3 CDE
43.3 ± 1.4
40.3 ± 1.3 ABC
3.0 ± 0.2 F

47.7 ± 0.7
6.9 ± 0.3 F
45.4 ± 0.7
41.5 ± 0.5 AB
3.9 ± 0.2 F

45.7 ± 0.5
14.9 ± 0.3 A
39.4 ± 0.4
31.7 ± 0.4 DEF
6.9 ± 0.2 E

46.4 ± 1.5
15.3 ± 0.5 A
38.3 ± 1.4
29.9 ± 1.2 DEF
8.1 ± 0.3 CDE

47.4 ± 1.2
10.2 ± 0.5 CDE
42.3 ± 1.2
33.2 ± 1.0 D
9.2 ± 0.2 CDE

48.8 ± 1.5
7.7 ± 0.5 EF
43.5 ± 1.4
33.6 ± 1.2 D
9.9 ± 0.3 CD

48.2 ± 1.8
10.7 ± 0.5 BC
41.1 ± 1.5
32.0 ± 1.5 DE
8.9 ± 0.6 CDE

45.7 ± 1.5
9.2 ± 0.3 CDEF
45.1 ± 1.5
34.9 ± 1.1 CD
10.1 ± 0.5 BC

48.3 ± 0.9
7.7 ± 0.9 EF
44.1 ± 1.3
31.3 ± 1.1 DEF
12.8 ± 0.3 AB

47.6 ± 1.1
9.9 ± 0.7 CDE
42.4 ± 1.2
26.5 ± 1.7 EF
15.9 ± 1.4 A

49.6 ± 1.7
8.0 ± 0.6 DEF
42.4 ± 1.3
25.3 ± 0.9 F
17.0 ± 0.7 A

44.2 ± 3.8
13.3 ± 0.9 AB
42.5 ± 3.4
35.1 ± 2.9 BCD
7.2 ± 0.8 DE

3.8 ± 0.2 D

7.0 ± 0.2 D

8.5 ± 0.4 D

17.9 ± 0.4 C

21.4 ± 0.6 C

21.7 ± 0.3 C

22.7 ± 0.5 C

21.9 ± 1.6 C

22.5 ± 0.6 C

29.1 ± 0.3 B

37.6 ± 3.3 A

40.2 ± 1.2 A

17.1 ± 1.6 C

SFA
MUFA *
PUFA
n-6 PUFA*
n-3 PUFA*
PUFA
Balance *

10.5 ± 0.5 ABC 11.9 ± 0.5 A
0.3 ± 0.0 BC
0.3 ± 0.0 BC
CDEF
0.6 ± 0.0
0.6 ± 0.0 BCDEF
BCD
21.2 ± 0.8
20.2 ± 0.7 CDE
DEF
0.5 ± 0.0
0.4 ± 0.0 DEF
D
0.1 ± 0.0
0.1 ± 0.0 D

* Values for each fatty acid without a common superscript in each row are significantly different (P<0.0001)
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11.8 ± 0.6 A
8.8 ± 0.7 ACDE 10.5 ± 0.6 ABC
BC
0.3 ± 0.0
0.2 ± 0.0 C
0.3 ± 0.0 BC
ABCD
BCDE
0.6 ± 0.0
0.6 ± 0.1
0.6 ± 0.0 CDEF
DEF
EF
18.3 ± 0.8
16.6 ± 1.1
13.8 ± 0.4 F
EF
EF
0.2 ± 0.0
0.2 ± 0.1
0.1 ± 0.0 F
D
D
0.0 ± 0.0
0.0 ± 0.0
0.0 ± 0.0 D

8.0 ± 0.6 DE
0.3 ± 0.1 BC
0.7 ± 0.0 ABCD
24.6 ± 2.0 ABC
1.1 ± 0.2 C
0.4 ± 0.1 CD

4.2 Effect of diet SFA on membrane SFA composition
Membrane SFA content is unresponsive to diet SFA content
The majority of the tissues examined regulated a constant membrane SFA
content despite very large changes in diet SFA content (8 - 88% of total diet fatty acids),
with slopes ≤ 0.02 for muscle, heart, brain, liver and RBC (Figure 4.1; linear regression
equations are presented in Appendix 3). Adipose tissue membranes are most responsive
to diet SFA content (slope 0.28). This indicates that adipose tissue phospholipid SFAs
changed by 28% for a 100% change in diet SFA. This is reflected in the range of
adipose tissue membrane SFA content which varied from 30 – 54% of total fatty acids
(Table 4.5).
In contrast, the phospholipid SFA content of the other tissues measured remains
fairly constant (varying by only 1-5% over the full diet SFA range of 80%). All tissues
maintain a membrane SFA content less than 50% of total fatty acids, with brain, liver
and RBC containing very similar amounts of membrane SFA (~45%) and muscle and
heart membranes slightly lower amounts (~35%).

Figure 4.1 Saturated fatty acid (SFA) content of rat tissue phospholipids relative to
SFA content of diet. (a) Skeletal muscle - ο; Heart - . (b) Brain - Δ; Liver - . (c)
Adipose tissue (perirenal) - ; Red blood cells (RBC) - ∇. In each graph the solid
coloured square symbol represents the value for initial rats and all open symbols
represent data from the twelve experimental diets. Error bars show ± S.E.M. and if they
are not visible they are smaller than symbol. The dotted line in each graph indicates line
of perfect diet-membrane conformity. See Appendix 3 for regression equations and
statistical values.
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4.3 Effect of diet MUFA on membrane MUFA composition
Diet MUFA content has very little influence on membrane fat profile
Most of the tissues are only slightly responsive to large changes in diet MUFA
content (6 – 64% of total diet fatty acids), with muscle, heart, liver and RBC responding
similarly (slopes 0.07 – 0.11; Figure 4.2; for linear regression equations see the
Appendix 4). In contrast, the brain MUFA composition is strictly regulated in response
to diet MUFA content (slope 0.00). Again, the most responsive membrane
phospholipids are those of the adipose tissue (slope 0.52).
The MUFA content of the membranes is generally lower than SFA content, with
the exception of the adipose tissue which varied by 20-52% of total fatty acids. Muscle,
heart, liver and RBC membranes maintain similar MUFA levels (≤ 15% of total fatty
acids), while the brain phospholipids have higher levels of MUFA content at ~ 25%.

Figure 4.2 Monounsaturated fatty acid (MUFA) content of rat tissue phospholipids
relative to MUFA content of diet. (a) Skeletal muscle - ο; Heart - . (b) Brain - Δ;
Liver - . (c) Adipose tissue (perirenal) - ; Red blood cells (RBC) - ∇. In each graph
the solid coloured square symbol represents the value for initial rats and all open
symbols represent data from the twelve experimental diets. Error bars show ± S.E.M.
and if they are not visible they are smaller than symbol. The dotted line in each graph
indicates line of perfect diet-membrane conformity. See Appendix 4 for regression
equations and statistical values.
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4.4 Effect of diet PUFA on membrane PUFA composition
Membrane PUFA content is slightly responsive to diet fat profile
Similar to the membrane MUFA content, the total PUFA content of most tissues
is fairly unresponsive to great changes in diet PUFA content (4 – 80% of total diet fatty
acids), with slopes ranging 0.06 – 0.10 in RBC, liver, heart and muscle (Figure 4.3; for
linear regression equations see Appendix 5). Again, the brain is the most regulated
tissue in terms of total PUFA content (slope 0.01) while the adipose tissue membranes
are the most responsive to diet PUFA (slope 0.44). PUFA levels are lowest in the brain
(~30% of total fatty acids), with higher levels seen in the other tissues (muscle, heart
and liver ~50% of total fatty acids and ~40% in RBC). Adipose tissue membrane PUFA
content is highly variable, ranging 17-51% total fatty acids.
The results show that the membranes of all tissues (except adipose tissue) are
regulating the composition of the three major fatty acid classes (SFA, MUFA and total
PUFA). Muscle, heart, liver and RBC membranes consist of similar amounts of each fat
type and respond in a similar manner to changes in diet SFA, MUFA and total PUFA
content. Brain phospholipid composition is comparable to the other tissues for SFA, but
consists of higher MUFA and lower PUFA contents when compared to the membranes
of the other tissues. The brain membranes are the most regulated for all fatty acid types,
while those of adipose tissue are the most responsive to changes in diet SFA, MUFA
and PUFA content.

Figure 4.3 Polyunsaturated fatty acid (PUFA) content of rat tissue phospholipids
relative to PUFA content of diet. (a) Skeletal muscle - ο; Heart - . (b) Brain - Δ; Liver
- . (c) Adipose tissue (perirenal) - ; Red blood cells (RBC) - ∇. In each graph the
solid coloured square symbol represents the value for initial rats and all open symbols
represent data from the twelve experimental diets. Error bars show ± S.E.M. and if they
are not visible they are smaller than symbol. The dotted line in each graph indicates line
of perfect diet-membrane conformity. See Appendix 5 for regression equations and
statistical values.
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4.5 Effect of diet n-6 PUFA on membrane n-6 PUFA composition
Membrane n-6 PUFA content is responsive to diet n-6 PUFA
The diet n-6 PUFA is present in the form of 18:2n-6 while the membrane n-6
PUFA content includes 18C and 20-22C n-6 PUFA. Of all the major fatty acid classes,
membranes are most responsive to diet n-6 PUFA content (Figure 4.4; for linear
regression equations see Appendix 6). Muscle, heart, liver and RBC membrane respond
similarly to diet n-6 PUFA (slopes 0.21 – 0.24). Brain n-6 PUFA composition is the
most constant, but shows a slight increase in response to diet n-6 PUFA (slope 0.05).
Adipose tissue membranes are highly responsive to diet n-6 PUFA (slope 0.50).
The amount of n-6 PUFA in the phospholipids varies between tissues. The
lowest amount of n-6 PUFA is found in the brain (~15% total fatty acids). Adipose
tissue membranes vary in the n-6 PUFA composition the most with values between 14 –
48%, but this variation is mainly due to the membrane 18:2n-6 content and to a lesser
extent due to membrane 20:4n-6 content. All other tissues maintain n-6 PUFA levels
between 25 - 54%.

Figure 4.4 n-6 polyunsaturated fatty acid (n-6 PUFA) content of rat tissue
phospholipids relative to n-6 PUFA content of diet. (a) Skeletal muscle - ο; Heart - .
(b) Brain - Δ; Liver - . (c) Adipose tissue (perirenal) - ; Red blood cells (RBC) - ∇.
In each graph the solid coloured square symbol represents the value for initial rats and
all open symbols represent data from the twelve experimental diets. Error bars show ±
S.E.M. and if they are not visible they are smaller than symbol. The dotted line in each
graph indicates line of perfect diet-membrane conformity. See Appendix 6 for
regression equations and statistical values.
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4.6 Effect of diet n-3 PUFA on membrane n-3 PUFA composition
Membrane n-3 PUFA content is moderately responsive to diet n-3 PUFA
The diet n-3 PUFA contained only 18:3n-3 while the n-3 PUFA content of the
membrane lipids includes 18C and 20-22C n-3 PUFA. Membrane n-3 PUFA content is
also quite responsive to diet n-3 PUFA content in most tissues (Figure 4.5; for linear
regression equations see Appendix 7). This is the case for muscle, heart, liver and RBC
phospholipids (slopes 0.12 – 0.17) and to a greater extent in the adipose tissue
membranes (slope 0.40). The n-3 PUFA content of the brain membranes is more
regulated (slope 0.02) than the n-6 PUFA content. The membrane lipids of all tissues
have similar levels of n-3 PUFA (< 30% of total fatty acids).
Although the total PUFA content of the membranes is constant, when
considered individually the essential fatty acids (n-6 and n-3 PUFA) exert a greater
influence on membrane composition than total PUFA. This is especially evident when
comparing the response of each tissue to diet fat profile.

Figure 4.5 n-3 polyunsaturated fatty acid (n-3 PUFA) content of rat tissue
phospholipids relative to n-3 PUFA content of diet. (a) Skeletal muscle - ο; Heart - .
(b) Brain - Δ; Liver - . (c) Adipose tissue (perirenal) - ; Red blood cells (RBC) - ∇.
In each graph the solid coloured square symbol represents the value for initial rats and
all open symbols represent data from the twelve experimental diets. Error bars show ±
S.E.M. and if they are not visible they are smaller than symbol. The dotted line in each
graph indicates line of perfect diet-membrane conformity. See Appendix 7 for
regression equations and statistical values.
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4.7 Comparison of response of membranes between fatty acid types and
between tissues
The response of membrane lipids from each tissue to diet fat profile is displayed
in Figure 4.6, where the slope of each relationship is plotted. Adipose tissue
phospholipids show the greatest responsivity of all tissues to all diet fat types, being
especially responsive to diet MUFA and n-6 PUFA (slopes 0.52 and 0.50 respectively).
For all other tissues (muscle, heart, brain, liver and RBC) the results show that
the membrane fatty acid composition is regulated relatively constant even over large
changes in diet fatty acid profile. Membrane SFA content is the most highly regulated
fatty acid class (slopes ≤0.02 ) and membrane MUFA and PUFA content only slightly
more responsive for all tissues (slopes ≤0.12 and 0.10 respectively).
The membranes are more responsive to diet n-3 PUFA (slopes ≤0.17) and to an
even greater extent to diet n-6 PUFA (slopes ≤0.24), and this relationship is significant
even for brain phospholipids, which are the most regulated membranes (slope 0.02 and
0.05 for n-3 PUFA and n-6 PUFA respectively). The highest slope value (disregarding
the adipose tissue) of 0.24 for liver n-6 PUFA indicates that a 100% change in diet n-6
PUFA results in a 24% change in n-6 PUFA content of liver membrane lipids. This
shows that although the composition of the essential fatty acids in the membranes can
be altered, this can only occur to a small degree.

Figure 4.6 The responsiveness of tissue phospholipids to diet fatty acid composition (%
total fatty acids). (a) SFA (b) MUFA (c) PUFA (d) n-6 PUFA (e) n-3 PUFA. A value
of zero indicates no relationship, while a value of 1 indicates that the phospholipid fatty
acid composition perfectly conforms to diet fat profile. Tissues include skeletal muscle,
heart, brain, liver, adipose tissue and red blood cells (RBC). Values are slopes ± S.E.M..
Significant relationships are shown where the slope of the line of fit is significantly
different from zero: * P < 0.05.
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The results of the present study show that the membrane fatty acid composition
of muscle, heart, brain, liver, RBC and to a lesser extent, adipose tissue, are fairly
unresponsive to large changes in diet fat profile, with diet n-3 and n-6 PUFA the most
influential fatty acid classes. These essential fatty acids compete for the same enzymes
for incorporation into the cell membrane (the acyltransferases), so the proportion of diet
n-3 PUFA relative to n-6 PUFA should have a significant influence on the membrane
fatty acid composition.
Some comment needs to made concerning the findings for adipose tissue
phospholipids in this study. Adipose tissue consists of over 90% lipids (of dry weight),
which further consists of 90-98% triglycerides and only 0.25% phospholipids (Shapiro
1977). This could potentially lead to problems in determining the phospholipid fatty
acid composition due to contamination from the fatty acid composition of the
triglycerides in adipose tissue (the results for which will be presented in Chapter 5).
Thus particular care was taken to ensure that phospholipid fatty acid composition of
adipose tissue was the parameter being measured. Firstly, during the solid phase
extraction step (see page 33) twice normal the volume of solvent was used to make sure
that all triglyceride was eluted prior to phospholipid collection. For the adipose tissue
samples initially run on the GC the total peak area for the phospholipid samples from
each rat were < 0.5% of the total peak areas for the triglyceride samples (0.34 ± 0.02%;
n=5). This indicates that the triglyceride fraction did not appear to be contaminating the
phospholipids. Furthermore, whereas the triglyceride fatty acid methyl ester samples
injected onto the GC required dilution to prevent FID overload, the fatty acid methyl
ester samples from the adipose tissue phospholipids required concentration by
additional steps (an increased injection volume and split ratio) to maximise
measurement.
In addition to this, although the fatty acid composition of the adipose tissue
phospholipids is quite similar to those of the triglycerides, there are some differences.
The content of 18:0 and 20:4n-6 is much higher in the phospholipids, with only
negligible amounts of 20:4n-6 present in the triglycerides. There have been limited
studies done in the past which have looked at both the phospholipid and triglyceride
fatty acid composition of the adipose tissue. One study in mice demonstrated similar
results, with both the adipose tissue phospholipids and triglycerides showing a high
responsivity to diet fat profile and much lower levels of 20-22C PUFA present in the
triglycerides (Tallman and Taylor 2003). Together these reasons support the proposition
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that the fatty acid analysis of the adipose tissue phospholipids were a reasonably true
measure of their composition.
Compared to the other diets, diet 7, 8 and 11 contain higher levels of short- and
medium-chain SFA (i.e. 8:0, 10:0, 12:0 and 14:0). The adipose tissue shows increased
incorporation of 12:0 and 14:0 in both the phospholipids and triglycerides when
compared to other tissues (see Chapter 5 for triglyceride composition). The increased
levels of these SFA in the adipose tissue phospholipids may be due to direct transfer
from the triglycerides or simply due to contamination from the adipose tissue
triglyceride fraction during analysis. To further confirm the purity of the adipose tissue
phospholipid fraction perhaps thin layer chromatography should be employed.
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4.8 Effect of the balance between diet n-3 & n-6 PUFA on membrane
composition
Most tissues respond to diet PUFA balance in a biphasic manner
A single linear relationship did not best describe the diet-membrane PUFA
balance relationship for most tissues (Figure 4.7; see Appendix 8 for linear regression
equations). A biphasic plot with two linear relationships provided a better fit for the
muscle, heart, brain, liver and RBC membrane PUFA balance (Figure 4.7). Justification
for the use of biphasic relationships for some tissues is described in the next section.
The results show that for these tissues membrane lipid composition is highly responsive
to diet PUFA balance < 10% (slopes 0.65 – 1.47; P≤0.0007 for all tissues) whereas at
diet PUFA balances >10% the membranes are able to maintain and a more constant
PUFA balance (slopes 0.07 – 0.40; P<0.0001 for all tissues).

Figure 4.7 PUFA balance of rat tissue phospholipids relative to PUFA balance of diet
(n-3 PUFA as % of total PUFA). (a) Skeletal muscle - ο; Heart - . (b) Brain - Δ; Liver
- . (c) Adipose tissue (perirenal) - ; Red blood cells (RBC) - ∇. In each graph the
solid coloured square symbol represents the value for initial rats and all open symbols
represent data from the twelve experimental diets. Error bars show ± S.E.M. and if they
are not visible they are smaller than symbol. The dotted line in each graph indicates line
of perfect diet-membrane conformity. See Appendix 8 for regression equations and
statistical values.
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Interestingly, adipose tissue phospholipids did not show the strong biphasic
response present in the other tissues, but showed a single linear response to diet PUFA
balance (Figure 4.7c). The membranes of adipose tissue are highly responsive to diet
PUFA balance (slope 0.60; P<0.0001). At diet PUFA balances < 10% the membrane
PUFA balance of adipose tissue appears to conform quite closely to diet PUFA balance
(i.e. data for adipose tissue falls on the line of perfect diet-membrane conformity).
Variation in PUFA balance between the tissues is not huge, however, the brain is
quite unique in regulating membrane PUFA balance at higher levels than the membrane
lipids of other tissues (42 – 55%). The PUFA balance of heart, liver and RBC
membranes is slightly lower than the brain ranging from ~4 – 40% for all tissues, while
muscle levels are maintained at slightly higher levels (18 - 48%). The PUFA balance of
the adipose tissue phospholipids is the most variable, ranging from 2 – 59%.
The results indicate that the n-3 PUFA component of membrane fatty acid
composition is driving the biphasic nature of diet-membrane relationship. Since the
PUFA balance describes the interaction between n-6 and n-3 PUFA and while the n-6
PUFA diet-membrane relationship is clearly linear (Figure 4.4), the n-3 PUFA content
of the membranes appears to deviate from the single linear relationship when diet n-3
PUFA drops below 10% (Figure 4.5).
From these results it can be concluded that diet PUFA balance is the most
important parameter influencing membrane fatty acid composition. Although the
membranes of all tissues measured showed an increased responsiveness to diet n-3
PUFA and n-6 PUFA when considered individually, the balance between these diet
essential fatty acids elicits an even greater response in all membranes. In particular, the
greatest overall response is seen in muscle, heart, liver, brain and RBC membranes
when diet PUFA balance dropped below 10%. If the findings in rats also apply to
humans, then this finding that diet PUFA balance < 10% results in significantly reduced
membrane PUFA balance for all tissues could have important health implications for
humans.
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4.9 Responsivity of membranes to diet PUFA balance for each tissue
The response of the membranes to diet PUFA balance is shown in Figure 4.8,
with a comparison of slopes used to indicate responsiveness of either a single linear
relationship (Figure 4.8a) or as a biphasic relationship (Figure 4.8b and c). To
determine whether the diet-membrane PUFA balance relationship was biphasic or
linear, the slopes of the biphasic relationships were compared to one another, with a
significant difference in the slopes for diet PUFA balance 0-10% and PUFA balance 11100% indicating a biphasic relationship.
For muscle, heart, brain, liver and RBC the plot clearly demonstrates that the
biphasic response provides a better description of the diet-membrane PUFA balance
relationship. Significant differences are evident between the slopes of diet PUFA
balance 0-10% relative to diet PUFA balance 11-100% for these tissues (Figure 4.8b
and c). Furthermore, the slope of the single linear relationship (PUFA balance 0 –
100%) is significantly lower than the response of the membranes to diet PUFA balance
< 10% for these tissues. For example, in the skeletal muscle a single linear relationship
gives a slope of 0.29, while the biphasic response provides a slope of 0.98 for diet
PUFA balance <10%. This shows that muscle membrane is responding almost perfectly
to diet PUFA balance below 10% (i.e. a 100% change in diet PUFA balance resulting in
a 98% change in membrane PUFA balance).
In contrast, adipose tissue membranes respond to diet PUFA balance with a
single linear response. For the adipose tissue membranes there is no significant
difference between slopes for diet PUFA balance 0-100%, 0-10% or 11-100% (Figure
4.8a, b and c respectively), justifying a single linear response. Although not biphasic,
the adipose tissue membranes are still highly responsive to diet PUFA balance (slope
0.60).
The tissue most highly responsive to low diet PUFA balance is the heart (slope
1.47). At diet PUFA balances below 10%, heart membranes are gaining n-6 PUFA at
the expense of n-3 PUFA to a greater degree than the change in diet PUFA balance (i.e.
a 100% change in diet PUFA balance results in a 147% change in membrane PUFA
balance). Muscle and liver membranes responded similarly to diet PUFA balance <
10%, with slopes ~ 1.0 and this indicates that the membrane PUFA balance is changing
in perfect balance with PUFA balance of the diet.
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Figure 4.8 The responsiveness of tissue phospholipids to diet PUFA balance (n-3 as %
total PUFA). (a) A single linear relationship for diet PUFA balance ranging from 0 –
100%. A biphasic relationship using two linear relationships for diet PUFA balance
from: (b) 0 – 10% and (c) 11 – 100%. A value of zero indicates no relationship, while a
value of 1 indicates that the phospholipid fatty acid composition perfectly conforms to
diet PUFA balance. Tissues include skeletal muscle, heart, brain, liver, adipose tissue,
and red blood cells (RBC). Values are slopes ± S.E.M.. The vertical dotted line in each
graph indicates line of perfect diet-membrane conformity. Tissues above the solid
horizontal line are best described by a biphasic relationship, while tissues below this
line are better represented by a single linear relationship. All slopes are significantly
different from zero (P < 0.05). Slope values for each tissue were compared between
plots a, b and c with a common superscript indicating no significant difference in slope.

A diet PUFA balance of 10% seems to be a critical level for the membranes of
muscle, heart, liver, brain and RBC. At diet PUFA balance > 10% the tissues are
basically maintaining their membrane PUFA balance relatively constant, but if diet
PUFA balance drops below 10% there is a sharp decline in phospholipid PUFA balance,
indicating that these membranes are highly sensitive to diet PUFA balance <10%.
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In summary, the results show that the diet PUFA balance affects membrane fatty
acid composition to a much greater extent than diet SFA, MUFA, total PUFA, n-6
PUFA or n-3 PUFA for all tissues, and this influence is most pronounced at diet PUFA
balance < 10%. Although the diet contains only 18C n-3 and n-6 PUFA, the membranes
consist of a number of 20-22C PUFA. These long-chain PUFA (particularly 20:4n-6
and 22:6n-3) are essential structural and functional components of cell membranes and
also serve as precursors to important signalling molecules, such as the eicosanoids and
endocannabinoids (Hansen and Artmann 2008).

4.10 Long-chain n-6 PUFA in membranes
Membrane 20:4n-6 content is reduced by increasing the diet PUFA balance
The relative percentage of 20:4n-6 in the phospholipids of heart, muscle, liver,
brain, RBC and adipose tissue plotted against either the amount of precursor 18:2n-6 in
the diet (left-hand graphs) or the diet PUFA balance (right-hand graphs) are presented in
Figure 4.9 (see Appendix 9 for linear regression equations). Similar plots for the other
long-chain n-6 PUFA (22:4n-6 and 22:5n-6) are presented in Figure 4.10 (for linear
regression equations see Appendix 10 and 11 respectively). For simplicity the means
were plotted without error bars (standard error values are available in the fatty acid
composition table for each tissue in Section 4.1).
Arachidonic acid (20:4n-6) is the long-chain n-6 PUFA found in the highest
proportion in the membranes of all tissues (Figure 4.9). For all tissues there is a
significant increase in membrane 20:4n-6 levels with increasing diet 18:2n-6 (Figure
4.9; P≤0.0003 for muscle, heart, brain and liver; P=0.0255 for adipose tissue) and a
corresponding decrease in 20:4n-6 content with increasing diet PUFA balance (Figure
4.9; P<0.0001 for all tissues). For example, liver 20:4n-6 levels increase with diet
18:2n-6 (slope = 1.69; Figure 4.9c) and decrease with diet PUFA balance (slope = -0.18;
see Figure 4.9d).
This trend is consistent for all tissues measured, although the degree of response
varied. In terms of diet PUFA balance, membrane 20:4n-6 levels are highly responsive
in liver, muscle, heart and RBC (slopes -0.18, -0.15, -0.12 and -0.14 respectively), but
less so in the brain and adipose tissue membranes (slopes -0.02 and -0.05 respectively).
Levels of 20:4n-6 are also lowest in the adipose tissue (3-10% of total fatty acids) and
brain membranes (9-11% of total fatty acids).
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Figure 4.9 Relationship between 20:4n-6 content of rat tissue phospholipids and the
amount of 18:2n-6 in the diet (left-hand graphs) and diet PUFA balance (right-hand
graphs). Tissues included are skeletal muscle - ο; heart -  (a-b); brain - Δ; liver - (cd); adipose tissue (perirenal) - <; red blood cells (RBC) - ∇ (e-f). In each graph the
solid coloured square symbol represents the value for initial rats (values not used to
determine line of best fit) and all open symbols represent data from the twelve
experimental diets. See Appendix 9 for regression equations and statistical values.
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Although the relationships between brain 20:4n-6 levels and diet fat profile are
highly significant (P<0.0001), it is clear that the proportion of 20:4n-6 in the brain
membranes is fairly well-regulated in response to changes in diet fat profile, with brain
20:4n-6 levels maintained at ~10% of total fatty acids (Figure 4.9c and d).
For all tissues (except adipose tissue), 20:4n-6 is the fatty acid that varies the
most, with the highest range in the membranes. This is most pronounced in the liver,
where the proportion of 20:4n-6 in the membranes varies from 13% to 31% of total fatty
acids, while in the brain 20:4n-6 varies by only 2% (i.e. from 9% - 11%) over similar
large changes in diet fat profile. These results emphasise the importance of dietary fat
profile in determining the membrane 20:4n-6 levels for most tissues.
The levels of other long-chain n-6 PUFA, namely 22:4n-6 and 22:5n-6, in the
membranes are much lower than 20:4n-6 levels (i.e. Figure 4.10 compared to Figure
4.9). Similar to membrane 20:4n-6, the levels of 22:4n-6 and 22:5n-6 in the membranes
increase linearly with diet 18:2n-6 content (22:4n-6: Figure 4.10a, c, e; P≤0.0005 and
22:5n:6: Figure 4.10g, i, k; P≤0.0016). Membrane 22:4n-6 and 22:5n-6 levels decrease
with diet PUFA balance in a biphasic manner for all tissues (22:4n-6: Figure 4.10b, d, f
and 22:5n:6: Figure 4.10h, j, l).
For diet PUFA balances <10% the levels of 22:4n-6 and 22:5n-6 increase in all
membranes. This response to low diet PUFA balance is significant for membrane 22:5n6 level of all tissues, with slopes ranging from -0.06 to -0.66 (P≤0.0037 for all tissues).
The level of membrane 22:4n-6 is generally less responsive to diet PUFA balance <
10%, with slopes ranging from -0.03 to -0.10 (significant only in muscle, heart, liver
and RBC; P≤0.0055).
With the diet PUFA balance maintained above 10% tissue phospholipids contain
negligible proportions of both 22:4n-6 (except brain) and 22:5n-6 (membrane levels
≤0.8% of total fatty acids for both 22:4n-6 and 22:5n-6). In contrast, brain 22:4n-6 level
is maintained at ~2-3% of total fatty acids when diet PUFA balance is above 10%.
The results show that increasing the diet PUFA balance leads to significantly
reduced membrane levels of 20:4n-6, 22:4n-6 and 22:5n-6, with heart, liver, muscle and
RBC membranes being the most responsive to changes in diet PUFA balance.
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Figure 4.10 Relationship between 22:4n-6 (a-f) and 22:5n-6 (g-l) content of rat tissue
phospholipids and the amount of 18:2n-6 in the diet (left-hand graphs) and diet PUFA
balance (right-hand graphs). Tissues included are skeletal muscle - ο; heart -  (a-b);
brain - Δ; liver - (c-d); adipose tissue (perirenal) - <; red blood cells (RBC) - ∇ (e-f).
In each graph the solid coloured square symbol represents the value for initial rats
(values not used to determine line of best fit) and all open symbols represent data from
the twelve experimental diets. See Appendix 10 and 11 for regression equations and
statistical values for 22:4n-6 and 22:5n-6 respectively.
77

An important feature of both Figure 4.9 and Figure 4.10, is the greater strength
of the linear relationships when 20- and 22-carbon n-6 PUFA are plotted against diet
PUFA balance rather than when plotted against the amount of 18:2n-6 (their 18-carbon
precursor) in the diet. This is most pronounced for membrane 20:4n-6. For example in
muscle, when membrane 20:4n-6 content is plotted against diet 18:2n-6 content the R2 =
0.35 compared to R2 = 0.83 when plotted against diet PUFA balance. Thus variation in
diet PUFA balance can explain 83% of variation in muscle 20:4n-6 level while variation
in diet 18:2n-6 amount explains only 35% of muscle 20:4n-6 variation. This means that
diet PUFA balance is a much better predictor of muscle 20- and 22-carbon n-6 PUFA
content than the amount of 18-carbon precursor in the diet.

4.11 Long-chain n-3 PUFA in membranes
Diet PUFA balance < 10% dramatically reduces membrane 22:6n-3 levels
The level of 22:6n-3 in the phospholipids of heart, muscle, liver, brain, RBC and
adipose tissue plotted against either the amount of precursor 18:3n-3 in the diet (lefthand graphs) or the diet PUFA balance (right-hand graphs) are presented in Figure
4.11. Similar plots for 20:5n-3 and 22:5n-3 are given in Figure 4.12.
Docosahexaenoic acid (22:6n-3) is the long-chain n-3 PUFA present in the
highest proportion in all tissues (Figure 4.11; see Appendix 12 for linear regression
equations). Membrane 22:6n-3 levels show a biphasic response to both diet 18:3n-3
amount and diet PUFA balance (in all tissues except adipose tissue). The level of
membrane 22:6n-3 is very reduced when diet 18:3n-3 content drops below 1g/100g
(Figure 4.11a, c, e; significant only for muscle, heart, brain and liver; P≤0.01). A
similarly reduction in membrane 22:6n-3 occurs with diet PUFA balance <10% (Figure
4.11b, d, f; significant for all tissue; P≤0.0015).
The level of membrane 22:6n-3 is most responsive in the heart, muscle and liver,
and less so in the brain and RBC phospholipids. For example, when diet PUFA balance
is <10%, the slopes for heart, muscle and liver 22:6n-3 content are 6.07, 3.66 and 3.62
respectively, while the slopes for brain and RBC are lower at 1.32 and 0.99
respectively. The level of 22:6n-3 in the adipose tissue phospholipids is extremely low
and relatively unresponsive to diet fat profile (Figure 4.11e and f). Brain, muscle, heart
and liver membranes contain the highest levels of 22:6n-3 and the brain phospholipids
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are able to maintain these high levels of 22:6n-3 (12 – 14% of total fatty acids) over a
wide range of diet n-3 PUFA content (Figure 4.11c and d).

Figure 4.11 Relationship between 22:6n-3 content of rat tissue phospholipids and the
amount of 18:3n-3 in the diet (left-hand graphs) and diet PUFA balance (right-hand
graphs). Tissues included are skeletal muscle - ο; heart -  (a-b); brain - Δ; liver - (cd); adipose tissue (perirenal) - ; red blood cells (RBC) - ∇ (e-f). In each graph the
solid coloured square symbol represents the value for initial rats (values not used to
determine line of best fit) and all open symbols represent data from the twelve
experimental diets. See Appendix 12 for regression equations and statistical values.
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Membranes for all tissues contain low levels of 20:5n-3 and 22:5n-3 (Figure
4.12; for linear regression equations see Appendix 13 and 14 respectively). In general,
the membrane content of 20:5n-3 in all tissues increase with both the amount of 18:3n-3
in the diet (Figure 4.12a, c, e) and with increasing the diet PUFA balance (Figure 4.12b,
d, f). A similar increase is shown for membrane 22:5n-3 content (diet 18:3n-3: Figure
4.12g, i, k and diet PUFA balance: Figure 4.12h, j, l). However, the response to diet
18:3n-3 and diet PUFA balance varies for membrane 20:5n-3 and 22:5n-3. Membrane
20:5n-3 shows a linear response to diet 18:3n-3 and a biphasic response to diet PUFA
balance for all tissues, while membrane 22:5n-3 shows the opposite pattern.
The lowest levels of membrane 20:5n-3 and 22:5n-3 are found in the brain and
adipose tissue phospholipids (Figure 4.12). Liver and RBC contained similar levels of
20:5n-3, with lower levels found in the heart and muscle membranes, while 22:5n-3 is
higher in muscle, heart and RBC and lower in the liver phospholipids.
In contrast to the membrane long-chain n-6 PUFA, the diet PUFA balance and
diet 18:3n-3 demonstrate equally strong relationships with membrane long-chain n-3
PUFA (i.e. the R2-values being comparable between the two diet variables; see Figure
4.11 and Figure 4.12). Thus the amount of diet precursor 18C n-3 PUFA is as useful as
the diet PUFA balance in predicting the membrane 20-22C n-3 PUFA content.
In summary, the membrane content of 20-22C n-3 PUFA in all tissues increases
with both diet 18:3n-3 amounts and diet PUFA balance. When diet PUFA balances are
>10% membrane 20:5n-3 and 22:5n-3 are significantly increased and membrane 22:6n3 content is maintained at fairly stable levels for all tissues. When the diet PUFA
balance drops to below 10%, 20:5n-3 is essentially absent from the membranes, and
22:5n-3 and 22:6n-3 are significantly reduced in all tissue phospholipids. A similar
pattern was observed for diet 18:3n-3 amounts.
The plots of long-chain PUFA clearly indicate that it is the n-3 PUFA
component of the diet driving the biphasic nature of some of these relationships.
Biphasic relationships are not evident between 20-22C n-6 PUFA and diet 18:2n-6,
however they are present in the diet PUFA balance plots (Figure 4.9 and Figure 4.10).
Furthermore, for 20-22C n-3 PUFA, biphasic plots are present for both the diet 18:3n-3
and diet PUFA balance (Figure 4.11 and Figure 4.12). This indicates that while
membranes respond in a linear fashion to the amount of diet 18:2n-6 (over the full
dietary range), membranes are more sensitive to low levels of diet n-3 PUFA with a
critical level at 1g 18:3n-3 /100g diet and a 10% PUFA balance.
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Figure 4.12 Relationship between 20:5n-3 (a-f) and 22:5n-3 (g-l) content of rat tissue
phospholipids and the amount of 18:3n-3 in the diet (left-hand graphs) and diet PUFA
balance (right-hand graphs). Tissues included are skeletal muscle - ο; heart -  (a-b);
brain - Δ; liver - (c-d); adipose tissue (perirenal) - <; red blood cells (RBC) - ∇ (e-f).
In each graph the solid coloured square symbol represents the value for initial rats
(values not used to determine line of best fit) and all open symbols represent data from
the twelve experimental diets. See Appendix 13 and 14 for regression equations and
statistical values for 20:5n-3 and 22:5n-3 respectively.
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Chapter 5
Results: Effects of diet on transport & storage lipid fatty
acid composition
In this chapter I present the fatty acid composition results for the triglycerides
(both adipose tissue and plasma) as well as those for plasma phospholipids. Adipose
tissue triglycerides are obviously storage lipids and for the sake of convenience I have
categorised both plasma phospholipids and plasma triglycerides as transport lipids.
It is worth noting that because all blood and tissue samples were taken from the
rats after the 24 hour oxygen consumption measurement, during which no food was
provided, the plasma phospholipid and triglyceride measurements reported in this
chapter can be regarded as fasting levels.
Results for this chapter will be presented in the same order as Chapter 4, namely:
i.

Examining the effect of the experimental diets on the fatty acid
composition of each of the three lipid sources (i.e. adipose tissue
triglycerides and plasma phospholipids/triglycerides);

ii.

Quantifying the relationship between diet fat type (i.e. SFA, MUFA,
PUFA, n-6 PUFA, n-3 PUFA and PUFA balance) and the fatty acid
composition of each lipid source;

iii.

Investigating the relationship between the diet precursor PUFA levels and
the long-chain PUFA composition of the plasma lipids (long-chain PUFA
were absent in the adipose tissue triglycerides).
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5.1 Effects of diets on plasma & adipose tissue fatty acid composition
Tissue phospholipid and triglyceride fatty acid compositions are presented in the
following tables: plasma phospholipids (Table 5.1), plasma triglycerides (Table 5.2)
and adipose tissue triglycerides (Table 5.3). Significant differences between diet groups
are found for all fatty acids in the adipose tissue triglycerides and plasma triglycerides
(except 18:0). For plasma phospholipids most fatty acid levels are different between diet
groups, except for total SFA, 24:0, 16:1n-7 and 24:1n-9 content.
The PUFA in the adipose tissue triglycerides consist primarily of those provided
in the diet; i.e. 18:2n-6 and 18:3n-3. This differed from the PUFA composition of the
adipose tissue phospholipids, which contain more long-chain PUFA with higher levels
of 20:4n-6 and slightly higher levels of 20:5n-3 and 22:5n-3 (see Table 4.5). The total
levels of SFA, MUFA and total PUFA are similar in both adipose tissue triglycerides
and phospholipids, however the n-3 PUFA content of the phospholipids are slightly
lower than in the triglycerides, resulting in a corresponding decrease in PUFA balance
in the adipose tissue phospholipids.
The results show that the most notable difference between adipose tissue
phospholipids and triglycerides is the distinct lack of 20-22C PUFA in the triglycerides.
A previous study in rabbits showed that the relative mobilisation of fatty acids from the
adipose tissue triglycerides is 20:5n-3>20:4n-6>18:3n-3>22:6n-3 and then 18:2n-6
(Zhou and Nilsson 2001), which may provide an explanation for the limited storage of
20-22C PUFA in the adipose tissue. Longer-chain PUFA, particularly 20:4n-6 and
22:6n-3 are preferentially esterified, rather than undergoing degradation in the
peroxisomes (Sprecher 2000), which may be another reason why these 20-22C are
found primarily in the lipid membranes and not in the storage lipids. However, 20-22C
PUFA can be stored in adipose tissue to some extent if they are supplied in the diet
(Raclot and Groscolas 1993).
In the plasma phospholipids and triglycerides the main n-6 PUFAs are 18:2n-6
and 20:4n-6, with the triglycerides containing slightly higher levels of total n-6 PUFA
than the phospholipids. Compared to plasma phospholipids, plasma triglycerides also
contain more total n-3 PUFA, with 18:3n-3 the predominant n-3 PUFA and very low
levels of 20-22C n-3 PUFA, compared to the phospholipids that contain a mixture of
18:3n-3 and 22:6n-3.
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Table 5.1 Fatty acid composition (% of total fatty acids) of plasma phospholipids from rats fed experimental and initial diets; values are mean ± S.E.M.;
n=6. See Table 2.4 for diet fatty acid composition.
Diet
12:0 *
14:0 *
16:0 *
17:0 *
18:0 *
24:0

0.0 ± 0.0 C
0.1 ± 0.0 C
21.6 ± 0.7 B
0.4 ± 0.0 BCD
21.9 ± 0.3 A
0.6 ± 0.2

0.0 ± 0.0 C
0.4 ± 0.1 C
21.5 ± 0.4 B
0.7 ± 0.0 AB
23.1 ± 0.7 A
0.3 ± 0.1

16:1n-7
18:1n-9 *
18:1n-7 *
20:3n-9 *
24:1n-9

0.4 ± 0.1
4.6 ± 0.2 B
1.6 ± 0.1 ABC
0.0 ± 0.0 E
0.7 ± 0.2

0.7 ± 0.1
6.3 ± 0.8 AB
1.4 ± 0.1 C
0.1 ± 0.1 DE
0.6 ± 0.1

18:2n-6 *
20:3n-6 *
20:4n-6 *
22:4n-6 *
22:5n-6 *

12.9 ± 0.5 CDEF 12.1 ± 0.8 DEF
0.3 ± 0.1 C
0.5 ± 0.1 BC
A
28.3 ± 0.3
25.7 ± 1.7 AB
1.0 ± 0.2 A
0.4 ± 0.1 B
1.7 ± 0.2 A
0.5 ± 0.1 B

18:3n-3 *
20:5n-3 *
22:5n-3 *
22:6n-3 *

1

0.0 ± 0.0 C
0.0 ± 0.0 B
0.2 ± 0.0 E
2.7 ± 0.2 E

2

0.1 ± 0.0 C
0.1 ± 0.1 B
0.4 ± 0.0 DE
4.4 ± 0.6 CDE

3

4

0.1 ± 0.1 C
0.0 ± 0.0 C
C
0.4 ± 0.1
0.4 ± 0.1 C
23.9 ± 1.1 AB
22.3 ± 1.0 AB
0.5 ± 0.1 ABCD 0.7 ± 0.1 A
21.2 ± 1.1 AB
23.2 ± 0.8 A
0.7 ± 0.1
0.3 ± 0.1

5

0.1 ± 0.1 C
0.3 ± 0.1 C
22.6 ± 0.7 AB
0.3 ± 0.0 D
19.4 ± 1.3 AB
0.4 ± 0.2

0.7 ± 0.2
5.4 ± 2.5 B
1.7 ± 0.3 ABC
0.1 ± 0.1 CDE
0.8 ± 0.1

0.9 ± 0.2
10.3 ± 0.6 AB
1.5 ± 0.0 BC
0.9 ± 0.1 AB
0.9 ± 0.1

2.8 ± 2.2
13.7 ± 2.6 A
1.7 ± 0.1 ABC
0.3 ± 0.0 BCD
0.9 ± 0.2

15.3 ± 0.6 ABCDE
0.6 ± 0.2 BC
22.5 ± 1.5 ABC
0.4 ± 0.0 B
0.0 ± 0.0 C

10.0 ± 0.4 F
1.1 ± 0.0 A
18.4 ± 0.9 CD
0.1 ± 0.0 BC
0.2 ± 0.1 BC

10.8 ± 0.3 EF
0.9 ± 0.1 BC
16.9 ± 1.5 CD
0.1 ± 0.1 BC
0.0 ± 0.0 C

0.2 ± 0.1 C
0.0 ± 0.0 B
0.4 ± 0.0 DE
3.9 ± 0.4 CDE

0.1 ± 0.0 C
0.4 ± 0.1 B
0.5 ± 0.0 DE
7.0 ± 0.5 A

0.4 ± 0.1 C
0.8 ± 0.2 B
0.9 ± 0.1 CD
5.8 ± 0.6 ABC

6

7

0.0 ± 0.0 C
0.3 ± 0.0 C
22.2 ± 1.0 AB
0.4 ± 0.0 CD
20.8 ± 0.9 AB
0.3 ± 0.1
0.6 ± 0.1
6.9 ± 1.4 AB
1.4 ± 0.1 C
0.0 ± 0.0 BCDE
0.9 ± 0.1

1.3 ± 0.5 A
1.2 ± 0.2 A
26.2 ± 0.5 A
0.4 ± 0.0 D
19.7 ± 0.7 AB
0.7 ± 0.1

0.6 ± 0.1
4.0 ± 0.5 B
1.3 ± 0.0 C
0.0 ± 0.0 BCD
0.7 ± 0.1

1.3 ± 0.2
5.7 ± 0.7 B
2.1 ± 0.2 A
0.3 ± 0.0 A
0.7 ± 0.2

17.0 ± 1.1 ABCD 17.4 ± 0.8 ABC
0.7 ± 0.1 C
0.8 ± 0.1 C
CD
18.6 ± 0.7
19.4 ± 0.7 BCD
0.0 ± 0.0 C
0.0 ± 0.0 C
0.0 ± 0.0 C
0.0 ± 0.0 C
1.8 ± 0.5 BC
0.6 ± 0.1 B
1.2 ± 0.1 BC
5.2 ± 0.1 ABCD

8

0.4 ± 0.1 BC
0.5 ± 0.1 BC
22.7 ± 0.5 AB
0.4 ± 0.0 BCD
21.8 ± 0.4 A
0.5 ± 0.0

1.9 ± 0.4 BC
0.8 ± 0.1 B
1.4 ± 0.1 BC
4.7 ± 0.4 BCDE

9

0.2 ± 0.2 BC
0.4 ± 0.2 BC
22.4 ± 1.0 AB
0.6 ± 0.1 ABC
23.4 ± 0.8 A
0.4 ± 0.1
0.6 ± 0.0
5.6 ± 0.7 B
1.1 ± 0.1 C
0.0 ± 0.0 BCDE
0.7 ± 0.1

14.1 ± 0.6 BCDEF 17.3 ± 0.8 ABC
1.4 ± 0.1 B
0.7 ± 0.1 C
D
14.5 ± 0.1
17.1 ± 1.6 CD
0.0 ± 0.0 C
0.0 ± 0.0 C
0.0 ± 0.0 C
0.0 ± 0.0 C
0.3 ± 0.1 C
1.2 ± 0.2 B
1.2 ± 0.1 BC
6.6 ± 0.3 AB

1.7 ± 0.3 BC
0.7 ± 0.1 B
1.3 ± 0.1 BC
4.7 ± 0.6 BCDE

10

11

0.0 ± 0.0 C
1.0 ± 0.3 AB
C
0.2 ± 0.1
1.0 ± 0.1 AB
22.3 ± 1.1 AB
24.9 ± 1.1 AB
0.5 ± 0.1 ABCD 0.3 ± 0.0 D
21.8 ± 0.8 A
19.6 ± 1.2 AB
0.4 ± 0.1
0.5 ± 0.1
0.7 ± 0.1
4.7 ± 1.5 B
1.2 ± 0.1 C
0.2 ± 0.1 BCD
0.7 ± 0.1
17.2 ± 2.0 ABC
0.9 ± 0.2 BC
17.7 ± 1.7 CD
0.1 ± 0.1 BC
0.2 ± 0.2 BC
2.8 ± 1.1 AB
1.1 ± 0.3 B
1.3 ± 0.3 BC
5.0 ± 0.5 ABCD

0.9 ± 0.2
5.5 ± 0.4 B
1.6 ± 0.1 ABC
0.0 ± 0.0 ABC
0.6 ± 0.1

12

0.0 ± 0.0 C
0.3 ± 0.0 C
25.2 ± 0.5 AB
0.5 ± 0.0 ABCD
17.3 ± 0.6 B
0.6 ± 0.0

0.7 ± 0.2
8.2 ± 3.2 AB
1.2 ± 0.1 C
0.0 ± 0.0 ABCD
0.6 ± 0.2

0.8 ± 0.1
6.7 ± 0.1 AB
2.0 ± 0.1 AB
0.1 ± 0.0 BCDE
0.8 ± 0.1

15.7 ± 1.3 ABCD 19.8 ± 1.0 A
1.0 ± 0.1 BC
0.9 ± 0.0 BC
DE
13.4 ± 2.6
7.8 ± 0.3 E
0.0 ± 0.0 C
0.0 ± 0.0 C
0.0 ± 0.0 C
0.0 ± 0.0 C
4.8 ± 0.8 A
3.4 ± 0.4 A
1.8 ± 0.2 AB
3.6 ± 0.2 DE

0.2 ± 0.0 C
0.1 ± 0.1 B
0.5 ± 0.0 DE
3.3 ± 0.3 DE
44.6 ± 0.2
10.5 ± 0.2 B
44.9 ± 0.2 AB
40.6 ± 0.4 AB
4.2 ± 0.4 FG

46.7 ± 1.0
47.7 ± 2.1
9.2 ± 0.8 B
8.8 ± 2.7 B
ABC
44.1 ± 1.7
43.5 ± 1.9 ABC
AB
39.1 ± 2.5
39.0 ± 1.6 AB
DEFG
4.9 ± 0.7
4.4 ± 0.4 EFG

47.5 ± 0.9
13.7 ± 0.7 AB
38.7 ± 1.2 BC
29.8 ± 0.9 CD
8.0 ± 0.4 CDEF

43.8 ± 1.9
19.4 ± 3.7 A
36.9 ± 1.9 C
28.7 ± 1.6 D
7.9 ± 0.5 CDEF

44.6 ± 1.0
10.1 ± 1.5 B
45.3 ± 1.0 AB
36.5 ± 1.0 BC
8.9 ± 0.7 BCD

46.7 ± 0.3
6.8 ± 0.6 B
46.5 ± 0.7 A
37.7 ± 1.1 AB
8.7 ± 0.8 CD

50.1 ± 0.9
10.0 ± 1.1 B
39.9 ± 0.7 ABC
30.1 ± 0.6 CD
9.4 ± 0.6 BC

48.1 ± 2.1
8.2 ± 0.6 B
43.7 ± 2.6 ABC
35.3 ± 2.3 BCD
8.4 ± 0.4 CDE

45.6 ± 1.2
7.6 ± 1.7 B
46.8 ± 2.3 A
36.1 ± 1.5 BC
10.4 ± 1.8 ABC

48.0 ± 0.7
8.9 ± 0.7 B
43.1 ± 1.0 ABC
30.2 ± 2.1 CD
12.8 ± 1.2 AB

46.4 ± 1.9
11.0 ± 3.4 AB
42.6 ± 1.8 ABC
28.7 ± 1.2 D
13.9 ± 1.1 A

PUFA
Balance *

11.6 ± 2.4 DE

21.2 ± 0.9 C

21.6 ± 1.1 C

19.5 ± 1.4 CD

18.8 ± 1.7 CD

23.7 ± 1.4 BC

19.4 ± 0.7 CD

21.9 ± 3.1 BC

30.2 ± 3.2 AB

32.5 ± 1.6 A

10.2 ± 0.5 E

* Values for each fatty acid without a common superscript in each row are significantly different (P<0.003)
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18.4 ± 1.5 AB
0.7 ± 0.1 BC
21.1 ± 1.4 BC
0.2 ± 0.0 BC
0.0 ± 0.0 C

1.9 ± 0.5 BC
2.9 ± 0.7 A
2.1 ± 0.3 A
5.8 ± 0.6 ABC

SFA
45.1 ± 0.8
MUFA *
7.6 ± 0.2 B
PUFA *
47.3 ± 0.8 A
n-6 PUFA* 44.4 ± 0.7 A
n-3 PUFA* 2.9 ± 0.2 G
6.1 ± 0.3 E

Initial__

0.1 ± 0.0 C
0.6 ± 0.1 BC
22.3 ± 1.1 AB
0.5 ± 0.1 ABCD
21.7 ± 0.9 A
0.5 ± 0.1

9.3 ± 0.9 E

Table 5.2 Fatty acid composition (% of total fatty acids) of plasma triglycerides from rats fed experimental and initial diets; values are mean ± S.E.M.; n=6
for all diets, except Diet 12 (n=5). See Table 2.4 for diet fatty acid composition.
Diet
12:0 *
14:0 *
16:0 *
18:0

0.2 ± 0.1 A
0.5 ± 0.1 A
18.1 ± 1.0 AB
2.8 ± 0.5

0.1 ± 0.0 C
0.5 ± 0.1 C
18.5 ± 1.6 AB
2.6 ± 0.4

0.1 ± 0.0 C
0.6 ± 0.1 C
18.1 ± 1.8 ABC
4.6 ± 1.0

0.1 ± 0.0 C
0.8 ± 0.1 C
25.7 ± 0.7 BC
5.4 ± 0.9

0.1 ± 0.0 C
0.6 ± 0.1 C
23.0 ± 0.4 BC
2.5 ± 0.7

0.1 ± 0.0 BC
0.5 ± 0.1 C
18.8 ± 0.5 BC
2.8 ± 0.7

0.4 ± 0.1 C
0.8 ± 0.1 C
19.0 ± 0.9 BC
3.1 ± 0.6

1.2 ± 0.2 C
2.5 ± 0.3 C
22.7 ± 1.4 BC
2.9 ± 1.2

0.1 ± 0.0 C
0.6 ± 0.0 C
19.2 ± 1.0 A
3.9 ± 0.5

0.1 ± 0.0 C
0.5 ± 0.1 C
20.5 ± 1.5 ABC
4.4 ± 1.1

1.0 ± 0.3 C
1.5 ± 0.2 C
21.4 ± 0.7 BC
3.6 ± 0.6

0.1 ± 0.1 AB
0.6 ± 0.1 B
20.4 ± 0.7 ABC
3.8 ± 0.8

0.2 ± 0.1 C
0.6 ± 0.1 C
16.9 ± 1.4 C
3.0 ± 0.7

16:1n-7 *
18:1n-9 *
18:1n-7 *
20:3n-9 *

1.0 ± 0.2 B
18.0 ± 1.3 B
1.5 ± 0.1 B
0.1 ± 0.0 B

1.4 ± 0.1 B
16.9 ± 1.2 A
1.7 ± 0.1 B
0.1 ± 0.0 BC

1.1 ± 0.2 B
9.9 ± 1.4 BC
1.6 ± 0.1 B
0.0 ± 0.0 D

2.1 ± 0.4 B
33.9 ± 2.4 C
2.4 ± 0.2 B
0.7 ± 0.1 D

1.8 ± 0.5 B
38.5 ± 1.4 B
2.4 ± 0.1 B
0.2 ± 0.0 D

1.4 ± 0.2 B
20.1 ± 0.5 BC
1.8 ± 0.1 B
0.0 ± 0.0 D

1.4 ± 0.2 B
11.7 ± 0.7 BC
1.7 ± 0.1 B
0.0 ± 0.0 BCD

4.1 ± 0.5 B
20.5 ± 2.0 BC
3.5 ± 0.2 B
0.3 ± 0.0 CD

1.3 ± 0.2 B
15.7 ± 1.0 A
1.6 ± 0.1 B
0.1 ± 0.0 A

1.6 ± 0.3 B
17.2 ± 4.6 BC
1.7 ± 0.2 B
0.1 ± 0.1 CD

2.6 ± 0.4 B
15.4 ± 0.6 BC
2.0 ± 0.1 B
0.1 ± 0.0 CD

1.2 ± 0.0 AB
14.0 ± 0.9 BC
1.6 ± 0.1 B
0.0 ± 0.0 CD

2.4 ± 0.8 A
16.6 ± 2.0 BC
2.0 ± 0.4 A
0.2 ± 0.0 BCD

18:2n-6 *
20:4n-6 *
22:4n-6 *
22:5n-6 *

23.8 ± 1.6 EF
29.6 ± 3.4 BCD
0.9 ± 0.1 C
0.8 ± 0.1 C

21.9 ± 1.2 F
31.6 ± 4.4 CD
0.6 ± 0.2 BC
0.4 ± 0.1 C

26.4 ± 1.5 CDE
32.1 ± 1.6 D
0.5 ± 0.1 C
0.1 ± 0.0 C

8.6 ± 0.7 A
14.5 ± 2.0 A
0.1 ± 0.0 AB
0.1 ± 0.0 C

10.3 ± 0.4 ABCD 21.5 ± 1.4 AB
25.0 ± 1.1 ABCD 13.7 ± 0.5 ABC
ABCD
ABCD
13.0 ± 1.6
19.1 ± 3.1
18.9 ± 2.5 A
16.7 ± 2.6 ABC
C
C
A
0.2 ± 0.0
0.1 ± 0.0
0.1 ± 0.0
0.1 ± 0.0 C
C
C
B
0.0 ± 0.0
0.0 ± 0.0
0.0 ± 0.0
0.0 ± 0.0 C

22.3 ± 0.6 F
20.5 ± 2.7 CD
0.1 ± 0.0 C
0.0 ± 0.0 C

19.4 ± 2.0 BCDE 16.4 ± 1.7 ABC
14.8 ± 2.0 CD
14.0 ± 2.5 AB
C
0.0 ± 0.0
0.1 ± 0.1 A
C
0.0 ± 0.0
0.0 ± 0.0 A

18.0 ± 0.7 DE
5.2 ± 0.5 CD
0.0 ± 0.0 C
0.0 ± 0.0 C

20.1 ± 1.0 BCD
31.6 ± 4.9 A
0.2 ± 0.1 BC
0.1 ± 0.0 C

18:3n-3 *
20:3n-3 *
20:5n-3 *
22:5n-3 *
22:6n-3 *

0.2 ± 0.0 D
0.1 ± 0.1 BC
0.0 ± 0.0 CD
0.0 ± 0.0 CD
0.5 ± 0.0 A

0.4 ± 0.0 CDC
0.1 ± 0.1 BC
0.1 ± 0.0 CDE
0.2 ± 0.0 DEF
1.0 ± 0.1 CD

0.8 ± 0.1 A
0.2 ± 0.1 A
0.2 ± 0.0 AB
0.2 ± 0.0 A
1.4 ± 0.1 CD

22.1 ± 1.2 AB
20.9 ± 1.4 BC
57.0 ± 1.7 BC
56.1 ± 1.8 DEF
0.9 ± 0.1 DEF

22.5 ± 2.0 ABC
20.3 ± 1.2 A
57.2 ± 3.0 C
55.3 ± 3.1 F
1.7 ± 0.1 EFG

24.3 ± 2.8 ABC
12.8 ± 1.6 DE
62.9 ± 2.6 A
60.0 ± 2.5 F
2.9 ± 0.2 A

1.5 ± 0.1 CD

3.1 ± 0.2 CDE

4.6 ± 0.2 A

SFA †
MUFA *
PUFA *
n-6 PUFA*
n-3 PUFA*
PUFA
Balance *

1

2

3

4

0.5 ± 0.1 D
0.1 ± 0.0 BC
0.5 ± 0.1 E
0.3 ± 0.1 F
2.0 ± 0.2 CDE

5

6

7

8

10

11

12

Initial__

1.8 ± 0.1 B
0.1 ± 0.0 BC
1.1 ± 0.1 CDE
0.7 ± 0.1 CDE
2.0 ± 0.1 CD

7.0 ± 0.9 B
0.2 ± 0.0 BC
1.6 ± 0.2 CD
1.0 ± 0.1 ABC
2.1 ± 0.1 BC

9.0 ± 0.9 D
0.2 ± 0.1 BC
2.6 ± 0.3 E
1.6 ± 0.3 F
2.4 ± 0.2 DE

1.5 ± 0.2 BC
0.1 ± 0.1 BC
2.7 ± 0.2 CDE
1.2 ± 0.2 CD
4.1 ± 0.4 BC

6.9 ± 1.0 D
0.2 ± 0.1 BC
1.8 ± 0.2 DE
1.2 ± 0.1 EF
2.3 ± 0.2 CD

10.7 ± 2.9 B
0.4 ± 0.1 AB
3.1 ± 0.5 BC
1.4 ± 0.3 BCD
2.2 ± 0.3 BC

7.8 ± 1.2 D
0.3 ± 0.0 BC
6.9 ± 1.5 E
2.0 ± 0.3 F
3.3 ± 0.2 E

22.7 ± 1.6 B
0.6 ± 0.0 BC
5.5 ± 0.7 A
2.4 ± 0.1 AB
1.9 ± 0.2 AB

1.2 ± 0.2 D
0.1 ± 0.0 C
0.6 ± 0.1 DE
0.3 ± 0.1 EF
2.2 ± 0.5 BC

33.1 ± 1.4 BC
38.9 ± 2.6 E
28.0 ± 2.1 A
23.9 ± 2.0 A
3.5 ± 0.3 G

26.7 ± 1.0 BC
43.3 ± 1.6 CD
30.0 ± 1.8 AB
24.1 ± 1.9 CDE
5.7 ± 0.2 CDE

22.9 ± 1.3 BC
23.7 ± 0.6 DE
53.4 ± 1.2 A
41.3 ± 1.9 BCD
12.0 ± 1.0 BCD

24.0 ± 1.4 BC
15.4 ± 0.8 CDE
60.7 ± 2.1 A
44.8 ± 2.6 AB
15.9 ± 1.2 G

30.1 ± 2.5 BC
28.6 ± 2.2 CDE
41.3 ± 2.6 A
31.4 ± 3.1 BCDE
9.6 ± 0.7 CD

24.8 ± 1.3 A
19.1 ± 1.2 AB
56.2 ± 2.2 C
46.3 ± 3.1 F
12.5 ± 0.9 FG

26.2 ± 1.9 ABC
21.1 ± 5.1 CDE
52.7 ± 5.8 AB
34.9 ± 3.3 DEF
17.7 ± 3.6 BC

28.1 ± 1.2 BC
20.4 ± 0.9 CDE
51.5 ± 1.9 A
31.1 ± 3.5 AB
20.4 ± 2.5 G

25.7 ± 1.6 ABC
17.5 ± 1.0 CDE
56.8 ± 0.7 AB
23.8 ± 1.0 EF
33.1 ± 1.0 B

21.6 ± 1.5 C
21.2 ± 3.1 CDE
57.2 ± 4.4 A
52.6 ± 4.2 ABC
4.4 ± 0.7 FG

13.0 ± 1.4 F

19.6 ± 1.6 CD

22.7 ± 2.1 C

26.4 ± 2.3 F

24.2 ± 2.8 CD

22.8 ± 2.9 DEF

31.8 ± 4.5 BC

40.1 ± 5.5 F

58.2 ± 1.7 B

* Values for each fatty acid without a common superscript in each row are significantly different (P<0.0001)

†

9

Values for each fatty acid without a common superscript in each row are significantly different (P=0.0002)
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7.8 ± 1.1 EF

Table 5.3 Fatty acid composition (% of total fatty acids) of adipose tissue triglycerides from rats fed experimental and initial diets; values are mean ±
S.E.M.; n=5 for all diets, except Diet 2 and 9 (n=6). See Table 2.4 for diet fatty acid composition.
Diet
10:0 *
12:0 *
14:0 *
16:0 *
18:0 *

0.0 ± 0.0 D
0.1 ± 0.0 D
1.0 ± 0.1 EF
18.2 ± 0.8 EF
2.9 ± 0.1 CDE

0.0 ± 0.0 D
0.1 ± 0.0 D
1.8 ± 0.1 DEF
21.5 ± 0.3 BCD
4.8 ± 0.3 A

14:1n-7 *
16:1n-7 *
18:1n-9 *
18:1n-7 *

0.0 ± 0.0 E
2.5 ± 0.3 E
36.5 ± 0.8 C
1.7 ± 0.1 CDE

0.2 ± 0.0 C
0.0 ± 0.0 E
3.5 ± 0.3 BCDE 2.3 ± 0.4 E
34.6 ± 0.2 CD
19.4 ± 0.4 F
CD
1.9 ± 0.1
1.4 ± 0.1 E

18:2n-6 *
20:4n-6 *
22:4n-6 *
22:5n-6 *

35.3 ± 0.7 B
0.3 ± 0.0 A
0.1 ± 0.0 A
0.1 ± 0.0 A

28.9 ± 0.4 C
0.2 ± 0.0 AB
0.1 ± 0.0 B
0.0 ± 0.0 B

18:3n-3 *
20:5n-3 *
22:5n-3 *
22:6n-3 *

0.4 ± 0.0 H
0.0 ± 0.0 F
0.0 ± 0.0 E
0.0 ± 0.0 D

SFA *
MUFA *
PUFA *
n-6 PUFA*
n-3 PUFA*
PUFA
Balance *

1

2

0.8 ± 0.0 GH
0.0 ± 0.0 F
0.0 ± 0.0 DE
0.0 ± 0.0 BCD

3

0.0 ± 0.0 D
0.1 ± 0.0 D
1.0 ± 0.1 EF
17.4 ± 0.8 F
3.2 ± 0.1 BC

4

5

6

7

0.0 ± 0.0 D
0.2 ± 0.0 D
2.4 ± 0.1 D
24.2 ± 0.3 AB
4.8 ± 0.2 A

0.0 ± 0.0 D
0.1 ± 0.0 D
0.9 ± 0.0F
19.2± 0.2 DEF
2.8 ± 0.0 CDE

0.1 ± 0.0 D
1.0 ± 0.5 D
1.5 ± 0.2 DEF
19.1 ± 0.4 DEF
3.0 ± 0.1 BCD

0.3 ± 0.0 C
5.8 ± 0.2 C
4.1 ± 0.1 C
20.7 ± 1.0 CDE
2.8 ± 0.1 CDE

0.4 ± 0.0 B
5.2 ± 0.6 BCD
51.7 ± 0.7 B
2.5 ± 0.1 AB

0.0 ± 0.0 E
2.6 ± 0.1 E
58.6 ± 0.8 A
2.1 ± 0.0 BC

0.1 ± 0.0 DE
3.2 ± 0.4 CDE
32.4 ± 0.5 D
1.7 ± 0.1CDE

51.0 ± 1.2 A
0.3 ± 0.0 A
0.1 ± 0.0 AB
0.0 ± 0.0 BCD

6.2 ± 0.7 F
0.0 ± 0.0 C
0.0 ± 0.0 D
0.0 ± 0.0 D

9.4 ± 0.6 EF
0.1 ± 0.0 C
0.0 ± 0.0 D
0.0 ± 0.0 D

2.7 ± 0.1 FG
0.0 ± 0.0 F
0.0 ± 0.0 DE
0.0 ± 0.0 BCD

0.9 ± 0.1 GH
0.0 ± 0.0 F
0.0 ± 0.0 E
0.0 ± 0.0 CD

3.3 ± 0.0 F
0.0 ± 0.0 EF
0.0 ± 0.0 DE
0.0 ± 0.0 BCD

8

0.9 ± 0.0 A
18.0 ± 1.1A
11.7 ± 0.5 A
26.0 ± 0.5 A
2.2 ± 0.1 E

9

10

0.0 ± 0.0 D
0.1 ± 0.0 D
1.6 ± 0.0 DEF
21.4 ± 0.3 BCD
4.8 ± 0.2 A

0.0 ± 0.0 D
0.1 ± 0.0 D
1.2 ± 0.0 EF
18.9 ± 0.3 DEF
3.1 ± 0.1 BCD

0.2 ± 0.0 CD
0.7 ± 0.0 A
4.0 ± 0.4 BCDE 7.8 ± 0.5 A
19.6 ± 0.2 F
21.7 ± 0.5 F
DE
1.5 ± 0.1
2.6 ± 0.1 AB

0.2 ± 0.0 CD
3.3 ± 0.3 DE
29.2 ± 0.3 E
1.7 ± 0.1 CDE

22.7 ± 0.8 D
0.1 ± 0.0 C
0.0 ± 0.0 D
0.0 ± 0.0 CD

24.3 ± 1.2 D
0.1 ± 0.0 BC
0.0 ± 0.0 CD
0.0 ± 0.0 BCD

5.4 ± 0.7 F
0.0 ± 0.0 C
0.0 ± 0.0 D
0.0 ± 0.0 D

13.9 ± 0.2 CD
0.1 ± 0.0 DE
0.1 ± 0.0 BCD
0.1 ± 0.0 BCD

15.3 ± 0.1 C
0.1 ± 0.0 ABC
0.2 ± 0.0 A
0.1 ± 0.0 B

11

0.7 ± 0.1 B
14.2 ± 1.3 B
8.3 ± 0.5 B
23.7 ± 1.0 ABC
2.4 ± 0.1 DE

12

Initial__

0.1 ± 0.0 D
0.6 ± 0.0 D
1.3 ± 0.1 DEF
17.2 ± 0.9 F
3.1 ± 0.1 BCD

0.2 ± 0.0 C
0.7 ± 0.1 D
2.0 ± 0.1 DE
24.9 ± 0.4 A
3.7 ± 0.1 B

0.1 ± 0.0 DE
0.4 ± 0.0 B
3.5 ± 0.4 BCDE 5.5 ± 0.4 B
20.4 ± 0.6 F
20.7 ± 1.2 F
E
1.4 ± 0.1
1.8 ± 0.1 CDE

0.1 ± 0.0 DE
2.5 ± 0.4 E
20.0 ± 0.4 F
1.4 ± 0.1 E

0.1 ± 0.0 CDE
5.4 ± 0.6 BC
35.5 ± 0.2 CD
2.8 ± 0.1 A

22.7± 0.5 D
0.1 ± 0.0 BC
0.0 ± 0.0 D
0.0 ± 0.0 CD

20.6 ± 0.8 D
0.1 ± 0.0 C
0.0 ± 0.0 D
0.0 ± 0.0 BCD

9.6 ± 1.6 EF
0.1 ± 0.0 C
0.0 ± 0.0 D
0.0 ± 0.0 CD

13.7 ± 0.8 E
0.0 ± 0.0 C
0.0 ± 0.0 D
0.0 ± 0.0 BC

20.0 ± 0.8 D
0.3 ± 0.0 A
0.0 ± 0.0 BC
0.0 ± 0.0 BC

2.2 ± 0.1 FGH
0.0 ± 0.0 F
0.0 ± 0.0 DE
0.0 ± 0.0 BCD

13.2 ± 0.3 DE
0.1 ± 0.0 CD
0.2 ± 0.0 AB
0.1 ± 0.0 B

29.2 ± 0.3 B
0.1 ± 0.0 AB
0.2 ± 0.0 AB
0.1 ± 0.0 BCD

11.6 ± 1.0 E
0.1 ± 0.0 BCD
0.1 ± 0.0 ABC
0.1 ± 0.0 BC

38.7 ± 0.8 A
0.1 ± 0.0 A
0.2 ± 0.0 AB
0.1 ± 0.0 BCD

2.4 ± 0.1 FGH
0.0 ± 0.0 EF
0.1 ± 0.0 CDE
0.2 ± 0.0 A

22.6 ± 0.9 F
41.0 ± 0.4 BC
36.4 ± 0.6 B
36.0 ± 0.6 B
0.4 ± 0.0 H

29.3 ± 0.3 DE
40.5 ± 0.3 C
30.3 ± 0.4 C
29.4 ± 0.4 C
0.8 ± 0.0 GH

22.1 ± 0.8 F
23.4 ± 0.5 G
54.5 ± 1.1 A
51.7 ± 1.2 A
2.8 ± 0.1 FG

32.8 ± 0.2 CD
60.0 ± 0.7 A
7.2 ± 0.8 F
6.3 ± 0.7 F
0.9 ± 0.1 GH

23.5 ± 0.3 F
63.6 ± 0.7 A
12.9 ± 0.6 E
9.5 ± 0.6 EF
3.4 ± 0.0 F

25.2 ± 0.9 EF
37.6 ± 0.6 CD
37.2 ± 0.7 B
23.0 ± 0.8 D
14.2 ± 0.2 CD

34.1 ± 0.9 C
25.5 ± 0.3 FG
40.4 ± 1.1 B
24.6 ± 1.2 D
15.8 ± 0.1 C

59.4 ± 1.5 A
32.9 ± 1.0 E
7.7 ± 0.8 F
5.5 ± 0.8 F
2.2 ± 0.1 FGH

28.8 ± 0.2 DE
34.5 ± 0.4 DE
36.6 ± 0.5 B
23.0 ± 0.6 D
13.6 ± 0.3 DE

23.8 ± 0.3 F
25.6 ± 1.0 FG
50.7 ± 1.0 A
20.9 ± 0.8 D
29.8 ± 0.3 B

49.8 ± 1.7 B
28.5 ± 1.2 F
21.8 ± 1.1 D
9.7 ± 1.6 EF
12.0 ± 1.0 E

22.7 ± 1.0 F
24.2 ± 0.4 G
53.1 ± 1.3 A
13.9 ± 0.8 E
39.2 ± 0.9 A

32.4 ± 0.6 CD
44.2 ± 0.5 B
23.4 ± 0.9 D
20.6 ± 0.8 D
2.7 ± 0.2 FG

1.1 ± 0.1 F

2.7 ± 0.1 F

5.1 ± 0.3 EF

13.2 ± 0.9 E

26.9 ± 1.1 D

38.3 ± 0.9 C

39.4 ± 1.2 C

30.7 ± 4.0 CD

37.2 ± 0.9 CD

58.8 ± 0.9 B

56.1 ± 5.6 B

73.9 ± 1.1 A

11.7 ± 0.7 EF

* Values for each fatty acid without a common superscript in each row are significantly different (P<0.0001)
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5.2 Effect of SFA, MUFA, PUFA, n-6 PUFA & n-3 PUFA on plasma &
adipose tissue fatty acid composition
Storage lipids are most responsive to diet fat profile
The relationship between diet fat profile and transport fatty acids (plasma
phospholipids and triglycerides) and storage fatty acids (adipose tissue triglycerides) are
presented in Figure 5.1 (left and right-hand graphs respectively), with the linear
regression equations listed in the Appendix 15.
The results for the transport lipids suggest that the SFA content is relatively
constant despite variation in diet levels, with slopes of 0.05 and 0.08 for plasma
phospholipids and triglycerides respectively (Figure 5.1a). Levels of SFA in the plasma
phospholipids are similar to those found in the membranes of muscle, heart, brain, liver
and RBC (Figure 4.1), while the SFA content in the plasma triglycerides is much lower.
MUFA content of the plasma phospholipids is nominally more responsive to diet
MUFA levels (slope 0.14; Figure 5.1c), being similar to muscle, heart, liver and RBC
(Figure 4.2). The plasma triglycerides are considerably more responsive to diet MUFA
(slope 0.37; Figure 5.1c), and MUFA is also present in higher amounts (13-43% of total
fatty acids) compared to SFA levels.
The total PUFA content of plasma triglycerides are responsive to diet PUFA
levels (slope 0.32; Figure 5.1e), while the PUFA content of the plasma phospholipids is
more regulated (slope 0.08; Figure 5.1e). Plasma phospholipids contained ~ 40%
PUFA, which is similar to the RBC membranes (Figure 4.3). The plasma triglyceride
PUFA content ranged 28 – 63%, which spans the PUFA content of the membranes of
all tissues measured.
The relationship for each of the diet essential fatty acids, n-6 PUFA and n-3
PUFA, show a similar pattern to the PUFA content of the transport lipids. That is, levels
of both PUFA classes are similar for plasma phospholipids and triglycerides, with the
triglycerides more responsive to both diet n-6 PUFA and n-3 PUFA (slopes 0.57 and
0.33; Figure 5.1g and i respectively). The levels of n-6 PUFA in the plasma
phospholipids are similar to the muscle, liver and RBC membranes (see Figure 4.4),
while the n-3 PUFA content of plasma phospholipids is similar to the heart, liver and
RBC membranes (see Figure 4.5). The n-6 and n-3 PUFA content of the plasma
triglycerides is comparable to the adipose tissue membranes.
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Figure 5.1 Fatty acid profile of rat transport and storage tissues relative to fatty acid
profile of diet. Transport includes plasma phospholipids (PL- ο) and triglycerides
(TG- ), (left-hand graphs). Storage includes adipose tissue triglycerides (TG -),
(right-hand graphs). (a-b) SFA content. (c-d) MUFA content. (e-f) total PUFA content
(g-h) n-6 PUFA content. (i-j) n-3 PUFA content. In each graph the solid coloured
symbol represents the value for initial rats and all open symbols represent data from the
twelve experimental diets. Error bars show ± S.E.M. and if they are not visible they are
smaller than symbol. The dotted line in each graph indicates line of perfect dietmembrane conformity. See Appendix 15 for regression equations and statistical values.
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The fatty acid results show that plasma phospholipids exhibit a fat profile
comparable to the RBC and liver membranes (for all fat types and most individual fatty
acids). This is interesting as the liver is the main organ responsible for the synthesis of
phospholipids for membranes and triglycerides for fuel, which are subsequently
transported in the blood to other tissues as lipoproteins (van Golde and van den Bergh
1977). Since mature RBCs cannot synthesise phospholipids de novo and lack the
enzymes for elongation and desaturation, membrane renewal occurs via phospholipids
acquired from the plasma (Hodson et al. 2008). These are likely some of the reasons for
the very similar fatty acid profiles of plasma, RBC and liver phospholipids.
The storage lipids of the adipose tissue are more responsive to diet fat profile
than the transport lipids (for all fatty acid classes), and are also more responsive than the
membranes of any of the other tissues measured. Adipose tissue triglycerides are most
responsive to diet n-6 PUFA (slope 0.67) and least responsive to diet SFA (slope 0.45),
which still indicates relatively high responsivity.
The proportion of each fatty acid class in the adipose tissue triglycerides is
similar to that of the adipose tissue phospholipids, however, the triglycerides are more
responsive to diet fat profile, resulting in a wider range for each fatty acid class in the
storage lipids. For example, n-6 PUFA content of the adipose tissue phospholipids
ranges from 14 – 48% of total fatty acids compared to 6 – 52% in the triglycerides. A
study in humans found similar results, with adipose tissue phospholipids and
particularly, adipose triglycerides reflecting the fatty acid composition of the diet (Field
et al. 1985). This study also found that there was a strong correlation between the
phospholipid and triglyceride fat profile (Field et al. 1985). Due to the similar
composition, it is likely that adipose tissue membranes are acquiring their fatty acids
directly from the pool of fat stored as triglyceride in adipose tissue triglycerides.
However, the adipose tissue triglycerides seem to store only the 18C PUFA, so it is
unlikely that the storage lipids are providing the adipose tissue membrane with longerchain EFA. The fatty acid composition of the adipose tissue phospholipids is similar to
the plasma triglycerides, with regards to the n-6 PUFA, n-3 PUFA and PUFA balance.
So the adipose tissue membranes may be sourcing the essential fatty acids from the
plasma triglyceride pool.
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5.3 Effect of PUFA balance on plasma & adipose tissue fatty acid
composition
Storage lipids are most responsive to diet PUFA balance
The adipose tissue triglycerides are the most responsive of all the tissue lipids to
diet PUFA balance (over the full linear range) with a slope of 0.79 (Figure 5.2b). This
relationship is closest to the line of perfect diet-membrane conformity (the dotted line in
the graph) found for all tissues and fatty acid types. At diet PUFA balance < 10% the
adipose tissue triglycerides actually fall on the line of perfect conformity. The only
higher responsivity to diet occurs in the muscle, heart and liver at diet PUFA balances <
10%. However, the adipose tissue triglycerides are highly responsive to diet PUFA
balance across the full linear range, resulting in an impressive range of 1 – 74% in the
adipose tissue triglycerides (Table 5.3).
The transport lipids are also highly responsive to diet PUFA balance with slopes
of 0.25 and 0.50 for plasma phospholipids and triglycerides respectively (Figure 5.2a).
In respect to the membranes of the other tissues, these responses to diet PUFA balance
are lower, with all membrane slopes > 0.60 (except RBC; slope 0.38). The PUFA
balance of the plasma phospholipids (6 – 33%) is similar to levels seen in RBC, liver
and heart membranes (see Figure 4.7). The plasma triglycerides have PUFA balances
similar to adipose tissue phospholipids (2 – 58%).

Figure 5.2 PUFA balance of rat transport and storage tissues relative to PUFA balance
of diet (n-3 as % of total PUFA). Transport includes plasma phospholipids (PL- ο) and
triglycerides (TG- ), (left-hand graph). Storage includes adipose tissue triglycerides
(TG -), (right-hand graph). In each graph the solid coloured symbol represents the
value for initial rats and all open symbols represent data from the twelve experimental
diets. Error bars show ± S.E.M. and if they are not visible they are smaller than symbol.
The dotted line in each graph indicates line of perfect diet-membrane conformity. See
Appendix 15 for regression equations and statistical values.
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5.4 Comparison of the responsivity of transport and storage lipids to diet
fat type
The responsivities (i.e. slope of the relationship) of plasma phospholipids,
plasma triglycerides and adipose tissue triglycerides to diet fat profile are compared in
Figure 5.3. The plasma phospholipids and triglycerides respond similarly to changes in
diet SFA content, however responsivity to MUFA, PUFA, n-3 PUFA and PUFA
balance of the plasma triglycerides is about 25% higher than that of the phospholipids
(i.e. slopes were ~ 0.25 higher in triglycerides) and for n-6 PUFA the response is 36%
higher in the plasma triglycerides. So overall, the plasma phospholipids are less
responsive to diet fat than plasma triglycerides (for all fat types).
The highest response for both plasma phospholipids and triglycerides is for diet
n-6 PUFA (slopes 0.21 and 0.57 respectively) and diet PUFA balance (slopes 0.25 and
0.5 respectively; see Figure 5.3d and f). The response of plasma phospholipids and
triglycerides is moderate for diet MUFA (slopes 0.14 and 0.32), PUFA (slopes 0.08 and
0.32) and n-3 PUFA (slopes 0.1 and 0.33 respectively; see Figure 5.3b, c and e), while
the SFA content is quite strongly regulated in both plasma phospholipids and
triglycerides (slopes 0.05 and 0.08; see Figure 5.3a).
Adipose tissue “storage lipids” are more responsive to diet fat type than the
transport lipids and also the membrane lipids of all the tissues for all fatty acid types
(except for muscle, heart and liver for diet PUFA balances < 10%). The adipose tissue
triglycerides are most responsive to diet PUFA balance (slope 0.79). In comparison to
the adipose tissue phospholipids, the triglycerides are consistently more responsive to
diet fat profile with the triglycerides showing a 15 – 19% higher responsivity to each
fatty acid type.
The analysis of the membranes shows that adipose tissue phospholipids are the
most responsive of any tissue to diet fat profile. Examination of the adipose tissue
triglycerides indicates that these lipids are more responsive to diet fat, and similarly to
the membranes, this response is profoundly linked to diet PUFA balance. This shows
the expected results that storage fats are highly reflective of the diet fat profile for all fat
types. For plasma lipids different responses to diet fat profile are evident in the
phospholipid and triglyceride fractions. Plasma phospholipids show a similar response
and fatty acid composition as found for most membranes (including liver and RBC, and
to a lesser extent, heart and muscle), while the plasma triglycerides are similar to the
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adipose tissue phospholipid fatty acid composition, which are more responsive to diet
fat profile.

Figure 5.3 The responsiveness of transport and storage tissues to diet fatty acid
composition. Transport includes plasma phospholipids (PL) and plasma triglycerides
(TG). Storage includes adipose tissue triglycerides (TG). (a) SFA (b) MUFA (c) PUFA
(d) n-6 PUFA (e) n-3 PUFA (f) PUFA balance. The major fatty acids expressed as % of
total fatty acid and PUFA balance expressed as n-3 as % of total PUFA. A value of zero
indicates no relationship, while a value of 1 indicates that the tissue fatty acid
composition perfectly conforms to diet fat profile. Values are slopes ± S.E.M. (see
Appendix 15 for slope and statistical values). Significant relationships are shown where
the slope of the line of fit is significantly different from zero: * P < 0.05.
Diet fatty acid profile can be difficult to determine in humans and quite often
blood or tissue lipid profiles are used as biomarkers for dietary status (see Hodson et al.
2008). To test which tissue was the best biomarker in this study in rats, the strength of
each correlation between tissue fatty acid composition and diet fat type was compared
(i.e. R2-value for diet SFA, MUFA, PUFA, n-6 PUFA, n-3 PUFA and PUFA balance).
Compared to the other tissues lipids, adipose tissue triglycerides consistently showed
the strongest correlation to diet fat profile for all fat classes (R2-values 0.86 – 1.00).
This tissue also showed the highest response to diet fat profile, with slopes ranging
0.45-0.79, indicating that adipose tissue triglycerides are an extremely useful biomarker
of diet fatty acid status. This confirms the results of previous studies in humans (Beynen
et al. 1980; Garland et al. 1998; Baylin et al. 2005) and adipose tissue triglyceride
composition is generally used as a long-term biomarker, as the half life of adipose tissue
is about 1 – 2 years in weight stable individuals (Hodson et al. 2008).
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5.5 Long-chain n-6 PUFA in plasma phospholipids and triglycerides
Plasma 20:4n-6 content is highly responsive to diet PUFA balance
The effect of diet fat composition on the long-chain n-6 PUFA content of the
plasma phospholipids and triglycerides are shown in Figure 5.4 (see Appendix 16 for
linear regression equations). The adipose tissue triglycerides contained no significant
amount of 20-22C PUFA, so these were not plotted (see Table 5.3).
The long-chain n-6 PUFA present in the highest amounts for both plasma
phospholipids and triglycerides is 20:4n-6 (Figure 5.4a and b). The amount of 20:4n-6
in both the plasma phospholipids and triglycerides increases with the amount of 18:2n-6
in the diet and decreases with increasing diet PUFA balance (Figure 5.4a and b
respectively).
The response of the plasma triglyceride 20:4n-6 content is greater than those
found for plasma phospholipids and for any membrane phospholipids measured. For
example, in response to diet PUFA balance the slope for plasma triglyceride 20:4n-6
content is -0.24, while the plasma phospholipids show a response of -0.17 and the
response of the membranes are all ≤ -0.18.
Similar levels of 20:4n-6 are found in both the plasma phospholipids (8 - 28%
total fatty acids) and triglycerides (5 – 32% total fatty acids), with these levels
comparable to the 20:4n-6 content of muscle, heart, liver and RBC membrane
phospholipids (see Figure 4.9).
The strength of the relationship found between 20:4n-6 and diet PUFA balance
for both plasma phospholipids and triglycerides is increased (R2=0.61 and 0.46
respectively) compared to the amount of diet 18:2n-6 (R2=0.37 and 0.42 respectively).
This indicates that, similar to the membranes, diet PUFA balance is a better predictor of
plasma phospholipid and triglyceride 20:4n-6 content than the amount of 18-carbon
precursor in the diet.
The plasma phospholipids and triglycerides contain very low levels of 22:4n-6
(Figure 5.4c, d) and 22:5n-6 (Figure 5.4e, f). The response to diet fat profile is similar
for both 22:4n-6 and 22:5n-6, increasing with diet 18:2n-6 and decreasing with diet
PUFA balance. In the same manner as the membranes, the response of the 22:4n-6 and
22:5n-6 content of the plasma lipids follows a single linear trend for diet 18:2n-6
amounts and a biphasic response when plotted against diet PUFA balance. So at higher
diet PUFA balance there is virtually no 22:4n-6 or 22:5n-6 in the plasma lipids, but
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these levels rapidly increase when the diet PUFA balance drops below 10%. Plasma
lipid 22:4n-6 content is lower than that of the brain and RBC membranes, but similar to
levels found in the membranes of the other tissues measured. The levels of 22:5n-6 in
the plasma lipids are lower than those found in the heart membranes, but similar to all
other tissue phospholipid levels (see Figure 4.10).

Figure 5.4 Relationship between 20:4n-6, 22:4n-6 and 22:5n-6 content of rat plasma
phospholipids (PL- ο) and triglycerides (TG- ) and the amount of precursor 18carbon PUFA in the diet (g/100g diet; graphs a & c) and diet PUFA balance (n-3 as %
total PUFA; graphs b & d). In each graph the solid coloured symbol represents the value
for initial rats (value not used to determine line of best fit) and all open symbols
represent data from the twelve experimental diets. See Table 5.1 and Table 5.2 for
S.E.M. values of plasma phospholipids and triglycerides respectively. See Appendix 16
for regression equations and statistical values.
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5.6 Long-chain n-3 PUFA in plasma phospholipids and triglycerides
Plasma 22:6n-3 content is greatly reduced at diet PUFA balances < 10%
Plasma phospholipids and triglycerides contain similar levels of both 20:5n-3
and 22:6n-3, with slightly higher levels of 20:5n-3 in the plasma triglycerides compared
to the plasma phospholipids (Figure 5.5a, b) and slightly elevated levels of 22:6n-3 in
the plasma phospholipids compared to the plasma triglycerides (Figure 5.5e, f). Lower
levels of 22:5n-3 are found in both the plasma phospholipids and triglycerides
compared to both 20:5n-3 and 22:6n-3 (Figure 5.5c, d). For linear regression equations
see Appendix 17.
The response of 20:5n-3 content of the plasma lipids to diet 18:3n-3 is linear,
while the response to diet PUFA balance is biphasic (Figure 5.5a and b respectively).
This trend is similar to that found for 20:5n-3 content in all membranes (see Figure
4.12). The levels of 20:5n-3 in the plasma phospholipids are similar to those found in
the muscle and heart membranes, while the levels in the plasma triglycerides are
comparable to those of liver and RBC membranes (Figure 4.12).
Plasma phospholipid and triglyceride 22:5n-3 content respond linearly to both
diet 18:3n-3 and diet PUFA balance (Figure 5.5c and d respectively). The response of
plasma 22:5n-3 to diet 18:3n-3 is linear (Figure 5.5c), similar to the response of all
membranes (see Figure 4.12), while the response to diet PUFA balance is biphasic
(Figure 5.5d), which is different to the membrane response found in other tissues (see
Figure 4.12). The levels of 22:5n-3 in plasma phospholipids and triglycerides are
comparable to levels seen in the brain, liver and adipose tissue membranes, while higher
levels of 22:5n-3 are present in heart, muscle and RBC membranes.
The relationship of the 22:6n-3 in the plasma lipids is biphasic in response to
both diet 18:3n-3 and diet PUFA balance (Figure 5.5e and f respectively), similar to the
response seen in the membranes (see Figure 4.11). The results show that below 1g/100g
diet 18:3n-3 and 10% diet PUFA balance the levels 22:6n-3 in the plasma lipids are
severely reduced, but above these dietary levels, 22:6n-3 content is maintained.
In general, the plasma phospholipids contain slightly higher amounts of 22:6n-3
when compared to the plasma triglycerides (Figure 5.5e, f). The 22:6n-3 content of the
plasma lipids is similar to the levels found in the RBC membranes, but lower than those
found

in

the

muscle,

heart,
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brain

and

liver

membranes.

Figure 5.5 Relationship between 20:5n-3, 22:5n-3 and 22:6n-3 content of rat plasma
phospholipids (PL- ο) and triglycerides (TG- ) and the amount of precursor 18carbon PUFA in the diet (g/100g diet; graphs a & c) and diet PUFA balance (n-3 as %
total PUFA; graphs b & d). In each graph the solid coloured symbol represents the value
for initial rats (value not used to determine line of best fit) and all open symbols
represent data from the twelve experimental diets. See Table 5.1 and Table 5.2 for
S.E.M. values of plasma phospholipids and triglycerides respectively. See Appendix 17
for regression equations and statistical values.
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Chapter 6

Discussion

This study represents one of the most comprehensive investigations and analyses
of the influence of diet fatty acid profile on membrane fatty acid composition of the rat.
The main aim of this study was to quantify the “normal” relationship between diet fat
profile and membrane fatty acid composition. I have examined the “normal” situation
by using moderate-fat diets (25%en) rather than the more commonly used high-fat diets.
They differed only in fatty acid composition (as well as non-saponifiable components)
and were complete in all other respects. The fatty acid composition of the twelve diets
was wide ranging for all fat types, including both the essential fatty acids (n-3 PUFA
and n-6 PUFA) and the non-essential fatty acids (SFA and MUFA). The PUFA
provided in the diets were 18C PUFA, which is the “normal” diet for both rats (see
composition of rat chow in Table 2.4) as well as for humans (Arterburn et al. 2006).
Being young adults from an outbred strain, the rats can be regarded as “normal” rats
(i.e. they were not inbred). They were provided the diets for a reasonable time period of
8 weeks (which in metabolic rate units is equivalent to about one year in humans) but
not an extremely long period.
Furthermore, to obtain the most comprehensive picture of the effects of diet fat
profile on the rat, for each diet I measured the fatty acid composition of phospholipids
from seven tissues as well as for triglycerides from two sources (plasma and adipose
tissue). Combining the total number of diets, the sources of membrane and storage
lipids and rats per diet; a total of ~720 fatty acid analyses were carried out! As well, the
daily metabolic rate and body composition of these same rats was determined, allowing
me to quantify the relationship between membrane fat profile, metabolic rate and body
composition.
Although there have been many previous studies showing that diet fat profile
influences membrane composition, they have been more limited. Generally, they have
either only looked at one aspect of this analysis. For example, they have examined only
a single tissue (e.g. McLennan 1993; Ayre and Hulbert 1996b), or only the effect of a
particular fat such as an essential fat (e.g. Mohrhauer and Holman 1963c; Bourre et al.
1989; Stubbs and Kisielewski 1990; Broughton et al. 1991), or only fish oil (e.g. Liu et
al. 1994; Fickova et al. 1998), or used a diet with a high content of fat (e.g. Storlien et
al. 1991; Pan and Storlien 1993) etc.
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I used the conformer/regulator paradigm, as introduced in the review by Hulbert
et al. (2005), to analyse my results. Using this method of analysis the slope of the
relationship indicates how responsive the membranes are to diet fat profile. The results
show that under “normal” situations membrane fatty acid composition is in general
regulated relatively constant despite extensive changes in diet fatty acid composition.
The aspect of diet fat profile that showed the greatest effect on membrane composition
was the balance between the two types of PUFA (n-3 and n-6) in the diet.
In this chapter I will focus on the following:
•

The influence of diet fat on food intake and body composition.

•

The relationship between diet fat and membrane composition (including the
possible mechanisms regulating membrane composition); in particular
discussion of the diet PUFA balance (the most important parameter influencing
membrane composition).

•

The relationship between membrane fatty acid composition and minimum
metabolic rate (which combines results from Chapter 3 and Chapter 4).

•

The effect of diet 18C PUFA on membrane long-chain PUFA content,
concentrating on the influence of diet PUFA balance on membrane 20:4n-6
levels (this is the most important and novel finding of my study with very
significant implications).

•

The relevance of the findings of this study on rats for human nutrition and
health.

6.1 Relationship between dietary fat & food intake & body composition
If we view the twelve groups of rats as a single population we see that there is a
large amount of variation between individual rats in terms of body mass gain and food
intake (Figure 3.6). However, dietary fat profile itself had a relatively small influence on
this variation in food intake and body composition (see Chapter 3). The total variation
was not unexpected as Sprague Dawley rats are an outbred strain and it is well
established that Sprague Dawley rats show great variation in their susceptibility to dietinduced obesity when fed a high-fat diet (Levin et al. 1983; Lauterio et al. 1994). This
variability in response to increased dietary fat has been shown in diets ranging from 25
– 45% energy (Brown et al. 2002; Ghibaudi et al. 2002; Dourmashkin et al. 2005). The
amount of diet fat used in the current study (25%en) falls into the lower end of this
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range, and it has been shown that even 6 months of feeding a moderate-fat diet (32%en)
produced no significant increase in mass gain when compared to a low-fat diet (10%en).
This indicates that this diet-induced obesity generally only develops in Sprague Dawley
rats fed a higher fat content for a substantial time (Ghibaudi et al. 2002). For these
reasons, the tendency for Sprague Dawley rats to develop obesity is not likely to have
been a major factor for body mass gain in the current study. Although it was not a
statistically significant effect it is interesting that the change in body fat content over the
8 week experimental period was more variable between the different diets than the
change in lean body mass (compare graphs a and b of Figure 3.5).
Because I have examined Sprague Dawley rats, background genetic variation is
possibly a strong influence on all metabolic variables measured in the current study. In
(outbred) humans it has been suggested that 67% of variation in BMI is due to genetic
factors (Ravussin and Bogardus 2000) and thus environmental factors (e.g. diet fatty
acid composition) can only be responsible for a maximum of 33% of variation in BMI.
The genetic factors making up the 67% variation included metabolic rate (12%), fat
oxidation (5%), spontaneous physical activity (10%) with food intake being responsible
for 40% (Ravussin and Bogardus 2000). The major variable responsible for obesity is
likely to be food intake, which I have shown to be highly correlated with body mass
gain in rats. If outbred rats show a similar genetic predisposition as humans for obesity,
then we would assume that environmental factors, such as diet fat profile, have only a
limited opportunity for influencing body mass and metabolic rate.
Increased diet SFA led to increased levels of body fat (Figure 3.10). As SFA had
little effect on membrane composition, this may be related to SFA effects on fat
oxidation rates as SFA oxidise less readily than other fats (particularly PUFA) and
consequently may be more likely to be stored as fat, thus leading to increased body
adiposity (Leyton et al. 1987; Pan et al. 1994; Pellizzon et al. 2002). Due to the higher
susceptibility of n-3 PUFAs to be oxidised, one might expect body fat content to
correlate negatively to diet n-3 PUFA, however this was not the case in the current
study. A study in chickens has found similar results, where increased SFA intake
resulted in a greater body fat content (Newman et al. 2002). However, studies in rodents
have shown mixed results. In some studies, high SFA diets resulted in reduced body fat
(Pellizzon et al. 2002) while other studies report increased body fat content (Takeuchi et
al. 1995). Both these rodent studies used high-fat diets, with differing sources of n-3
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PUFA in the comparison diets, i.e. fish oil in (Pellizzon et al. 2002) and linseed oil in
(Takeuchi et al. 1995), which may have influenced the difference in their results.
Some previous studies have shown increased adipogenesis in animals fed diets
high in n-6 PUFA (Fickova et al. 1998; Ailhaud et al. 2006), presumably through the
increased production of prostacyclin from 20:4n-6, which triggers adipogenesis in
adipose tissue. However, I have shown no relationship between total body fat content
and diet n-6 PUFA content. Perhaps this trend only becomes evident in high-fat diets,
while the current study used a moderate-fat diet. Another possible reason is that
alterations in membrane fatty acid composition post-weaning have little influence on
adipose tissue development as adipocytes have been shown to differentiate and
proliferate mainly during early postnatal development (Ailhaud and Guesnet 2004).
Another possibility is that moderate-fat diets need to be fed for extremely long-periods
to have significant effects on body composition.
A high diet SFA content and a low diet n-6 PUFA was associated with increased
food intake in this study (Figure 3.11). Previous studies in rodents have shown no
influence of diet SFA or n-6 PUFA content in moderate-fat feeding on food
consumption (Ayre and Hulbert 1996b) and similarly in chickens (Newman et al. 2002).
However, a recent study has shown a significant reduction in food intake in pigs fed an
n-6 PUFA diet when compared to feeding either n-3 PUFA or SFA (R.E. Newman,
personal communication). This reduced food intake may be due to an immune response
modulated by increased cytokine synthesis. Diets high in n-6 PUFA lead to increased
cytokine production in mice (when compared to a n-3 PUFA diet; Sierra et al. 2006)
and it has also been shown that increased levels of inflammatory cytokines (including
IL-1, IL-6 and TNF-α) result in reduced food intake (Johnson 1997).
There is some evidence that a high SFA diet may increase neuronal activity in
areas of the hypothalamus associated with feeding while decreasing activity in the
satiety centre (Wang et al. 1999), which might be involved in the increased food intake
and body fat content found in rats fed a high SFA diet in this study. Diet n-6 PUFA may
be influencing food intake through the endocannabinoid system, which will be
discussed in more detail later in this chapter.

6.2 Relationship between dietary fat & membrane composition
I have compared my fatty acid composition results to those of previous studies
that approximately match the conditions of the current study (i.e. diets with a moderate102

fat content and 18C PUFA only, adult outbred rats). Results for liver and RBC
membranes, plasma phospholipids and triglycerides, and adipose tissue triglycerides
were equivalent to those reported by Lands et al. (1990), while those for skeletal muscle
and adipose tissue membrane are similar to Soriguer et al. (2000), and the fatty acid
composition of heart and brain membranes are similar to Barcelo-Coblijn et al. (2005).
In all tissues, except adipose tissue (to be considered in two paragraphs time) the
relative composition of the major fatty acid classes (SFA, MUFA and PUFA) in
membranes was highly regulated over very large variation in diet composition. Diet
SFA had essentially no influence on membrane SFA composition (slopes
≤0.02). The
unsaturated fatty acid (UFA) composition of the membranes was not plotted in the
present study, but as fatty acids can only be saturated or unsaturated it can be concluded
that diet UFA also has essentially no influence on membrane UFA content. The
membrane response to both diet MUFA and PUFA was slightly greater than the
response to SFA with slopes ≤0.12 and ≤0.09 respectively.
Cerebral cortex was the brain region measured in the current study and the brain
is known to be a heterogeneous tissue in comparison to other tissues. Brain PUFA
composition has been shown to be highly region specific (Diau et al. 2005). The brain
membranes consistently showed the lowest responsiveness to diet fat profile. Brain
membrane fatty acid composition was also distinctive, containing higher MUFA with a
corresponding lower total PUFA compared to the other tissues. Between species
comparisons have shown that brain PUFA content is conserved over large changes in
body mass, while the PUFA content of the heart and skeletal muscle decreases with
body size (Hulbert et al. 2002). Rats have a lower PUFA content in their brain
membranes relative to other tissues (muscle, heart, liver, RBC), while the opposite trend
is observed in humans.
Although only limited studies have analysed both adipose tissue phospholipid
and triglyceride fatty acid composition, the results of the current study agree with
studies in mice (Tallman and Taylor 2003) and humans (Field et al. 1985). In contrast to
other tissues, the adipose tissue phospholipids were more responsive to all diet fat types
(slopes ranging from 0.28 – 0.52 for SFA, MUFA, PUFA, n-3 PUFA and n-6 PUFA)
and similar to the response of the adipose tissue triglycerides to diet (slopes 0.45 –
0.69). The greater slopes for adipose tissue phospholipids may be due to some
contamination from adipose tissue triglycerides, however as discussed in Chapter 4 I
believe that this is minimal.
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Although the membranes were relatively unresponsive to diet total PUFA
(slopes ≤0.09 for all tissues) they show a higher responsivity to the individual PUFA
classes (n-3 PUFA slopes ≤0.17 and n-6 PUFA slopes ≤0.24). The essential requirement
of rats for polyunsaturates was first shown by Burr and Burr (1929). Collins et al.
discovered that n-6 PUFA was an essential fatty acid for humans in 1971 (Collins et al.
1971), but it was another 11 years before it was shown that n-3 PUFA was also an
essential component of our diets (Holman et al. 1982). Thus, n-3 PUFA and n-6 PUFA
have independently been shown to be essential fats, and should be considered
separately.
The requirement of the diet essential fatty acids in rats has been estimated to be
2.4%en for 18:2n-6 and 0.4%en for 18:3n-3 (Bourre et al. 1989; Bourre et al. 1990),
which equates to 12g 18:2n-6 / kg diet and 2g 18:3n-3 / kg diet. This leads to the
possibility that diets 1, 2, 4, 8 and 11 may be considered to be EFA-deficient. To
determine whether this was the case the ratio of 20:3n-9/20:4n-6 present in the
membranes was calculated. This ratio is considered a good indicator of essential fatty
acid deficiency, with values < 0.4 indicating that the minimum requirement for diet n-3
and n-6 PUFA has been met (Holman 1960). Omega-3 deficiency can also be
specifically measured using the ratio of 22:5n-6/22:6n-3 (Galli et al. 1971). In the
present study the ratio of 20:3n-9/20:4n-6 present in the phospholipids of all tissues was
0 - 0.08, which indicates the rats were not suffering from EFA deficiency. It is possible
that a longer time period is required for a deficiency to manifest, however, it can be
concluded that EFA deficiency did not occur under the current study conditions.
My study has shown that membrane composition is a highly regulated
parameter with the membrane n-3 and n-6 PUFA showing the greatest diet
responsivities. Although little is known about this regulation, it is likely occurring at the
level of the acyltransferases. Acyltransferases catalyse the incorporation of n-3 and n-6
PUFA into the sn-2 position of the membrane phospholipids during membrane
remodeling, and although they have a very high preference for PUFA, they do not
discriminate between n-3 PUFA and n-6 PUFA, as described by the earlier work of
William Lands (Lands et al. 1982). The relative abundance of these two types of fat in
the diet will strongly influence their membrane levels. This likely provides an
explanation as to why the balance between the n-3 and n-6 PUFA in the diet (i.e. PUFA
balance) had the greatest influence on membrane fatty acid composition.
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The relationship between diet and membrane lipid PUFA balance was biphasic
for all tissues (except adipose tissue phospholipids). A diet PUFA balance of ~10% is
the critical level required to maintain membrane PUFA balance in skeletal muscle,
heart, liver, brain and RBC. At diet PUFA balances < 10% the membrane PUFA
balance of these tissues was highly responsive (slopes of 0.65 – 1.47), indicating that
the membranes are essentially completely conforming to diet PUFA balance at these
low levels.
A number of studies (Bourre et al. 1989; Bourre et al. 1993) found a similar
biphasic relationship between diet PUFA balance and the membrane fatty acid
composition for a number of tissues. The general aim of these studies was to determine
the requirement of brain and other tissues for diet 18:3n-3 during development (prior to
weaning). Wistar rats were fed a low-fat diet with only 18C PUFA (Bourre et al. 1989)
or 18C PUFA mixed with bovine brain phospholipids (Bourre et al. 1993). I have
calculated the PUFA balance of both diets and membrane lipids (for liver and brain) of
these studies and plotted them against each other (see Appendix 18). This also revealed
a biphasic pattern, with a break at a diet PUFA balance of 6% for liver and 4% for brain
(Bourre et al. 1993). The plots in their 1989 paper (Bourre et al. 1989) present findings
analogous to the findings of the current study. They show that for diets with a PUFA
balance less than 6%, membrane 22:6n-3 is highly responsive to diet (in brain, liver,
heart and muscle), but above this diet PUFA balance the membrane 22:6n-3 is relatively
constant. The inverse was true for membrane 22:5n-6 content of all tissues. In contrast,
the adipose tissue demonstrated a linear relationship over the full range of diet PUFA
balance (also similar to my findings). So although not directly comparable to the current
study these results confirm that skeletal muscle, heart, liver and brain membranes
require a certain diet PUFA balance to be able to maintain membrane PUFA balance.
This level may vary depending on the total amount of fat in the diet and also the stage
of development of the animal.
It is interesting that this biphasic pattern for diet PUFA balance occurs only in
some tissues, with a linear relationship seen for the adipose tissue phospholipids and
triglycerides, as well as for the plasma phospholipids and triglycerides. These results
show that it is the tissues responsible for the transport (i.e. blood) and storage of lipids
(i.e. adipose tissue) demonstrating a linear response.
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6.3 Relationship between membrane composition & metabolic rate
The membrane pacemaker theory of metabolism was proposed in the 1990’s to
explain differences in basal metabolic rate (BMR) between species (Hulbert and Else
1999; Hulbert 2007). The size of metabolically active tissues could not alone explain
the variation in BMR between species and this theory postulated that variation in BMR
results from changes in both organ size and cellular metabolic rate. Higher membrane
PUFA content (and subsequently lower MUFA content) was found to be associated
with an elevated BMR in between-species comparisons (Gudbjarnason et al. 1978;
Hulbert and Else 1989; Brand et al. 1991; Couture and Hulbert 1995). It was suggested
that membrane fatty acid composition is an important determinant of cellular metabolic
rate (Hulbert and Else 1999).
However, questions still remain as to whether membrane composition is
associated with metabolic rate variation within species. For example, studies in mice
have demonstrated no relationship between membrane fatty acid composition and BMR
(Brzek et al. 2007; Haggerty et al. 2008). Similarly in dogs, differences in metabolic
rate between small and large dogs are related to relative organ size, rather than
membrane composition (A.J. Hulbert, personal communication).
Some previous studies in mice have shown mixed results for the relationship
between organ size and changes in metabolic rate. One reports a positive relationship
(Selman et al. 2001), while another found no relationship between the two (Speakman
and Johnson 2000). The results of the current study have shown that kidney size was the
only organ to correlate with whole-animal DMR (see page 47).
In Chapter 3 the results showed that diet fat profile significantly influences
mass-specific daily metabolic rate (see Figure 3.12), and in Chapter 4 diet fat profile
was also shown to have a significant effect on membrane fatty acid composition
(particularly n-6 PUFA, n-3 PUFA and PUFA balance; see Figure 4.6 and Figure 4.8).
Combining the results from these two chapters allowed me to analyse the
potential role of membrane composition on metabolic rate variation of the rats in my
study. Although BMR was not measured in this study (as metabolic rate of the rats was
measured at 23ºC and thus not in their thermoneutral zone), minimal metabolic rate
(MMR) was calculated for each individual rat (see Table 3.1). I am assuming that MMR
(at 23ºC) of each rat is directly comparable to it’s BMR. This assumes that dietary
treatment had no effect on insulation.
106

I have analysed the relationship between the mass-specific MMR of individual
rats and aspects of membrane composition (i.e. SFA, MUFA, PUFA, n-6 PUFA, n-3
PUFA, PUFA balance) for each of the six tissues measured. The slopes of these
relationships and their significance are shown in Figure 6.1 (statistical results for the
linear regression analyses are accessible in Appendices 19 - 24).
There was no significant relationship between MMR and membrane content of
SFA, MUFA or PUFA for all tissues (Figure 6.1a, b & c). The membrane n-6 PUFA
composition of all tissue was negatively related with MMR (although the relationship
with muscle and adipose tissue membranes was not statistically significant; Figure
6.1d). In contrast, the membrane n-3 PUFA composition showed a significant positive
relationship with MMR for all tissues (Figure 6.1e). Similarly, the relationship between
membrane PUFA balance and MMR was significantly positive for all tissues (Figure
6.1f), indicating that increasing the membrane content of n-3 PUFA at the expense of n6 PUFA is associated with a significantly increased mass-specific MMR. Membrane
PUFA balance has the strongest association with MMR for all tissues.

Figure 6.1 A comparison of the slope of relationship between membrane fatty acid
composition (% total fatty acids) of various tissues and minimum metabolic rate of rats
(MMR @ 23ºC). (a) SFA (b) MUFA (c) PUFA (d) n-6 PUFA (e) n-3 PUFA (f) PUFA
balance. A slope of zero indicates no relationship between MMR and membrane fat
type. MMR expressed as ml O2.hr-1.g-1 total body mass; PUFA balance expressed as n-3
PUFA as % total PUFA. Values are slopes ± S.E.M. (see Appendices 19-24 for slope
and statistical values). * indicates slope of the line of fit is significantly different from
zero (P < 0.05).
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Previous studies have shown that increasing the PUFA content of the diet results
in increased BMR in rats (Shimomura et al. 1990) and humans (Couet et al. 1997). The
conclusions from these studies that total diet PUFA content influences BMR are drawn
primarily from comparisons of only two diets, both with very different types of PUFA
present. In the rat comparison a safflower diet was compared to a beef tallow diet
(Shimomura et al. 1990). In the human study the addition of fish oil to the diet resulted
in an increased diet PUFA balance from 9% up to 29%, which was associated with
increased metabolic rate (Couet et al. 1997). However, neither study measured
membrane composition and therefore it is not certain that diet-induced changes in
membrane composition were responsible for changes in metabolic rate.
The previous considerations of the membrane pacemaker theory by Hulbert and
Else have emphasised the total PUFA content of membranes. An interesting conclusion
from Figure 6.1 is that it may be the balance of n-3 PUFA and n-6 PUFA in membrane
lipids that is the important influence on metabolic rate. This suggests that n-3 PUFA are
influencing the membrane function in a different manner to the n-6 PUFA. Double
bonds are closer to the methyl (i.e. omega) end of the fatty acyl chain in n-3 PUFA
compared to n-6 PUFA, so membrane n-3 PUFA may be influencing the physical
properties of the membrane closer to the centre of the lipid bilayer.
It is well known that increased unsaturation of the fatty acyl chain leads to
greater flexibility (due to isomerisation of the single bonds adjacent to double bonds;
see Eldho et al. 2003; Gawrisch et al. 2003), but it has also been shown that rotation
around these single bonds increases towards the methyl end (Ollila et al. 2007), so that
in the six double bonds present in 22:6n-3 flexibility is greatest at the methyl end. This
increased flexibility towards the centre of the bilayer could be a mechanism for
increasing the activity of membrane-bound proteins.
Another possible mechanism is changes in lateral pressure within the membrane,
with 22:6n-3 shown to reduce the lateral pressure in the middle of the bilayer (Ollila et
al. 2007). This reduced pressure in the centre of the bilayer has been associated with
increased membrane protein activity, for example, in rhodopsin (Litman and Mitchell
1996; Cantor 1999). These studies have all focused on membrane 22:6n-3 content and
chain length may also influence physical properties of the membrane, however, these
results suggest that while increasing the general unsaturation of the fatty acyl chain
leads to increased activity of membrane associated processes, n-3 PUFA may be
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exerting an even greater influence due to the placement of the double bond close to the
methyl end of the hydrocarbon chain.
These findings could have important implications for human health, with a low
diet PUFA balance associated with a number of diseases prevalent in today’s society,
including metabolic and cardiovascular diseases as well as mental ill health (Storlien et
al. 1996; Hibbeln 1998; Vessby 2000; Hulbert et al. 2005; Allport 2006; Lands 2008).

6.4 Relationship of membrane long-chain PUFA to diet PUFA
All the long-chain PUFA measured in membrane lipids in the current study are
the product of enzymatic modifications of diet 18C PUFA, as these were the only PUFA
provided in the diet.
There are a number of enzymatic modifications involved in the regulatory
pathway between diet essential fatty acids and membrane 20-22C PUFA composition.
This includes conversion of the 18-carbon PUFA to longer chain PUFA by desaturases
and elongases. There are a number of desaturases that are responsible for the removal of
two hydrogens (to produce a C=C double bond) at specific locations in the hydrocarbon
chain. The elongases are responsible for adding two carbons at the carboxylic end of the
fatty acid molecule. Both types of enzymes are located in the endoplasmic reticulum.
The main long-chain PUFA produced by these two processes are 20:4n-6 (see Figure
4.9), 22:4n-6 (see Figure 4.10), 20:5n-3 and 22:5n-3 (see Figure 4.12).
The production of the highly polyunsaturated 22:6n-3 and 22:5n-6 involves an
additional peroxisomal step following the elongation/desaturation processes. These
long-chain PUFA undergo an additional elongation to 24-carbon PUFA which are then
transferred to peroxisomes where enzymes catalyse a single cycle of β-oxidation to
produce these 22-carbon PUFA (Sprecher 2000). Little is known about the regulation of
their production but my results suggest it differs from their 20C PUFA precursors.
For both the n-6 and n-3 20C PUFA there was a linear relationship between their
membrane composition and the amount of their 18C PUFA precursor in the diet (see
Figure 4.9 for membrane 20:4n-6/diet 18:2n-6 relationship and Figure 4.12 for
membrane 20:5n-3/diet 18:3n-3 relationship).
However, for 22:6n-3 the relationship from it’s 18C precursor was not linear
(Figure 4.11). For all tissues, there was no increase in 22:6n-3 content of membrane
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phospholipids with diets containing more than 1g 18:3n-3/100g diet. A similar trend
was previously demonstrated in liver, heart, muscle and brain membranes (Bourre et al.
1989). This suggests a limit to the capacity of the peroxisome to produce 22:6n-3.
It is interesting that the relationship between membrane 22:6n-3 and diet PUFA
balance produces essentially the same biphasic relationship as that with diet 18:3n-3
(see Figure 4.11). Once diet PUFA balance reaches 10% there is no increase in
membrane 22:6n-3 levels for all tissues. This suggests that diet n-6 PUFA is not
involved in this limit to the production of these long-chain PUFA.
Some further insight can be gained from considering the relationships between
diet PUFA balance and membrane 22:6n-3 and 22:5n-6 together. At diet PUFA
balances >10% there appears to be no increase in 22:6n-3 content of membrane
phospholipids and negligible change in 22:5n-6 content (for all tissues). However at diet
PUFA balances <10%, there is a dramatic increase in 22:5n-6 and a decrease in 22:6n-3.
When the levels of membrane 22:6n-3 and 22:5n-6 are summed this value is constant
over the complete range of diet PUFA balance (i.e. 1-86%; results not shown). For
example, in skeletal muscle the peroxisomal pathway may have a set capacity which
produces a steady total amount of these 22-carbon highly polyunsaturated fatty acids. It
preferentially converts the available n-3 PUFA to 22:6n-3, but will substitute n-6 PUFA
to make 22:5n-6 when there is inadequate n-3 PUFA for 22:6n-3 production.
Another possibility for limits in the production of 22:6n-3 and 22:5n-6 is the
second Δ6-desaturase (see Figure 1.2). An in vitro model investigating the influence of
increasing levels of 18:3n-3 supplementation on fatty acid metabolism in the HepG2
cell line (Portolesi et al. 2007) found similar results to in vivo studies (i.e. Mohrhauer
and Holman 1963b), indicating that Δ6-desaturation of 24:5n-3 is inhibited with
increasing levels of 18:3n-3, thus preventing the synthesis of 22:6n-3. This study also
concluded, however, that peroxisomal pathways may also be important in determining
membrane 22:6n-3 levels (see Portolesi 2007).
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Diet PUFA balance as an important determinant of membrane 20:4n-6
A surprising finding and, in my opinion, potentially the most important (for
health implications) of this study was the effect of diet PUFA balance on membrane
20:4n-6 levels (see Figure 4.9). In every tissue measured diet PUFA balance appears to
be an extremely accurate predictor of membrane 20:4n-6 content (more so than the
amount of diet 18:2n-6 by itself). There was large variation in membrane 20:4n-6
content with changes in diet PUFA balance, which will likely influence the production
of eicosanoids (including prostacyclin) and endocannabinoids, and consequently have
health effects which will be discussed later in this chapter.
I have demonstrated this relationship for total phospholipids of all tissues and
there are implications that this is not restricted to only one phospholipid class, but is
manifest in all phospholipids. Skeletal muscle samples from some of my rats were
analysed for molecular species via mass spectrometry in another study (see Nealon et al.
2008). This other study included analysis of muscle from rats consuming diets spanning
the full PUFA balance range (diets 1, 4 and 12). The PC and PE molecular species that
contained 20:4n-6 included PC16:0/20:4, PC18:1/20:4, PC18:0/20:4, PE16:0/20:4,
PE18:1/20:4 and PE18:0/20:4. Phospholipid 20:4n-6 was also present in one PS
molecular species (PS18:0/20:4). The effect of diet PUFA balance on the relative
amount of each of these 20:4n-6-containing molecular species (% of total
phospholipids) in the skeletal muscle is plotted in Figure 6.2.
This figure reveals a significant negative correlation between diet PUFA balance
and each phospholipid molecular species containing 20:4n-6 (P≤0.01 for all molecular
species). PC molecular species showed the greatest response to diet PUFA balance with
slopes of -0.18, -0.03 and -0.04 for PC16:0/20:4, PC18:1/20:4 and PC18:0/20:4
respectively. PE and PS were present in lower relative amounts and also showed a
reduced response to diet PUFA balance with slopes of -0.00, -0.01, -0.03 and -0.00 for
PE16:0/20:4, PE18:1/20:4, PE18:0/20:4 and PS18:0/20:4 respectively.
These results confirm that increasing the diet PUFA balance not only reduces
total membrane 20:4n-6 levels, but also the relative amount of PC, PE and PS
containing 20:4n-6 in the skeletal muscle. This has implications in the potential
production of signaling molecules derived from phospholipid 20:4n-6, including
eicosanoids and endocannabinoids.
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Figure 6.2 The effect of diet PUFA balance (n-3 PUFA as % total PUFA) on the
relative amount of each phospholipid molecular species that contained 20:4n-6 (% of
total phospholipids) in the skeletal muscle. (a) phosphatidylcholine (PC); (b)
phosphatidylethanolamine (PE); (c) phosphatidylserine (PS). Values are mean ± S.E.M.;
n=5 for all diets (includes diet 1, 4 and 12). * indicates a significant linear relationship
(P<0.05).
The incorporation of 20:4n-6 into rat liver and brain phospholipids appears to
primarily occur during the membrane remodeling (i.e. deacylation and reacylation)
phase rather than during de novo synthesis of phospholipids (van Golde and van den
Bergh 1977; Holub and Kuksis 1978; Schmid et al. 1995), however, it is not definitely
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known whether this also applies to the phospholipids of other tissues. Membrane lipid
remodeling

is

performed

by the

combined

action

of

phospholipases

and

acyltransferases. Lands et al. (1982) demonstrated that acyltransferases show no
discriminating ability for the incorporation of n-3 and n-6 PUFA and this may be the
mechanism responsible for the greater predictability of diet PUFA balance than diet
18:2n-6 content on muscle 20:4n-6.
This relationship between diet PUFA balance and membrane 20:4n-6 appears to
be relatively independent of the amount of fat in the diet. For example, although the fat
content of initial rat chow was 13%en compared to 25%en in the experimental diets the
values for the initial rats conform to the relationships determined from the experimental
rats (see Figure 4.9).
A similar relationship is also manifest in the important seminal studies of
Mohrhauer and Holman where rats were fed extremely low amounts of fat (<3%en).
They measured the fatty acid composition of total lipids of liver, heart and depot fat
(Mohrhauer and Holman 1963c) and brain lipids (Mohrhauer and Holman 1963a) from
male Sprague-Dawley rats fed a fat-free diet supplemented with daily oral doses of very
small amounts of 18:2n-6 and 18:3n-3 as their sole source of dietary fat. They compared
an impressive 18 combinations of these two essential fatty acids. Intakes of 18:2n-6
ranged from 0.07%en to 0.73%en while 18:3n-3 intakes ranged from 0.05%en to
1.92%en. Thus the range of total fat intake was from 0.13%en to 2.59%en (compared to
25%en from fat in the current study). They conclusively demonstrated that the
conversion of 18:2n-6 to 20:4n-6 (from the combination of Δ6 desaturase, elongase and
Δ5 desaturase activity) was inhibited by 18:3n-3.
Although they measured total lipids, I have assumed that for liver, heart and
brain these lipids will be predominantly membrane lipids and have plotted the 20:4n-6
content of these tissue lipids relative to diet 18:2n-6 content (Figure 6.3a and c) as well
as relative to diet PUFA balance (Figure 6.3b and d). This is analogous to the plot for
my own data in Figure 4.9. As can be seen from this figure diet PUFA balance is a
much better predictor of the 20:4n-6 content than is diet 18:2n-6 content. For liver
lipids, diet PUFA balance explained 90% of the variance compared to only 49%
explained by diet 18:2n-6 content. The respective values for heart lipids were 77%
versus 40%, while for brain lipids they were 89% compared to 39%.
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Figure 6.3 Analysis of results from Mohrhauer and Holman’s early study in rats
investigating the effect of diet 18:2n-6 and 18:3n-3 content on the total lipid 20:4n-6
content in the liver, heart (Mohrhauer and Holman 1963c) and brain (Mohrhauer and
Holman 1963a). Results presented as the 20:4n-6 content of each tissue relative to diet
18:2n-6 content (% energy; left-hand graphs) and diet PUFA balance (n-3 PUFA as %
total PUFA; right-hand graphs).

While the measurements of Mohrhauer and Holman are not directly comparable
to those of the present study in that these authors examined did not have a constant
amount of fat in their diets, they do show that PUFA balance of the diet is an important
determinant of the arachidonic acid content of membrane phospholipids for very low-fat
diets as well as for the moderate-fat diets examined in the present study.

6.5 Implications for human nutrition & health
The findings of this study on rats have relevance for humans. In any
extrapolation from findings of a small mammal (such as laboratory rodents) to a large
mammal (such as humans) the relationship between body size and the rate of metabolic
processes (and thus time) needs to be taken into account. It has been known for a long
time that metabolic processes are slower in larger animals (Kleiber 1961). The initial
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conclusion that humans, unlike rats, did not have an essential requirement for PUFA
was based on the error of not taking this relative time into account. The symptoms of
EFA deficiency take ~ 3 months to become manifest in rats and thus the original six
months testing period in humans was inadequate (see Holman 1988). We now know
that rats and humans essentially have the same dietary requirements for n-6 and n-3
PUFA (%en). As mentioned earlier, the 8 week feeding period in rats I used is
analogous to approximately one year in humans (see Kleiber 1961 for metabolic rate
data).
Metabolic syndrome, obesity and high-fat diets
A number of studies suggest that diet fat profile, specifically those with a low
PUFA balance (i.e. a low n-3 PUFA associated with a high n-6 PUFA) may be causal to
the increased incidence of some diseases in recent times. One such example is insulin
resistance which is the basis of the “metabolic syndrome” that includes dyslipidemias,
hypertension, chronic inflammation, obesity and type 2 diabetes (Reaven 1988;
Simopoulos 1999). One study examining the feeding of a high-fat (lard) diet to rats
showed that insulin-resistance precedes other aspects of the metabolic syndrome with
insulin resistance being manifest after two weeks but body mass was not significantly
different until 20 weeks (Barnard et al. 1998). Another study (Storlien et al. 1986)
showed feeding rats high-fat diets (59% energy as safflower oil; PUFA balance <1% )
to rats causes widespread insulin resistance; however when 20% of the safflower oil
was replaced with fish oil, insulin resistance did not occur (Storlien et al. 1987). This
effect was not restricted to long-chain n-3 PUFA but was also observed when rats are
fed 18:3n-3 (Storlien et al. 1991; Ghafoorunissa et al. 2005). Several studies report a
connection between membrane fatty acid composition and insulin sensitivity (Borkman
et al. 1993; Vessby et al. 1994; Pan et al. 1995).
The current study examined the influence of a moderate-fat diet on membrane
composition and it’s finding of the importance of the balance between n-6 and n-3
PUFA in the diet has, I believe, implications for the most common experimental
paradigm used to investigate obesity, namely the feeding of a high-fat diet to laboratory
rodents. Scientific papers that use this method of inducing obesity in rodents normally
emphasise the amount of fat in the diet as the cause of the induced obesity and rarely
consider the fatty acid profile of the diet as a possible cause of the obesity.
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I carried out a Medline search for papers published in 2008 using the terms
“high fat diet induced obesity” in “mice and rats” and analysed them for the types of
fats used in the diet. The average fat content of the diets was 51% energy as fat (range =
20-72%en) and the average time of feeding was 15 weeks (range = 2-36 weeks). Of the
86 papers obtained, 81 provided either (i) the fatty acid composition of the diet used, or
(ii) the source and proportions of the fats used to make the diet. For these I was able to
calculate the amount of both n-3 and n-6 PUFA in the diet and from these I calculated
the PUFA balance of the diet (see Appendix 25 for the details of each paper). Figure
6.4 provides the distribution of the ‘PUFA balance’ values calculated for the diets.

Figure 6.4 Results for Medline search of papers published in 2008 with keywords:
“high fat diet induced obesity” in “mice and rats”. Diet PUFA balance (n-3 as % total
PUFA) was calculated for 81 studies (out of a total of 86; see Appendix 25 for data).
The vast majority used either vegetable oils or lard, or a mixture of vegetable
oils and lard (>90% of the studies) as the source of dietary fats. As the PUFA of both
vegetable oils and lard are primarily n-6 PUFA (see Chapter 1) these studies will be
examining the effects of diets low in n-3 PUFA as well as the effects of a high-fat
content. This is rarely identified in such studies. The average PUFA balance was 7.2%
(n-3 PUFA as % of total PUFA), while the median value was 4.4%. About 55% of all
studies used a diet with a PUFA balance of less than 5% (see Figure 6.4).
In light of this it may be that many of the studies reporting an effect of a high-fat
diet are in fact reporting an effect of diet fatty acid profile without realizing it. A recent
meta-analysis examining the link between human diet and type 2 diabetes (i.e. insulin
resistance) showed that greater intake of green leafy vegetables was associated with a
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reduced risk of type 2 diabetes, while there was no significant benefit of increasing the
intake of vegetables, fruit, or fruit and vegetables combined (Carter et al. 2010).
Although green leafy vegetables contain very low levels of total PUFA (~0.2g/100g; see
Figure 1.7), they are high in 18:3n-3 and low in 18:2n-6, which suggests that food with
a high PUFA balance might be beneficial for preventing many of the conditions
associated with the metabolic syndrome (e.g. insulin resistance).
The potential health implications of high membrane arachidonic acid
If the strong relationship between diet PUFA balance and membrane 20:4n-6
content in rats also applies to humans there may be a number of very important
implications for human health. This is because of the central role of membrane 20:4n-6
plays in many parts of metabolic syndrome and chronic inflammation.
In the December 17th 2010 issue of Science the editors highlighted ten “Insights
of the Decade”. One of these insights was that chronic inflammation is the driving force
behind many diseases that have increased in recent time (including insulin resistance,
obesity, atherosclerosis, cancer, and neurodegenerative diseases, such as Alzheimer’s
disease) (Couzin-Frankel 2010). If the recent changes in the PUFA balance of the
Western diet (see Chapter 1) have resulted in increased membrane 20:4n-6 levels and
thus increasing chronic inflammation in many humans, this may be an explanation for
the increased incidence in these diseases. An obvious solution to moderate this chronic
inflammation might be to simply increase the diet PUFA balance.
Arachidonic acid is the substrate that the body uses to produce signalling
molecules for (i) inflammation (eicosanoids), (ii) adipogenesis (prostacyclin) and (iii)
appetite (endocannabinoids).
Eicosanoids & Inflammation
Work by William Lands in the 1970’s led to the hypothesis that increasing
membrane n-3 PUFA levels may prevent the inflammation problems associated with
20:4n-6-derived eicosanoids (Lands et al. 1973; Lands 1993; Lands 2008). Increased
membrane 20:4n-6 content is associated with a higher production of pro-inflammatory
eicosanoids (Whelan 2008). Production of these eicosanoids occurs when 20:4n-6 is
cleaved from the glycerophospholipid by phospholipase A2 (Hishikawa et al. 2008)
following which formation occurs through the action of either cyclooxygenase or
lipooxygenase (Pischon et al. 2003). Membrane 22:6n-3 and 20:5n-3 provide protection
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against inflammation by suppressing the production of pro-inflammatory eicosanoids
derived from membrane 20:4n-6 and also by producing resolvins and protectins, which
promote the termination of inflammation (Serhan and Savill 2005).
Diet PUFA balance has an important influence on the regulation of
inflammation. Depriving rats of diet n-3 PUFA results in upregulation of 20:4n-6
metabolism in the brain (Rapoport 2008), while increasing dietary n-3 PUFA levels (by
supplementing with flaxseed oil or fish oil) results in reduced synthesis of
prostaglandins and leukotrienes, as well as proinflammatory cytokines (such as
interleukin 1β and tumor necrosis factor α) (James et al. 2000). The balance of n-3
PUFA and n-6 PUFA in the diet may be of particular importance in neuroinflammation
(Farooqui et al. 2007), with evidence showing that, in contrast to proinflammatory n-6
PUFA metabolites, n-3 PUFA metabolites offer protection in neurodegenerative disease
(Bazan 2005; Serhan 2005).
The critical role diet PUFA balance plays in levels of chronic inflammation
highlights the importance of maintaining the diet PUFA balance above 10% to ensure
lower levels of membrane 20:4n-6 and a higher membrane n-3 PUFA content.
Prostacyclin & Adipogenesis
Membrane arachidonic acid is a precursor for prostacyclin (prostaglandin
I2), which is known to promote adipose tissue development in humans and rats (see
(Ailhaud et al. 2006; Ailhaud et al. 2008)). Both the size and number of adipocytes is
known to increase with a low diet PUFA balance (Fickova et al. 1998; Massiera et al.
2003; Ailhaud et al. 2006) and this has obvious implications in obesity, particularly
during early development. The adipogenic effect of 20:4n-6 has been demonstrated in
the early development of mice, with those fed a high-fat diet high in 18:2n-6 (2%
PUFA balance) having increased fat mass and size of adipocytes compared to those fed
a diet including both 18:2n-6 and 18:3n-3 (PUFA balance 33%) (Massiera et al. 2003).
A number of studies in humans have also demonstrated a strong association
between membrane 20:4n-6 content or low PUFA balance and the incidence of obesity.
A positive association has been shown between the 20:4n-6 content of adipose tissue
total lipids and BMI in children (Savva et al. 2004). Further to this, studies in humans
have shown that obese individuals have a reduced PUFA balance in the phospholipids
of muscle (Storlien et al. 1996; Haugaard et al. 2008), liver and red blood cells
(Elizondo et al. 2007) and also the triglycerides and phospholipids of adipose tissue
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(Hulbert et al. in preparation) compared to non-obese individuals. Together, these
studies indicate the problem of high membrane arachidonic acid levels in the
development and maintenance of obesity.
Endocannabinoids & Appetite
The endocannabinoids anandamide and 2-arachidonoyl glycerol (2-AG) are
signalling molecules derived from phospholipid 20:4n-6 that are involved in energy
homeostasis and are known to enhance appetite levels (Matias and Di Marzo 2007).
Endocannabinoids are present in all mammalian cells with the CB1 receptor present
both in the brain (Matias et al. 2006a) and peripherally, including liver (Osei-Hyiaman
et al. 2005), adipose tissue (Engeli et al. 2005; Roche et al. 2006) and skeletal muscle
(Pagotto et al. 2006). Anandamide is derived from phosphatidylethanolamine (PE) (Di
Marzo et al. 1994; Sugiura et al. 2002) while 2-AG is produced from
phosphatidylinositol (PI) (Sugiura et al. 2006). Results from the current study have
shown a reduction in all PE molecular species containing 20:4n-6 in the skeletal muscle
with increasing diet PUFA balance (see Figure 6.2), which could potentially lead to
reduced anandamide levels. Antagonists for the CB1 receptor have been suggested as
targets for the treatment of obesity and metabolic syndrome (Kyrou et al. 2006),
however the results from my study suggest that changing the balance of PUFA in the
diet may achieve the same health outcome.
Previous studies in rodents have shown that altering the diet essential fatty acid
levels can influence endocannabinoid levels in the brain (Berger et al. 2001; Watanabe
et al. 2003; Artmann et al. 2008) and liver (Osei-Hyiaman et al. 2005; Artmann et al.
2008), with increased diet PUFA balance generally leading to reduced endocannabinoid
levels. However, as far as I am aware there has been no previous study that has applied
such a wide-ranging diet fat profile as the current study to investigate the effects on
tissue endocannabinoid levels, as well as the possible influence on food intake and
appetite drive.
A previous study in rats demonstrated that those fed a diet containing 18:3n-3
early in life consumed less food (in response to appetite stimuli) than those fed a diet
lacking n-3 PUFA, but containing 18:2n-6 (Mathai et al. 2004). Although the levels of
20:4n-6 were not reported, these results corresponded with a reduction in the total n-6
PUFA present in the brain phospholipids, indicating that endocannabinoid production
may have been affecting appetite levels in these rats.
119

If phospholipid 20:4n-6 content is important for the production of appetiteenhancing endocannabinoids, a positive correlation between membrane 20:4n-6 content
and food consumption would be expected in the current study. However, no relationship
was evident between food intake and phospholipid 20:4n-6 content in brain, muscle,
heart, liver, adipose tissue, plasma or RBC (results not shown). A direct correlation
between food consumption and tissue anandamide and 2-AG levels would obviously be
more prudent and warrants further research.

6.6 A final comment
This study has successfully quantified the effect of diet fat profile on membrane
fatty acid composition and a number of metabolic variables in the rat. In these young
adult outbred rats fed a moderate-fat diet, fat profile of the diet had only modest
influence on body mass composition and food intake. This may be due to the limited
time the rats were fed the diets.
I found membrane fatty acid composition to be a highly regulated parameter by
varying the diet fat profile in a systematic manner. The results show that the diet
essential fatty acids have a strong influence on the membrane fat composition of all
tissues. And most importantly, diet PUFA balance elicited the greatest response.
There are implications of my findings for the current human diet. Dietary intake
studies have shown that the fat intake of the U.S. averages a PUFA balance of ~ 9.5%
(Ervin et al. 2004). If the current results in rats also apply to humans, an average PUFA
balance of 9.5% in the modern human diet is of considerable concern, as it indicates
there are huge numbers of people consuming a diet with a very low and likely
inadequate PUFA balance without knowing it.
For people to improve their diet they need to know what they are eating and
especially the balance between n-3 and n-6 PUFA in their food. An immediate step may
be for the Food Databases (e.g. www.nal.usda.gov/fnic/foodcomp/search and
www.foodstandards.gov.au/consumerinformation/nuttab2006;

accessed

10/01/11),

which currently provide information about the content of individual fatty acids in
various foods, to also include the total n-3 PUFA and total n-6 PUFA data. They
currently only provide the total PUFA content. A similar change in food labelling could
also be beneficial.
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Appendices
Appendix 1 Composition of initial diet (rat chow; % of total weight; Y.S. Feeds Pty
Ltd, Young, NSW, Australia).
Crude protein
Crude fat
Carbohydrate
Crude fibre
Actual salt

22.0%
6.0%
67.5%
4.0%
0.5%

Ingredients selected from:

Wheat, triticale, barley, oats, maize, sorghum, peas, lupins, bran, pollard, germ, ricehulls, meal, fishmeal,
sunflower meal, soyabean meal, cottonseed meal, rapeseed meal, linseed meal, biscuit meal, skim-milk
powder, salt, cereal meal, full fat soy, vegetable oil, whey, bentonite, synthetic amino acids, flavours,
vitamins, minerals, vitamin/mineral premix, ethoxyquin, selenium, lucerne meal.

Appendix 2 Linear regression analyses for the relationship between Week 8 Food
Intake (g) and the content of diet SFA, MUFA, PUFA, n-6 PUFA, n-3 PUFA and PUFA
balance. All fatty acid compositions expressed as % total fatty acids, except PUFA
balance expressed as n-3 PUFA as % total PUFA.
Food Intake (y)

Diet Composition (x)

Equation

R2

Slope standard error

P

Week 8 Food Intake

SFA

y = 149.10 + 0.26x

0.10

0.09

0.0097*

Week 8 Food Intake

MUFA

y = 160.17 - 0.13x

0.14

0.01

0.3533

Week 8 Food Intake

PUFA

y = 164.65 - 0.17x

0.09

0.05

0.0736

Week 8 Food Intake

n-6 PUFA

y = 163.44 - 0.26x

0.12

0.06

0.0386*

Week 8 Food Intake

n-3 PUFA

y = 157.69 - 0.04x

0.12

0.00

0.7618

Week 8 Food Intake

PUFA Balance

y = 150.84 + 0.14x

0.09

0.03

0.1157

Appendix 3 Linear regression analyses for the relationship between saturated fatty acid
(SFA) content of rat tissue phospholipids relative to SFA content of diet (as plotted in
Figure 4.1). Tissues include skeletal muscle, heart, brain, liver, adipose tissue and red
blood cells (RBC). All fatty acid compositions expressed as % total fatty acids.
Tissue Composition (y)

Diet Composition (x)

Equation

Slope standard error

R

P

Muscle SFA

SFA

y = 38.80 + 0.02x

0.01

0.31

0.0076*

Heart SFA

SFA

y = 34.26 + 0.00x

0.00

0.07

0.5395

Brain SFA

SFA

y = 46.62 + 0.00x

0.01

0.10

0.3991

Liver SFA

SFA

y = 44.04 + 0.02x

0.00

0.61

<0.0001*

Adipose SFA

SFA

y = 27.16 + 0.28x

0.02

0.84

<0.0001*

RBC SFA

SFA

y = 47.30 + 0.00x

0.02

0.01

0.9478

* The slope of the line of fit is significantly different from zero
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Appendix 4 Linear regression analyses for the relationship between monounsaturated
fatty acid (MUFA) content of rat tissue phospholipids relative to MUFA content of diet
(as plotted in Figure 4.2). Tissues include skeletal muscle, heart, brain, liver, adipose
tissue and red blood cells (RBC). All fatty acid compositions expressed as % total fatty
acids.
Tissue Composition (y)

Diet Composition (x)

Equation

Slope Standard Error

R

P

Muscle MUFA

MUFA

y = 6.73 + 0.11x

0.02

0.65

<0.0001*

Heart MUFA

MUFA

y = 6.27 + 0.07x

0.02

0.42

0.0003*

Brain MUFA

MUFA

y = 25.25 + 0.00x

0.01

0.02

0.8664

Liver MUFA

MUFA

y = 4.45 + 0.07x

0.01

0.58

<0.0001*

Adipose MUFA

MUFA

y = 17.77 + 0.52x

0.04

0.83

<0.0001*

RBC MUFA

MUFA

y = 7.18 + 0.12x

0.01

0.74

<0.0001*

* The slope of the line of fit is significantly different from zero

Appendix 5 Linear regression analyses for the relationship between polyunsaturated
fatty acid (PUFA) content of rat tissue phospholipids relative to PUFA content of diet
(as plotted in Figure 4.3). Tissues include skeletal muscle, heart, brain, liver, adipose
tissue and red blood cells (RBC). All fatty acid compositions expressed as % total fatty
acids.
Tissue Composition (y)

Diet Composition (x)

Equation

Slope Standard Error

R

P

Muscle PUFA

PUFA

y = 46.72 + 0.10x

0.01

0.83

<0.0001*

Heart PUFA

PUFA

y = 53.86 + 0.09x

0.01

0.89

<0.0001*

Brain PUFA

PUFA

y = 28.08 + 0.01x

0.01

0.12

0.3215

Liver PUFA

PUFA

y = 45.78 + 0.08x

0.01

0.82

<0.0001*

Adipose PUFA

PUFA

y = 14.07 + 0.44x

0.02

0.93

<0.0001*

RBC PUFA

PUFA

y = 40.09 + 0.06x

0.01

0.42

0.0002*

* The slope of the line of fit is significantly different from zero

Appendix 6 Linear regression analyses for the relationship between n-6
polyunsaturated fatty acid (n-6 PUFA) content of rat tissue phospholipids relative to n-6
PUFA content of diet (as plotted in Figure 4.4). Tissues include skeletal muscle, heart,
brain, liver, adipose tissue, plasma and red blood cells (RBC). All fatty acid
compositions expressed as % total fatty acids.
Tissue Composition (y)

Diet Composition (x)

Equation

Slope Standard Error

R

P

Muscle n-6 PUFA

n-6 PUFA

y = 26.99 + 0.23x

0.02

0.86

<0.0001*

Heart n-6 PUFA

n-6 PUFA

y = 38.61 + 0.21x

0.02

0.80

<0.0001*

Brain n-6 PUFA

n-6 PUFA

y = 13.04 + 0.05x

0.01

0.69

<0.0001*

Liver n-6 PUFA

n-6 PUFA

y = 31.13 + 0.24x

0.02

0.84

<0.0001*

Adipose n-6 PUFA

n-6 PUFA

y = 12.73 + 0.50x

0.03

0.91

<0.0001*

RBC n-6 PUFA

n-6 PUFA

y = 27.99 + 0.23x

0.02

0.75

<0.0001*

* The slope of the line of fit is significantly different from zero
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Appendix 7 Linear regression analyses for the relationship between n-3
polyunsaturated fatty acid (n-3 PUFA) content of rat tissue phospholipids relative to n-3
PUFA content of diet (as plotted in Figure 4.5). Tissues include skeletal muscle, heart,
brain, liver, adipose tissue and red blood cells (RBC). All fatty acid compositions
expressed as % total fatty acids.
Tissue Composition (y)

Diet Composition (x)

Equation

Slope Standard Error

R

P

Muscle n-3 PUFA

n-3 PUFA

y = 15.56 + 0.17x

0.02

0.64

<0.0001*

Heart n-3 PUFA

n-3 PUFA

y = 11.22 + 0.13 x

0.02

0.68

<0.0001*

Brain n-3 PUFA

n-3 PUFA

y = 13.52 + 0.02x

0.01

0.47

<0.0001*

Liver n-3 PUFA

n-3 PUFA

y = 9.33 + 0.12x

0.02

0.60

<0.0001*

Adipose n-3 PUFA

n-3 PUFA

y = 0.71 + 0.40x

0.01

0.96

<0.0001*

RBC n-3 PUFA

n-3 PUFA

y = 5.50 + 0.17x

0.02

0.77

<0.0001*

* The slope of the line of fit is significantly different from zero

Appendix 8 Linear regression analyses for the relationship between PUFA balance of
rat tissue phospholipids relative to diet PUFA balance (as plotted in Figure 4.7). Tissues
include skeletal muscle, heart, brain, liver, adipose tissue and red blood cells (RBC).
PUFA balance is expressed as n-3 PUFA as % total PUFA.
Tissue Composition (y)

Diet Composition (x)

Equation

Slope Standard Error

R

P

Muscle PUFA Balance†

PUFA Balance

y1 = 18.70 + 0.98x

0.23

0.72

0.0007*

Muscle PUFA Balance ‡

PUFA Balance

y2 = 31.62 + 0.16x

0.03

0.62

<0.0001*

Heart PUFA Balance

†

PUFA Balance

y1 = 7.70 + 1.47x

0.16

0.92

<0.0001*

Heart PUFA Balance ‡

PUFA Balance

y2 = 21.61 + 0.11x

0.02

0.57

<0.0001*

Brain PUFA Balance †

PUFA Balance

y1 = 41.95 + 0.66x

0.13

0.79

0.0001*

Brain PUFA Balance

‡

PUFA Balance

y2 = 47.14 + 0.07x

0.01

0.60

<0.0001*

Liver PUFA Balance †

PUFA Balance

y1 = 8.21 + 1.00x

0.15

0.85

<0.0001*

Liver PUFA Balance ‡

PUFA Balance

y2 = 16.40 + 0.22x

0.04

0.58

<0.0001*

RBC PUFA Balance

†

PUFA Balance

y1 = 3.98 + 0.65x

0.08

0.90

<0.0001*

RBC PUFA Balance ‡

PUFA Balance

y2 = 3.56 + 0.40x

0.03

0.91

<0.0001*

Adipose PUFA Balance

PUFA Balance

y = -1.40 + 0.60x

0.04

0.90

<0.0001*

* The slope of the line of fit is significantly different from zero
† Linear regression plotted below 10% diet PUFA balance
‡ Linear regression plotted above 10% diet PUFA balance
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Appendix 9 Linear regression analyses for the relationship between 20:4n-6 content of
rat tissue phospholipids and the amount of 18:2n-6 in the diet and diet PUFA balance
(as plotted in Figure 4.9). Tissues include skeletal muscle, heart, brain, liver, adipose
tissue and red blood cells (RBC). Diet 18:2n-6 expressed as g/100g diet (graphs a, c &
e) and PUFA balance expressed as n-3 PUFA as % total PUFA (graphs b, d & f).
Tissue Composition (y)

Diet Composition (x)

Equation

Slope Standard Error

R

P

Muscle 20:4n-6

18:2n-6

y = 8.86 + 1.17x

0.19

0.59

<0.0001*

Heart 20:4n-6

18:2n-6

y = 16.79 + 0.67x

0.18

0.42

0.0003*

Brain 20:4n-6

18:2n-6

y = 9.43 + 0.16x

0.04

0.47

<0.0001*

Liver 20:4n-6

18:2n-6

y = 17.38 + 1.69x

0.21

0.69

<0.0001*

Adipose 20:4n-6

18:2n-6

y = 4.28 + 0.32x

0.14

0.27

0.0255*

RBC 20:4n-6

18:2n-6

y = 18.92 + 0.93x

0.19

0.51

<0.0001*

Muscle 20:4n-6

PUFA Balance

y = 18.85 – 0.15x

0.01

− 0.91

<0.0001*

Heart 20:4n-6

PUFA Balance

y = 24.11 – 0.12x

0.01

− 0.91

<0.0001*

Brain 20:4n-6

PUFA Balance

y = 10.81 – 0.02x

0.00

− 0.73

<0.0001*

Liver 20:4n-6

PUFA Balance

y = 30.28 – 0.18x

0.01

− 0.89

<0.0001*

Adipose 20:4n-6

PUFA Balance

y = 7.47 – 0.05x

0.01

− 0.52

<0.0001*

RBC 20:4n-6

PUFA Balance

y = 27.68 – 0.14x

0.01

− 0.89

<0.0001*

* The slope of the line of fit is significantly different from zero

Appendix 10 Linear regression analyses for the relationship between 22:4n-6 content
of rat tissue phospholipids and the amount of 18:2n-6 in the diet and diet PUFA balance
(as plotted in Figure 4.9). Tissues include skeletal muscle, heart, brain, liver, adipose
tissue and red blood cells (RBC). Diet 18:2n-6 expressed as g/100g diet (graphs a, c &
e) and PUFA balance expressed as n-3 PUFA as % total PUFA (graphs b, d & f).
Tissue Composition (y)

Diet Composition (x)

Equation

Slope Standard Error

R

P

Muscle 22:4n-6

18:2n-6

y = 0.02 + 0.09x

0.02

0.59

<0.0001*

Heart 22:4n-6

18:2n-6

y = 0.02 + 0.14x

0.02

0.67

<0.0001*

Brain 22:4n-6

18:2n-6

y = 2.52 + 0.09x

0.01

0.61

<0.0001*

Liver 22:4n-6

18:2n-6

y = 0.04 + 0.06x

0.01

0.59

<0.0001*

Adipose 22:4n-6

18:2n-6

y = 0.03 + 0.05x

0.01

0.40

0.0005*

RBC 22:4n-6

18:2n-6

y = 0.11 + 0.28x

0.03

0.70

<0.0001*

Muscle 22:4n-6†

PUFA Balance

y1 = 1.14 – 0.07x

0.02

− 0.77

Muscle 22:4n-6‡

PUFA Balance

y2 = 0.32 + 0.00x

0.00

0.54

<0.0001*

22:4n-6†

PUFA Balance

y1 = 1.64 – 0.10x

0.02

− 0.84

<0.0001*

Heart 22:4n-6‡

PUFA Balance

y2 = 0.40 + 0.00x

0.00

0.82

<0.0001*

22:4n-6†

PUFA Balance

y1 = 3.35 – 0.03x

0.01

− 0.46

0.0568

Brain 22:4n-6‡

PUFA Balance

y2 = 3.15 – 0.01x

0.00

− 0.69

<0.0001*

22:4n-6†

PUFA Balance

y1 = 0.85 – 0.07x

0.01

− 0.87

<0.0001*

Liver 22:4n-6‡

PUFA Balance

y2 = 0.19 + 0.00x

0.00

0.62

<0.0001*

22:4n-6†

PUFA Balance

y1 = 0.69 – 0.06x

0.03

− 0.47

0.0581

Adipose 22:4n-6‡

PUFA Balance

y2 = 0.18 + 0.00x

0.00

0.16

0.2442

22:4n-6†

PUFA Balance

y1 = 2.79 – 0.08x

0.03

− 0.63

0.0055*

RBC 22:4n-6‡

PUFA Balance

y2 = 1.02 – 0.01x

0.00

− 0.75

<0.0001*

Heart
Brain
Liver

Adipose
RBC

* The slope of the line of fit is significantly different from zero
† Linear regression plotted below 10% diet PUFA balance
‡ Linear regression plotted above 10% diet PUFA balance
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0.0002*

Appendix 11 Linear regression analyses for the relationship between 22:5n-6 content
of rat tissue phospholipids and the amount of 18:2n-6 in the diet and diet PUFA balance
(as plotted in Figure 4.9). Tissues include skeletal muscle, heart, brain, liver, adipose
tissue and red blood cells (RBC). Diet 18:2n-6 expressed as g/100g diet (graphs g, i &
k) and PUFA balance expressed as n-3 PUFA as % total PUFA (graphs h, j & l).
Tissue Composition (y)

Diet Composition (x)

Equation

Slope Standard Error

R

P

Muscle 22:5n-6

18:2n-6

y = -0.05 + 0.20x

0.04

0.49

Heart 22:5n-6

18:2n-6

y = -0.19 + 0.36x

0.07

0.51

<0.0001*

Brain 22:5n-6

18:2n-6

y = 0.15 + 0.09x

0.02

0.54

<0.0001*

Liver 22:5n-6

18:2n-6

y = -0.04 + 0.12x

0.03

0.43

0.0002*

Adipose 22:5n-6

18:2n-6

y = -0.03 + 0.02x

0.01

0.37

0.0016*

RBC 22:5n-6

18:2n-6

y = 9.17 + 0.11x

0.02

0.53

<0.0001*

Muscle 22:5n-6†

PUFA Balance

y1 = 3.27 – 0.36x

0.04

− 0.92

<0.0001*

Muscle 22:5n-6‡

PUFA Balance

y2 = 0.35 + 0.00x

0.00

0.48

Heart 22:5n-6†

PUFA Balance

y1 = 5.62 – 0.66x

0.07

− 0.92

<0.0001*

Heart 22:5n-6‡

PUFA Balance

y2 = 0.39 + 0.00x

0.00

0.62

<0.0001*

22:5n-6†

PUFA Balance

y1 = 1.46 – 0.13x

0.02

− 0.87

<0.0001*

Brain 22:5n-6‡

PUFA Balance

y2 = 0.40 + 0.00x

0.00

0.58

<0.0001*

22:5n-6†

PUFA Balance

y1 = 2.24 – 0.29x

0.04

− 0.89

<0.0001*

Liver 22:5n-6‡

PUFA Balance

y2 = 0.22 + 0.00x

0.00

0.54

<0.0001*

22:5n-6†

PUFA Balance

y1 = 0.40 – 0.06x

0.02

− 0.66

Adipose 22:5n-6‡

PUFA Balance

y2 = 0.01 + 0.00x

0.00

0.12

RBC 22:5n-6†

PUFA Balance

y1 = 1.54 – 0.14x

0.03

− 0.80

<0.0001*

22:5n-6‡

PUFA Balance

y2 = 0.32 + 0.00x

0.00

0.58

<0.0001*

Brain
Liver

Adipose

RBC

* The slope of the line of fit is significantly different from zero
† Linear regression plotted below 10% diet PUFA balance
‡ Linear regression plotted above 10% diet PUFA balance
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<0.0001*

0.0002*

0.0037*
0.3966

Appendix 12 Linear regression analyses for the relationship between 22:6n-3 content
of rat tissue phospholipids and the amount of 18:3n-3 in the diet and diet PUFA balance
(as plotted in Figure 4.12). Tissues include skeletal muscle, heart, brain, liver, adipose
tissue and red blood cells (RBC). Diet 18:3n-3 expressed as g/100g diet (graphs a, c &
e) and PUFA balance expressed as n-3 PUFA as % total PUFA (graphs b, d & f).
Tissue Composition (y)

Diet Composition (x)

Muscle 22:6n-3

§

18:3n-3

Muscle 22:6n-3

‖

Equation

Slope Standard Error

R

y1 = 9.03 + 3.66x

1.08

0.65

P
0.0037*

18:3n-3

y2 = 14.89 – 0.49x

0.08

− 0.67

<0.0001*

Heart 22:6n-3§

18:3n-3

y1 = 6.56 + 6.07x

1.25

0.64

<0.0001*

Heart 22:6n-3

‖

18:3n-3

y2 = 11.79 – 0.41x

0.11

− 0.53

0.0008*

Brain 22:6n-3§

18:3n-3

y1 = 12.79 + 1.32x

0.47

0.43

0.0085*

Brain 22:6n-3‖

18:3n-3

y2 = 13.96 – 0.02x

0.06

− 0.06

§

18:3n-3

y1 = 6.53 + 3.62x

1.33

0.42

0.0100*

Liver 22:6n-3‖

18:3n-3

y2 = 9.11 – 0.34x

0.11

− 0.49

0.0026*

§

18:3n-3

y1 = 0.35 + 0.21x

0.13

0.27

0.1224

Adipose 22:6n-3‖

18:3n-3

y2 = 0.65 – 0.02x

0.02

− 0.15

0.3917

RBC 22:6n-3§

18:3n-3

y1 = 2.50 + 0.99x

0.63

0.26

0.1261

RBC 22:6n-3

Liver 22:6n-3

Adipose 22:6n-3

0.7278

18:3n-3

y2 = 3.52 – 0.18x

0.03

− 0.69

Muscle 22:6n-3†

PUFA Balance

y1 = 8.24 + 0.46x

0.10

0.75

0.0004*

22:6n-3‡

0.0213*

Muscle

‖

<0.0001*

PUFA Balance

y2 = 15.19 – 0.03x

0.01

− 0.31

Heart 22:6n-3†

PUFA Balance

y1 = 3.98 + 0.74x

0.08

0.92

Heart 22:6n-3‡

PUFA Balance

y2 = 13.14 – 0.05x

0.01

− 0.49

0.0002*

22:6n-3†

PUFA Balance

y1 = 12.09 + 0.21x

0.04

0.77

0.0002*

Brain 22:6n-3‡

PUFA Balance

y2 = 13.74 + 0.00x

0.010

0.03

0.8368

22:6n-3†

PUFA Balance

y1 = 3.78 + 0.46x

0.07

0.85

<0.0001*

Liver 22:6n-3‡

PUFA Balance

y2 = 10.80 – 0.04x

0.01

− 0.39

Adipose 22:6n-3

PUFA Balance

y = 0.31 + 0.00x

0.00

0.48

<0.0001*

22:6n-3†

PUFA Balance

y1 = 1.33 + 0.12x

0.03

0.69

0.0015*

RBC 22:6n-3‡

PUFA Balance

y2 = 4.46 – 0.02x

0.01

− 0.52

Brain
Liver

RBC

* The slope of the line of fit is significantly different from zero
§
Linear regression plotted below 1g/100g diet 18:3n-3
‖ Linear regression plotted above 1g/100g diet 18:3n-3
† Linear regression plotted below 10% diet PUFA balance
‡ Linear regression plotted above 10% diet PUFA balance
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<0.0001*

0.0032*

<0.0001*

Appendix 13 Linear regression analyses for the relationship between 20:5n-3 content
of rat tissue phospholipids and the amount of 18:3n-3 in the diet and diet PUFA balance
(as plotted in Figure 4.12). Tissues include skeletal muscle, heart, brain, liver, adipose
tissue and red blood cells (RBC). Diet 18:3n-3 expressed as g/100g diet (graphs a, c &
e) and PUFA balance expressed as n-3 PUFA as % total PUFA (graphs b, d & f).
Tissue Composition (y)

Diet Composition (x)

Equation

Slope Standard Error

R

P

Muscle 20:5n-3

18:3n-3

y = 0.30 + 0.22x

0.02

0.76

<0.0001*

Heart 20:5n-3

18:3n-3

y = 0.21 + 0.18x

0.03

0.63

<0.0001*

Brain 20:5n-3

18:3n-3

y = 0.02 + 0.02x

0.00

0.66

<0.0001*

Liver 20:5n-3

18:3n-3

y = 0.33 + 0.58x

0.07

0.73

<0.0001*

Adipose 20:5n-3

18:3n-3

y = 0.05 + 0.13x

0.02

0.68

<0.0001*

RBC 20:5n-3

18:3n-3

y = 0.52 + 0.70x

0.07

0.77

<0.0001*

20:5n-3†

PUFA Balance

y1 = 0.00 + 0.00x

0.00

0.00

n/a

Muscle 20:5n-3‡

PUFA Balance

y2 = -0.66 + 0.03x

0.00

0.88

<0.0001*

Heart 20:5n-3†

PUFA Balance

y1 = 0.00 + 0.00x

0.00

0.00

n/a

20:5n-3‡

PUFA Balance

y2 = -1.02 + 0.03x

0.00

0.83

<0.0001*

Brain 20:5n-3†

PUFA Balance

y1 = 0.01 + 0.00x

0.00

0.02

0.9228

Brain 20:5n-3‡

PUFA Balance

y2 = -0.09 + 0.00x

0.00

0.73

<0.0001*

20:5n-3†

PUFA Balance

y1 = -0.01 + 0.01x

0.00

0.86

<0.0001*

Liver 20:5n-3‡

PUFA Balance

y2 = -2.96 + 0.09x

0.01

0.82

<0.0001*

20:5n-3†

PUFA Balance

y1 = -0.00 + 0.00x

0.00

0.49

0.0447*

Adipose 20:5n-3‡

PUFA Balance

y2 = -0.65 + 0.02x

0.00

0.72

<0.0001*

RBC 20:5n-3†

PUFA Balance

y1 = -0.01 + 0.02x

0.00

0.90

<0.0001*

20:5n-3‡

PUFA Balance

y2 = -3.50 + 0.11x

0.01

0.91

<0.0001*

Muscle

Heart

Liver

Adipose

RBC

* The slope of the line of fit is significantly different from zero
† Linear regression plotted below 10% diet PUFA balance
‡ Linear regression plotted above 10% diet PUFA balance
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Appendix 14 Linear regression analyses for the relationship between 22:5n-3 content
of rat tissue phospholipids and the amount of 18:3n-3 in the diet and diet PUFA balance
(as plotted in Figure 4.12). Tissues include skeletal muscle, heart, brain, liver, adipose
tissue and red blood cells (RBC). Diet 18:3n-3 expressed as g/100g diet (graphs g, i &
k) and PUFA balance expressed as n-3 PUFA as % total PUFA (graphs h, j & l).
Tissue Composition (y)

Diet Composition (x)

Equation

Slope Standard Error

R

P

Muscle 22:5n-3§

18:3n-3

y1 = 1.82 + 1.63x

0.45

0.52

0.0010*

Muscle 22:5n-3‖

18:3n-3

y2 = 4.78 + 0.06x

0.08

0.13

0.4524

Heart 22:5n-3§

18:3n-3

y1 = 0.86 + 1.75x

0.24

0.78

<0.0001*

Heart 22:5n-3

‖

18:3n-3

y2 = 3.38 + 0.15x

0.04

0.50

0.0017*

Brain 22:5n-3§

18:3n-3

y = 0.12 + 0.12x

0.03

0.61

<0.0001*

Brain 22:5n-3

‖

18:3n-3

y = 0.24 + 0.05x

0.01

0.65

<0.0001*

Liver 22:5n-3§

18:3n-3

y1 = 0.56 + 0.88x

0.27

0.49

0.0025*

Liver 22:5n-3‖

18:3n-3

y2 = 1.82 + 0.44x

0.06

0.26

0.1230

§

18:3n-3

y1 = 0.11 + 0.28x

0.10

0.44

0.0074*

Adipose 22:5n-3‖

18:3n-3

y2 = 0.77 + 0.02x

0.03

0.13

0.4331

RBC 22:5n-3§

18:3n-3

y1 = 0.96 + 1.89 x

0.39

0.64

<0.0001*

RBC 22:5n-3

Adipose 22:5n-3

18:3n-3

y2 = 4.36 + 0.07x

0.06

0.19

0.2616

Muscle 22:5n-3

PUFA Balance

y = 1.45 + 0.05x

0.00

0.89

<0.0001*

Heart 22:5n-3

PUFA Balance

y = 0.82 + 0.05x

0.00

0.89

<0.0001*

Brain 22:5n-3

PUFA Balance

y = 0.02 + 0.01x

0.00

0.90

<0.0001*

Liver 22:5n-3

PUFA Balance

y = 0.26 + 0.03x

0.00

0.90

<0.0001*

Adipose 22:5n-3

PUFA Balance

y = -0.01 + 0.01x

0.00

0.78

<0.0001*

RBC 22:5n-3

PUFA Balance

y = 0.71 + 0.06x

0.00

0.92

<0.0001*

‖

* The slope of the line of fit is significantly different from zero
§
Linear regression plotted below 1g/100g diet 18:3n-3
‖ Linear regression plotted above 1g/100g diet 18:3n-3
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Appendix 15 Linear regression analyses for the relationship between the fatty acid
composition of rat transport/storage tissues and diet fat profile (as plotted in Figure 5.1
and Figure 5.2). Transport includes plasma phospholipids (PL) and plasma triglycerides
(TG). Storage includes adipose tissue TG. All fatty acid compositions expressed as %
total fatty acids, except for PUFA balance which is expressed as n-3 PUFA as % total
PUFA.
Tissue Composition (y)

Diet Composition (x)

Equation

Slope Standard Error

R

P

Plasma PL SFA

SFA

y = 45.14 + 0.05x

0.02

0.36

0.0021*

Plasma TG SFA

SFA

y = 2.35 + 0.08x

0.02

0.41

0.0004*

Adipose TG SFA

SFA

y = 17.48 + 0.45x

0.02

0.96

<0.0001*

Plasma PL MUFA

MUFA

y = 6.71 + 0.14x

0.03

0.47

<0.0001*

Plasma TG MUFA

MUFA

y = 14.60 + 0.37x

0.05

0.66

<0.0001*

Adipose TG MUFA

MUFA

y = 19.83 + 0.69x

0.04

0.93

<0.0001*

Plasma PL PUFA

PUFA

y = 39.44 + 0.08x

0.02

0.46

<0.0001*

Plasma TG PUFA

PUFA

y = 36.22 + 0.32x

0.04

0.67

<0.0001*

Adipose TG PUFA

PUFA

y = 4.94 + 0.61x

0.02

0.98

<0.0001*

Plasma PL n-6 PUFA

n-6 PUFA

y = 29.42 + 0.21x

0.03

0.69

<0.0001*

Plasma TG n-6 PUFA

n-6 PUFA

y = 25.54 + 0.57x

0.05

0.80

<0.0001*

Adipose TG n-6 PUFA

n-6 PUFA

y = 4.82 + 0.67x

0.02

0.98

<0.0001*

Plasma PL n-3 PUFA

n-3 PUFA

y = 6.24 + 0.10x

0.02

0.62

<0.0001*

Plasma TG n-3 PUFA

n-3 PUFA

y = -4.02 + 0.33x

0.03

0.77

<0.0001*

Adipose TG n-3 PUFA

n-3 PUFA

y = -0.13 + 0.55x

0.01

1.00

<0.0001*

Plasma PL PUFA Balance

PUFA Balance

y = 9.04 + 0.25x

0.02

0.82

<0.0001*

Plasma TG PUFA Balance

PUFA Balance

y = 0.02 + 0.50x

0.04

0.84

<0.0001*

Adipose TG PUFA Balance

PUFA Balance

y = -2.25 + 0.79x

0.03

0.95

<0.0001*

* The slope of the line of fit is significantly different from zero
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Appendix 16 Linear regression analyses for the relationship between 20:4n-6, 22:4n-6
and 22:5n-6 content of rat plasma phospholipids (PL) and triglycerides (TG) and the
amount of precursor 18-carbon PUFA in the diet and diet PUFA balance (as plotted in
Figure 5.4). Diet 18:2n-6 expressed (graphs a, c & e) and PUFA balance expressed as n3 PUFA as % total PUFA (graphs b, d & f).
Tissue Composition (y)

Diet Composition (x)

Equation

Slope Standard Error

R

P

Plasma PL 20:4n-6

18:2n-6

y = 13.75 + 1.57x

0.25

0.61

<0.0001*

Plasma TG 20:4n-6

18:2n-6

y = 11.43 + 2.68x

0.37

0.65

<0.0001*

Plasma PL 20:4n-6

PUFA Balance

y = 25.73 – 0.17x

0.02

− 0.78

<0.0001*

Plasma TG 20:4n-6

PUFA Balance

y = 29.56 – 0.24x

0.03

− 0.68

<0.0001*

Plasma PL 22:4n-6

18:2n-6

y = -0.04 + 0.07x

0.01

0.54

<0.0001*

Plasma TG 22:4n-6

18:2n-6

y = 0.01 + 0.08x

0.01

0.60

<0.0001*

Plasma PL 22:4n-6†

PUFA Balance

y1 = 0.86 – 0.08x

0.03

− 0.55

Plasma PL 22:4n-6‡

PUFA Balance

y2 = 0.10 – 0.00x

0.00

0.19

0.1707

Plasma TG 22:4n-6†

PUFA Balance

y1 = 0.85 – 0.05x

0.03

− 0.38

0.1166

Plasma TG 22:4n-6‡

PUFA Balance

y2 = 0.23 – 0.00x

0.00

− 0.42

0.0019*

Plasma PL 22:5n-6

18:2n-6

y = -0.02 + 0.08x

0.02

0.37

0.0015*

Plasma TG 22:5n-6

18:2n-6

y = -0.02 + 0.05x

0.01

0.45

<0.0001*

22:5n-6†

PUFA Balance

y1 = 1.61 – 0.23x

0.04

− 0.86

<0.0001*

Plasma PL 22:5n-6‡

PUFA Balance

y2 = 0.09 + 0.00x

0.00

0.09

Plasma TG 22:5n-6†

PUFA Balance

y1 = 0.78 – 0.09x

0.02

− 0.80

22:5n-6‡

PUFA Balance

y2 = 0.06 + 0.00x

0.00

0.30

Plasma PL

Plasma TG

* The slope of the line of fit is significantly different from zero
† Linear regression plotted below 10% diet PUFA balance
‡ Linear regression plotted above 10% diet PUFA balance
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0.0168*

0.5142
<0.0001*
0.0267*

Appendix 17 Linear regression analyses for the relationship between 20:5n-3, 22:5n-3
and 22:6n-3 content of rat plasma phospholipids (PL) and triglycerides (TG) and the
amount of precursor 18-carbon PUFA in the diet and diet PUFA balance (as plotted in
Figure 5.5). Diet 18:3n-3 expressed as g/100g diet (graphs a, c & e) and PUFA balance
expressed as n-3 PUFA as % total PUFA (graphs b, d & f).
Tissue Composition (y)

Diet Composition (x)

Equation

Slope Standard Error

R

P

Plasma PL 20:5n-3

18:3n-3

y = 0.33 + 0.27x

0.05

0.58

<0.0001*

Plasma TG 20:5n-3

18:3n-3

y = 0.92 + 0.51x

0.10

0.54

<0.0001*

Plasma PL 20:5n-3†

PUFA Balance

y1 = 0.03 + 0.00x

0.01

0.05

0.8382

20:5n-3‡

PUFA Balance

y2 = -1.57 + 0.05x

0.01

0.76

<0.0001*

Plasma TG 20:5n-3†

PUFA Balance

y1 = -0.02 − 0.03x

0.01

− 0.85

<0.0001*

20:5n-3‡

Plasma PL

PUFA Balance

y2 = -2.95 + 0.10x

0.01

0.78

<0.0001*

Plasma PL 22:5n-3

18:3n-3

y = 0.69 + 0.15x

0.02

0.58

<0.0001*

Plasma TG 22:5n-3

18:3n-3

y = 0.47 + 0.22x

0.03

0.68

<0.0001*

Plasma PL 22:5n-3

PUFA Balance

y = 0.20 + 0.02x

0.00

0.83

<0.0001*

Plasma TG 22:5n-3

PUFA Balance

y = -0.06 + 0.02x

0.00

0.84

<0.0001*

Plasma PL 22:6n-3§

18:3n-3

y1 = 4.70 + 0.98x

0.97

0.17

0.3193

Plasma PL 22:6n-3

Plasma TG

18:3n-3

y2 = 5.86 – 0.23x

0.09

− 0.41

Plasma TG 22:6n-3§

18:3n-3

y1 = 1.44 + 0.99x

0.63

0.26

Plasma TG 22:6n-3‖

18:3n-3

y2 = 3.00 – 0.14x

0.05

− 0.44

22:6n-3†

PUFA Balance

y1 = 3.14 + 0.14x

0.09

0.34

Plasma PL 22:6n-3‡

PUFA Balance

y2 = 7.24 − 0.03x

0.01

− 0.42

22:6n-3†

PUFA Balance

y1 = 0.48 + 0.12x

0.01

0.91

<0.0001*

Plasma TG 22:6n-3‡

PUFA Balance

y2 = 2.10 + 0.01x

0.01

0.14

0.3140

Plasma PL
Plasma TG

‖

* The slope of the line of fit is significantly different from zero
† Linear regression plotted below 10% diet PUFA balance
‡ Linear regression plotted above 10% diet PUFA balance
§
Linear regression plotted below 1g/100g diet 18:3n-3
‖ Linear regression plotted above 1g/100g diet 18:3n-3
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0.0134*
0.1225
0.0082*
0.1658
0.0018*

Appendix 18 Analysis of results from Bourre’s study in rats investigating the effect of
diet PUFA balance on total lipid PUFA balance in the liver () and brain (●); (Bourre
et al. 1993).
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Appendix 19 Linear regression analyses for the relationship between membrane
saturated fatty acid (SFA) content of various tissues and minimum metabolic rate
(MMR @ 23ºC; ml.hr-1.g-1 total body mass). Tissues include skeletal muscle, heart,
brain, liver, adipose tissue and red blood cells (RBC). Fatty acid composition expressed
as % total fatty acids.
Tissue Composition (y)

Metabolic Rate (x)

Equation

Slope standard error

R

P

Muscle SFA

MMR

y = 39.58 – 0.10x

1.19

– 0.01

0.9306

Heart SFA

MMR

y = 33.74 + 0.81x

0.47

0.20

0.0888

Brain SFA

MMR

y = 46.54 – 0.11x

0.79

– 0.02

0.8897

Liver SFA

MMR

y = 44.70 – 0.03x

0.55

– 0.01

0.9583

Adipose SFA

MMR

y = 32.92 + 4.21x

5.45

0.09

0.4428

RBC SFA

MMR

y = 45.07 + 3.13x

2.04

0.18

0.1297

Appendix 20 Linear regression analyses for the relationship between membrane
monounsaturated fatty acid (MUFA) content of various tissues and minimum metabolic
rate (MMR @ 23ºC; ml.hr-1.g-1 total body mass). Tissues include skeletal muscle, heart,
brain, liver, adipose tissue and red blood cells (RBC). Fatty acid composition expressed
as % total fatty acids.
Tissue Composition (y)

Metabolic Rate (x)

Equation

Slope Standard Error

R

P

Muscle MUFA

MMR

y = 11.06 – 2.37x

1.86

– 0.15

0.2057

Heart MUFA

MMR

y = 9.53 – 2.31x

1.77

– 0.15

0.1950

Brain MUFA

MMR

y = 24.79 + 0.56x

1.30

0.15

0.6681

Liver MUFA

MMR

y = 6.81 – 0.93x

1.37

– 0.08

0.4970

Adipose MUFA

MMR

y = 38.11 – 10.81x

6.97

– 0.18

0.1254

RBC MUFA

MMR

y = 11.08 – 1.42x

1.81

– 0.09

0.4367

Appendix 21 Linear regression analyses for the relationship between membrane
polyunsaturated fatty acid (PUFA) content of various tissues and minimum metabolic
rate (MMR @ 23ºC; ml.hr-1.g-1 total body mass). Tissues include skeletal muscle, heart,
brain, liver, adipose tissue and red blood cells (RBC). Fatty acid composition expressed
as % total fatty acids.
Tissue Composition (y)

Metabolic Rate (x)

Equation

Slope Standard Error

Muscle PUFA

MMR

y = 49.35 + 2.47x

1.98

Heart PUFA

MMR

y = 56.73 + 1.50x

Brain PUFA

MMR

y = 28.67 – 0.45x

Liver PUFA

MMR

Adipose PUFA
RBC PUFA

R

P

0.15

0.2153

1.65

0.11

0.3681

0.83

– 0.06

0.5903

y = 48.48 + 0.96x

1.54

0.07

0.5348

MMR

y = 28.97 + 6.60x

7.98

0.10

0.4108

MMR

y = 43.85 – 1.70x

2.24

– 0.09

0.4498
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Appendix 22 Linear regression analyses for the relationship between membrane n-6
PUFA content of various tissues and minimum metabolic rate (MMR @ 23ºC; ml.hr-1.g1
total body mass). Tissues include skeletal muscle, heart, brain, liver, adipose tissue and
red blood cells (RBC). Fatty acid composition expressed as % total fatty acids.
Tissue Composition (y)

Metabolic Rate (x)

Equation

Slope Standard Error

R

P

Muscle n-6 PUFA

MMR

y = 36.45 – 5.10x

3.40

– 0.18

0.1387

Heart n-6 PUFA

MMR

y = 48.92 – 7.18x

3.15

– 0.26

0.0258*

Brain n-6 PUFA

MMR

y = 15.78 – 2.10x

0.88

– 0.28

0.0192*

Liver n-6 PUFA

MMR

y = 44.36 – 10.04x

3.44

– 0.33

0.0047*

Adipose n-6 PUFA

MMR

y = 29.78 – 6.98x

6.70

– 0.12

0.3010

RBC n-6 PUFA

MMR

y = 43.08 – 13.17x

3.45

– 0.42

0.0003*

* The slope of the line of fit is significantly different from zero

Appendix 23 Linear regression analyses for the relationship between membrane n-3
PUFA content of various tissues and minimum metabolic rate (MMR @ 23ºC; ml.hr-1.g1
total body mass). Tissues include skeletal muscle, heart, brain, liver, adipose tissue and
red blood cells (RBC). Fatty acid composition expressed as % total fatty acids.
Tissue Composition (y)

Metabolic Rate (x)

Equation

Slope Standard Error

R

P

Muscle n-3 PUFA

MMR

y = 12.91 + 7.57x

2.85

0.30

0.0098*

Heart n-3 PUFA

MMR

y = 7.73 + 8.67 x

2.60

0.37

0.0014*

Brain n-3 PUFA

MMR

y = 12.83 + 1.62x

0.67

0.28

0.0179*

Liver n-3 PUFA

MMR

y = 4.03 + 10.84x

2.58

0.45

<0.0001*

Adipose n-3 PUFA

MMR

y = -0.82 + 13.60x

5.61

0.28

0.0179*

RBC n-3 PUFA

MMR

y = 0.69 + 11.42x

2.74

0.45

<0.0001*

* The slope of the line of fit is significantly different from zero

Appendix 24 Linear regression analyses for the relationship between membrane PUFA
balance of various tissues and minimum metabolic rate (MMR @ 23ºC; ml.hr-1.g-1 total
body mass). Tissues include skeletal muscle, heart, brain, liver, adipose tissue and red
blood cells (RBC). PUFA balance expressed as n-3 PUFA as % total PUFA.
Tissue Composition (y)

Metabolic Rate (x)

Equation

Slope Standard Error

R

P

Muscle PUFA Balance

MMR

y = 27.15 + 12.28x

5.69

0.25

0.0342*

Heart PUFA Balance

MMR

y = 14.14 + 14.05x

4.53

0.35

0.0028*

Brain PUFA Balance

MMR

y = 44.92 + 6.43x

2.29

0.32

0.0065*

Liver PUFA Balance

MMR

y = 9.01 + 21.30x

5.51

0.42

0.0002*

Adipose PUFA Balance

MMR

y = 1.57 + 32.05x

11.32

0.32

0.0061*

RBC PUFA Balance

MMR

y = 1.32 + 27.47x

6.36

0.46

<0.0001*

* The slope of the line of fit is significantly different from zero
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Appendix 25 Results for Medline search of papers published in 2008 (as plotted in Figure 6.4) with keywords: “high fat diet induced obesity” in “mice
and rats”. Diet PUFA balance (n-3 as % total PUFA) was calculated for 81 studies (out of a total of 86). Includes duration of diet study (weeks).
Species
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
rats
mice
mice
mice
mice
rats
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice

Fat (%en) Weeks
61
60
60
60
60
60
60
59
59
59
58
58
58
48
41
40
35
60
59
41
55
53
45
45
40
40
60
40
40
40
60
60
60
60
60
60
60
60
60
60
60
60

16
23
20
18
17
14
11
17
16
6
36
18
8
7
20
24
12
20
10
36
12
8
26
3
14
4
20
3
4
22
22
21
19
16
16
16
15
15
14
14
13

Diet PUFA
Balance
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.1
0.1
0.1
0.5
0.7
0.9
1.0
1.0
1.6
1.6
2.5
2.5
3.0
4.4
4.4
4.4
4.4
4.4
4.4
4.4
4.4
4.4
4.4
4.4
4.4

Source of fat
lard
lard
lard
lard
lard
lard
lard
lard
lard
lard
lard
lard
lard
lard
coconut
cocoa butter
lard
safflower
safflower
safflower
not specified
maize + lard
safflower + copha
maize + lard
maize + lard
sunflower + lard + copha
maize + lard
sunflower + lard + copha
sunflower + lard + copha
maize + milkfat
soybean + lard
soybean + lard
soybean + lard
soybean + lard
soybean + lard
soybean + lard
soybean + lard
soybean + lard
soybean + lard
soybean + lard
soybean + lard
soybean + lard

Authors

Journal

Begriche, K., Letteron, P., Abbey-Toby, A., et al.

American Journal of Physiology - Endocrinology and Metabolism. 294: E939-51 (2008)

Cong, W., Tao, R., Tian, J., et al.

Life Sciences. 82: 983-90 (2008)

Tsuboyama-Kasaoka, N., Sano, K., Shozawa, C., et al.

American Journal of Physiology - Endocrinology and Metabolism. 294: E600-06 (2008)

Jeoung, N.H., Harris, R.A.

American Journal of Physiology - Endocrinology & Metabolism. 295:E46-54 (2008)

Yamamoto E., Dong Y.F., Kataoka K., et al.
Labonte, E.D., Camarota, L.M., Rojas, J.C., et al.

Hypertension. 52:573-80 (2008)

Kebede, M., Alquier, T., Latour, M.G., et al.

Diabetes. 57:2432-7 (2008)

Ayala, J.E., Bracy, D.P., Hansotia, T., et al.

Diabetes. 57: 288-97 (2008)

American Journal of Physiology - Gastrointestinal & Liver Physiology. 295:G776-83 (2008)

Scheja, L., Heese, B., Zitzer, H., et al.

Experimental Diabetes Research. Article ID 230837, 11 pages (2008)

Guan, Z., Vgontzas, A.N, Bixler, E.O, et al.

Sleep. 31:627-33 (2008)

Strom, K., Hansson, O., Lucas, S., et al.

PLoS ONE. 3: e1793 (2008)

Mzhavia, N., Yu, S., Ikeda, S., et al.

Diabetes. 57:2774-83 (2008)

Lan, H., Hoos, L.M., Liu, L., et al.

Diabetes. 57:2999-3006 (2008)

Jang, A., Srinivasan, P., Lee, N.Y., et al.

Chemico-Biological Interactions. 174:109-17 (2008)

Newberry, E.P., Kennedy, S.M., Xie, Y., et al.

American Journal of Physiology - Gastrointestinal and Liver Physiology. 294: G307-14 (2008)

Matsuzawa-Nagata, N., Takamura, T., Ando H., et al.

Metabolism: Clinical & Experimental. 57:1071-7 (2008)

Roncon-Albuquerque, R. Jr., Moreira-Rodrigues, M., Faria, B., et al.

Life Sciences. 83:502-10 (2008)

Tsuboyama-Kasaoka, N., Sano, K., Shozawa, C., et al.

American Journal of Physiology - Endocrinology and Metabolism. 294: E600-06 (2008)

Sridhar, M.G., Vinayagamoorthi, R., Suyambunathan, V.A., et al.

British Journal of Nutrition. 99: 806-12 (2008)

Newberry, E.P., Kennedy, S.M., Xie, Y., et al.

American Journal of Physiology - Gastrointestinal and Liver Physiology. 294: G307-14 (2008)

Wunderlich, F.T., Luedde, T., Singer, S., et al.

Proceedings of the National Academy of Sciences of the United States of America. 105: 1297-1302 (2008)

Mendoza, J., Pevet, P., Challet, E.

Journal of Physiology. 586:5901-10 (2008)

Boey, D., Lin, S., Enriquez, R.F., et al.

Neuropeptides. 42: 19-30 (2008)

Torre-Villalvazo, I., Tovar, A.R., Ramos-Barragan, V.E., et al

The Journal of Nutrition. 138: 462-68 (2008)

Fearnside, J. F., Dumas, M., Rothwell, A.R., et al.

PLoS ONE. 3: e1668 (2008)

Huang, X.F., Yu, Y., Li, Y., et al.

Neurochemical Research. 33:1881-8 (2008)

Fukumitsu, S., Aida, K., Ueno, N., et al.

British Journal of Nutrition. 100:669-76 (2008)

South, T., Huang, X.F.

Journal of Neuroendocrinology. 20:1288-94 (2008)

South, T., Huang, X.F.

Neurochemical Research. 33: 598-605 (2008)

Bjursell, M., Gerdin, A., Lelliott, C.J., et al.

American Journal of Physiology - Endocrinology & Metabolism. 294: E251-60 (2008)

Chadt, A., Leicht, K., Deshmukh, A., et al.

Nature Genetics. 40:1354-9 (2008)

Judge, M.K., Zhang, J., Tumer, N., et al.

American Journal of Physiology - Regulatory Integrative & Comparative Physiology. 295:R773-80 (2008)

Quinn, L.S., Anderson, B.G., Strait-Bodey, L., et al.

American Journal of Physiology - Endocrinology & Metabolism. 296:E191-202 (2009)

Feral, C.C., Neels, J.G., Kummer, C., et al.

Diabetes. 57:1842-51 (2008)

Singh, R., Wang, Y., Xiang, Y., et al.

Hepatology. 49:87-96 (2009)

Bose, M., Lambert, J.D., Ju, J., et al.

Journal of Nutrition. 138:1677-83 (2008)

Shah, C., Yang, G., Lee, I., et al.

Journal of Biological Chemistry. 283: 13538-48 (2008)

Longo, K.A., Charoenthongtrakul, S., Giuliana, D.J., et al.

Regulatory Peptides. 150:55-61 (2008)

Yu, X.X., Pandey, S.K., Booten, S.L., et al.

American Journal of Physiology - Endocrinology and Metabolism. 294: E530-39 (2008)

Kim, F., Pham, M., Maloney, E., et al.
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Appendix 25 (continued from page 159)
Species
mice
mice
rats
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
rats
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice
mice

Fat (%en) Weeks
60
60
60
59
45
45
45
45
45
45
45
45
45
45
45
45
45
45
45
45
49
60
61
60
58
58
58
20
40
40
40
36
42
42
42
42
42
42
40
72
60
60
57
45

9
8
2
13
26
25
21
20
18
17
12
12
12
10
10
9
9
8
4
2
14
3
10
8
24
18
14
32
14
12
16
28
15
15
15
14
6
4
4
20
14
20
22

Diet PUFA
Balance
4.4
4.4
4.4
5.0
5.3
5.3
5.3
5.3
5.3
5.3
5.3
5.3
5.3
5.3
5.3
5.3
5.3
5.3
5.3
5.3
6.5
6.7
7.6
10.1
10.1
10.1
10.1
10.7
19.0
26.8
27.8
29.2
33.3
33.3
33.3
33.3
33.3
33.3
33.3

Source of fat
soybean + lard
soybean + lard
soybean + lard
soybean + lard
soybean + lard
soybean + lard
soybean + palm oil
soybean + lard
soybean + lard
soybean + lard
soybean + lard
soybean + lard
soybean + lard
soybean + lard
soybean + lard
soybean + lard
soybean + lard
soybean + lard
soybean + lard
soybean + lard
not specified
soybean + lard + tallow
lard
soybean + coconut
soybean + coconut
soybean + coconut
soybean + coconut
soybean + lard
beef tallow
not specified
canola + cocoa butter
canola + vegetable oil
milkfat
milkfat
milkfat
milkfat
milkfat
milkfat
butter
maize + lard
soybean + lard
coconut + copha
maize + copha
soybean + lard

Authors

Journal

Yang, J., Maika, S., Craddock, L., et al.
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Lan, H., Hoos, L.M., Liu, L., et al.
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Pauli, J.R., Ropelle, E.R., Cintra, D.E., et al.
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Fang, C.X., Dong, F., Thomas, D.P., et al.

American Journal of Physiology - Heart & Circulatory Physiology. 295:H1206-H1215 (2008)
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Morgan, D.A., Thedens, D.R., Weiss, R., et al.
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Diabetes. 57:3239-46 (2008)

Villena, J.A., Choi, C.S., Wang, Y., et al.

Diabetes. 57:3258-66 (2008)

Imai, Y., Patel, H.R., Doliba, N.M., et al.

Physiological Genomics. 36:43-51 (2008)

Shih, C.C., Lin, C.H., Lin, W.L.

Diabetes Research & Clinical Practice. 81:134-43 (2008)

Lee, J., Chae, K., Ha, J., et al.

Journal of Ethnopharmacology. 115: 263-70 (2008)

Bradley, R.L., Jeon, J.Y., Liu, F.F., et al.
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Singhal, N.S., Patel, R.T., Qi, Y., et al.
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Mori, M.A., Araujo, R.C., Reis, F.C.G., et al.

Diabetes. 57: 1491-1500 (2008)

Anderson, S., Gilge, D.A., Steiber, A.L., et al.

Metabolism Clinical and Experimental. 57: 347-54 (2008)

Takanabe, R., Ono, K., Abe, Y., et al.

Biochemical & Biophysical Research Communications. 376:728-32 (2008)
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American Journal of Physiology - Gastrointestinal & Liver Physiology. 295:G621-8 (2008)
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Physiology & Behavior. 93: 713-23 (2008)
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Molecular and Cellular Endocrinology. 286S: S66-78 (2008)

Takagi, T., Matsuda, M., Abe, M., et al.

Athersclerosis. 196: 114-21 (2008)

Jebelovski, E., Kiraly, C., Erdei, N., et al.

American Journal of Physiology - Heart and Circulatory Physiology. 294: H2558-64 (2008)

Ferron, M., Hinoi, E., Karsenty, G., et al.
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